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 SUMMARY 
 
Global human cytomegalovirus (HCMV) gene expression was investigated during 
replication in three permissive human cell types in tissue culture; human foetal foreskin 
fibroblasts (HFFF-2), human retinal pigmented epithelial (RPE) cells, and human 
astrocytoma cells (U373Mg). A custom HCMV DNA microarray based on recent re-
assessments of HCMV coding potential was designed. The Merlin strain of HCMV was 
used for these studies because it has been reported to contain the complete set of ORFs, 
only one of which (UL128) is mutated. The UL128 gene locus is invariably mutated in 
HCMV isolates propagated in fibroblasts, and the premature termination mutation of 
UL128 greatly enhanced infectious yields from Merlin passaged in HFFF-2 cells. The 
HCMV (Merlin) microarray consists of 60-mer oligonucleotide probes derived from both 
3’- and 5’-proximal regions of each recognised ORF, and 3’-proximal probes for novel 
ORFs that have been proposed from in silico studies. Probes were also included for several 
previously reported ORFs that are now considered to non-protein coding. Positive and 
negative-sense bacterial sequence probes were included on the array, and were used in 
conjuction with spiked-in cognate RNAs in the cDNA synthesis reaction as controls for 
normalisation. The quality of the printed HCMV microarray was assessed and its 
specificity validated using Cy3-labelled cDNAs prepared from total RNA extracted from 
mock-infected and HCMV-infected cells at 96 h PI. Hybridisation conditions were then 
investigated to achieve optimal specificity and sensitivity of cDNA binding to cognate 
probes on the array.  
 
Prior to commencing the microarray studies, the growth characteristics of HCMV (Merlin) 
were compared in each of the three cell lines. One-step virus growth curves revealed 
differential virus replication kinetics in the three cell types. Compared to infected HFFF-2 
cultures, there was a 24 h delay in exit of virus from the viral eclipse phase in RPE and 
U373Mg cells and little or no release of infectivity to the extracellular medium. 
Differential growth kinetics in the three cell types were not due to differences in the 
ability of HCMV to enter cells or to induce virus gene expression, nor was it due to gross 
differences in the temporal expression kinetics of immediate-early, early and late protein 
synthesis in the three cell types. However, differences in the amount of protein made 
were evident, with viral protein expression lowest in RPE cells. Differences in virus 
growth kinetics were probably due to differences in the numbers of virus particles 
assembled, and/or their maturation and egress. It was therefore considered valid to 
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compare the temporal kinetics of HCMV (Merlin) transcript expression in the three cell 
types in order to identify genes that were regulated differently.   
 
cDNAs were prepared from total RNA extracted from infected cells at 12, 24, 48 and 72 h 
PI, or at 72 h PI only from mock-infected cultures. After collection of the raw data, 
receiver operating characteristic (ROC) analysis was performed using the positive and 
negative control signals in order to determine cutoff points that discriminated between 
true-positive and true-negative hybridisation signals. The GeneSpring gene expression 
analysis software was used for statistical analysis of the microarray data. Human 
fibroblast cells have been extensively used in HCMV research, and so the HFFF-2 cell type 
was used as a reference cell type for the microarray work. Differential expression of a 
virus gene then relates to differences in amounts and/or expression kinetics between 
HFFF-2 and RPE cells, or between HFFF-2 and U373Mg cells. To identify differentially 
expressed virus genes, combined statistical tests were performed on the mean expression 
value for each gene from all data points over the time course, giving a single expression 
value for each gene in each cell type. The statistical tests then compared the expression 
values for individual HCMV genes in infected HFFF-2 cells against the corresponding 
expression values for individual HCMV genes in RPE or U373Mg cells.  
 
Comparing the microarray data from HFFF-2 and RPE infected cells, 13 HCMV ORFs 
(UL4, UL16, UL45, UL148, IRS1, US11, US12, US13, US14, US15, US18, US19, US20), were 
found to be differentially expressed, and this was confirmed by examination of the 
expression kinetics of the individual genes. When the microarray data from infected HFFF 
and U373Mg cells were compared, 26 ORFs appeared to be differentially expressed. 
However, the microarray showed that late HCMV genes were expressed at unusually 
early times (24 h PI) in U373Mg cells; in contrast to the expression of their protein 
products. The data suggested that in U373Mg cells, either the HCMV transcriptome 
cascade was completed more rapidly, or that there was a breakdown in regulation of 
transcription control. Most of the 26 ORFs differentially expressed in HFFF-2 and U373Mg 
cells (identified by combined statistical testing) are expressed at a significantly higher 
level in U373Mg cells, but 7 were made in significantly reduced amounts (UL4, IRS1, 
US12, US14, US18, US19 and US20), and these were considered more likely candidates for 
differential expression, and were also differentially expressed in RPE cells. The 
disregulation of transit through the HCMV transcript cascade in U373Mg cells is thought 
to be due to the fact that p53 is mutated in this cell line. It has been reported that p53 
mutants including the p53 mutation in U373Mg cells are capable of activating 
transcription from the HCMV MIEP and that the minimal promoter sequence is a TATA 
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box. It may be that mutant p53 activates HCMV early and late promoters resulting in an 
accelerated transit through the HCMV transcription cascade in infected U373Mg cells.  
 
Of the 13 ORFs differentially expressed in HFFF-2 and RPE cells, UL4 is reported to be 
under both transcriptional and translational control. Cellular and viral transcription 
factors are involved in both positive and negative regulation of the UL4 promoter making 
it a good candidate for differential regulation in different cell types, although the function 
provided by UL4 is unknown. The immediate-early IRS1 gene is an important viral 
transactivator required throughout the virus replication cycle, and also self regulates its 
gene expression though an internal ORF. The functions of the US12 family genes (US12, 
US13, US14, US15, US18, US19 and US20) are unknown, but it has been suggested that 
they have a role in virus particle tegumentation, envelopment, and egress from infected 
cells. However, the identification of multiple members of the US12 gene family as 
differentially regulated should be interpreted with caution, since US18, US19 and US20 
produce 3’ co-terminal transcripts, and it is probable that other family members also share 
polyadenylation sites. Down-regulation of US12 family genes with potential roles in virus 
maturation and egress are consistent with the impaired release of virus to the extracellular 
medium from RPE and U373Mg cells. Compared to HFFF-2 cells, the down-regulation of 
UL16 and US11 in RPE and U373Mg cells is interesting since the genes have immune 
evasion functions, and these cell types are located in immune-privileged organs, i.e. the 
brain (astrocytes) and eye (retinal epithelia). As yet, it remains unclear why the expression 
of two immune evasion genes from a total of ten, are down-regulated in these cell types. 
The down-regulation of UL45 in RPE cells may play a role in virus dissemination in the 
eye. While the HCMV UL45 gene product is a component of the virus tegument and 
might supply an important function early in the virus replication cycle, a UL45 mutant 
exhibited a growth defect in fibroblasts that changed cell-cell spread characteristics. 
Interestingly, M45, the MCMV homologue of HCMV UL45, is reported as a determinant 
of endothelial cell tropism.  
 
With respect to proposed novel ORFs identified by in silico analysis, in most cases, we 
found no evidence for transcript expression. Of those that gave positive hybridisation 
signals, most might be explained by overlapping transcripts from genes in the same 
region and coding in the same direction. Other novel ORFs lie within regions of the 
genome now considered to be non-coding, but where transcripts have previously been 
reported, while the remainder may represent genuine coding ORFs. The lack of signal for 
previously described ORFs that are now considered non-protein coding confirms their 
status as discounted genes.  
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In order to test the microarray system, the temporal expression kinetics of selected virus 
genes were investigated by alternative methods including; real-time PCR, and northern 
blots to check the identity of specific transcripts, and where antibodies were available, 
western immunoblotting to confirm the expression kinetics of specific proteins. The 
expression kinetics obtained for specific genes both differentially and non-differentially 
expressed by these various methods were entirely consistent with those obtained for the 
same genes with the HCMV microarray. It was concluded that the Merlin microarray 
system was a valid and reliable research tool for the investigation of HCMV gene 
expression.  
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HSV    Herpes Simplex Virus  
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1 INTRODUCTION 
1.1  The clinical problem 
The human cytomegalovirus (HCMV) is a member of the Herpesviridae, and is the 
prototype virus representing the Betaherpesvirinae, which includes two other human 
viruses, HHV-6 and HHV-7 (Roizman and Pellett, 2001). In developed countries, the 
prevalence of HCMV infection is estimated at 40 % to 60 % of the population, but the 
incidence increases in the developing world and in the lower socioeconomic groups of 
industrialised societies (Pass, 2001). Transmission of HCMV requires direct contact with 
persons excreting virus in fluids such as saliva, urine, tears, semen and cervical secretions. 
It is estimated that 1 % to 4 % of babies born in the United States and Europe are infected 
with HCMV; symptomatic disease can result in mental retardation, blindness and 
sensorineural deafness (Fisher et al., 2000). Mother to foetus/neonate transmission of 
HCMV is an important factor for maintaining infection within the population, as virus 
can be transmitted via the placenta, during birth, and in human milk (Pass, 2001). Breast-
feeding of neonates has been reported to be the most common route of mother-to-infant 
transmission (Dworsky et al., 1983). HCMV is also the leading opportunistic pathogen in 
immunosuppressed patients, specifically allograft recipients and patients in the advanced 
stages of AIDS. The severity of CMV infection in allograft recipients depends on whether 
HCMV infection was acquired from the donor, the type of organ transplanted and the 
degree of immunosuppression; bone marrow transplant recipients are particularly 
vulnerable to CMV-related pneumonia (Boeckh and Bowden, 1995). Clinical presentations 
of HCMV infection in AIDS patients include retinitis (blindness), oesophagitis and colitis 
(Cheung and Teich, 1999). However, the introduction of highly active anti-retroviral 
therapy (HAART) has resulted in a > 80 % reduction of cytomegalovirus disease in AIDS 
patients, due to the preservation of T-cells and associated cell-mediated immunity 
(Salmon-Ceron, 2001).  
Development of a vaccine for the prevention of maternal and congenital cytomegalovirus 
infection has not been successful. When compared to clinical isolates, the live attenuated 
vaccine strain, Towne, displayed phenotypic changes such as altered growth 
characteristics in vitro and increased trypsin resistance (Plotkin et al., 1975). Immunisation 
of individuals with the Towne strain induced both humoral and cell-mediated immune 
responses to cytomegalovirus (Starr et al., 1981). However, when challenged with the low-
passage Toledo strain (wild-type), volunteers inoculated with the Towne vaccine 
candidate exhibited only limited protective responses (Plotkin et al., 1989). In order to 
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develop a more potent immunogenic vaccine, recombinant Towne/Toledo chimeric 
vaccine strains have been generated. Phase I clinical trials with Towne/Toledo chimeric 
vaccine candidates were well-tolerated in HCMV-seropositive individuals but the 
vaccines failed to boost humoral or cell-mediated immune responses to HCMV, and the 
immunogenicity of the vaccine remains to be tested in HCMV-seronegative persons 
(Heineman et al., 2006). The development of subunit vaccines as an alternative to live 
virus candidates has focused on the viral glycoprotein, gB, a major antigen for the 
induction of neutralising antibodies (Speckner et al., 1999). Phase I clinical trials of gB 
subunit vaccines have been successful in eliciting neutralising antibody responses (Frey et 
al., 1999), but the need for a vaccine that can stimulate sufficient humoral and cell-
mediated immunity remains (Gonczol and Plotkin, 2001).  
Antiviral drugs currently licensed for the treatment of cytomegalovirus disease are 
significantly toxic. Ganciclovir, a nucleoside analogue and derivative of acyclovir, is 
recommended for prophylactic treatment of adult AIDS patients who are CMV 
seropositive, and have CD4+ T-lymphocyte counts of < 50/ml. However, treatment is not 
completely effective and ganciclovir is linked to myelotoxicity. In transplant recipients, 
foscarnet is administered as an alternative to ganciclovir, specifically in cases where bone 
marrow suppression is to be avoided; however, foscarnet has renal toxicity. Ganciclovir 
and foscarnet are reported to exhibit similar levels of effectiveness when used in 
preemptive therapy, where levels of viremia, detection of pp65 antigenemia and detection 
of CMV genomic DNA in the blood are used to monitor infection. Cidofovir is also 
licensed for the treatment of cytomegalovirus disease, but has renal toxicity and is linked 
to neutropenia (Pass, 2001).  
The development of vaccines and more effective anti-HCMV drugs has proved difficult 
due to the lack of an animal model system resulting from the strict species specificity 
exhibited by cytomegaloviruses. Murine cytomegalovirus (MCMV), however, has been 
used as a surrogate system in order to draw parallels for HCMV transmission, infection 
and/or reactivation after immunosuppression and transfusion, but not for the study of 
foetal infection as MCMV, unlike HCMV, does not cross the placenta (Xiao et al., 2000). 
The Guinea pig cytomegalovirus (GPCMV) is reported to be a more accurate model for 
HCMV foetal infection, since GPCMV is able to cross the placental barrier, and shares 
biological characteristics with HCMV (McGregor and Schleiss, 2001). More recently, a 
rhesus macaque model of rhesus cytomegalovirus (RhCMV) infection in utero has been 
used to draw parallels with HCMV infection, as RhCMV crosses the placental barrier and 
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exhibits a similar pathogenesis to that of HCMV in immunocompetent and 
immunocompromised individuals (Lockbridge et al., 1999).  
1.2  Structural components of HCMV particles 
HCMV-infected cells in culture produce three different types of virus particles: virions, 
non-infectious enveloped particles (NIEP), and dense bodies. The electron-dense DNA 
core, containing the viral genome present in virions is absent in NIEPs, while dense 
bodies lack both the nucleocapsid and its DNA core, and are predominantly composed of 
a single tegument protein, pp65 (pUL83) (Irmiere and Gibson, 1983). It is not known 
whether the production of dense bodies is an artefact of the in vitro culture system, as it 
has been suggested that excess viral products might be stored in vacuoles and deposited 
into the extracellular medium (Severi et al., 1992). Neither is it known whether NIEPs are 
produced in vivo.  
Several different types of nucleocapsid structure are produced in HCMV-infected cells 
(Type A, B and C). Type A capsids are dead-end products of abortive DNA packaging 
and lack the viral DNA genome, B capsids are precursors of fully mature particles and 
contain the scaffolding proteins, but lack the DNA genome, while C capsids are mature 
DNA containing nucleocapsids (Gibson, 1996). Fully mature herpesvirus particles contain 
a double-stranded DNA genome that is packaged into an icosahedral-shaped capsid that 
is surrounded by an amorphous protein layer known as the tegument, which is then 
enclosed in a lipid bilayer that is decorated with glycoprotein spikes (Roizman and Pellett, 
2001). Previous studies estimated that the HCMV particle contained ~ 30 viral proteins, 
but a more recent assessment of HCMV particles identified 71 virus-encoded proteins 
(Varnum et al., 2004).  
1.2.1 The  capsid 
All herpesvirus capsids are composed of 150 hexon capsomeres, 12 penton capsomeres 
and 320 triplex structures that bind the capsomeres together. The particle is organised on 
a  T = 16 icosahedral lattice; however, aspects of capsid structure can vary between 
members of the herpesvirus family. HCMV B capsids (precursors of fully mature C 
capsids) have a diameter of 130 nm, compared to 125 nm in HSV-1, resulting in a 17 % 
increase in the overall capsid volume. Such differences in capsid size between HCMV and 
HSV-1 have been attributed to the spacing between hexamers and their relative tilt, the 
morphology of the hexon tips and the average diameter of the scaffold (Butcher et al., 
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1998). The HCMV genome is ~ 50 % larger than HSV-1, thus a 17% increase in the capsid 
volume would not appear sufficient to allow packaging of the HCMV genome. However, 
the HCMV genome is packaged at a higher density, with an average inter-layer spacing of 
23 Å compared to 26 Å in HSV-1 (Bhella et al., 2000).  
The HCMV capsid contains four structural proteins: the major capsid protein (MCP; 
pUL86), the minor capsid protein (mCP; pUL85), the minor capsid binding protein (mC-
BP; pUL46) and the small capsid protein (SCP; pUL48A) (Mocarski and Tan Courcelle, 
2001). The MCP in HCMV (VP5 in HSV-1) forms the hexons (capsid faces) and pentons 
(capsid vertices), which are connected by the triplex proteins, themselves formed by the 
mCP (VP23 in HSV-1) and the mC-BP (VP19c in HSV-1). The SCPs share the least 
sequence similarity among the HCMV and HSV-1 capsid proteins. It has been reported 
that the SCP is essential for HCMV infection in vivo (Borst et al., 2001), but its homologue 
in HSV-1 (VP26) is dispensable for the formation of stable capsids in tissue culture (Desai 
et al., 1998). In HSV-1, VP26 is located at the hexon tips and was originally thought to 
have a role in directing tegument attachment to the capsid (Zhou et al., 1995), but it was 
later demonstrated that VP26 minus virions and wild-type virions are identical in 
tegument attachment patterns (Chen et al., 2001). Despite the sequence divergence 
between the HCMV SCP and HSV-1 VP26, it has been shown that SCPs also decorate the 
tips of the MCP hexon subunits (Yu et al., 2005). Tegument attachment to the capsid has 
not been fully resolved in either HCMV or HSV-1, but involves attachment to the capsid 
pentons, hexons and triplexes in HCMV (Chen et al., 1999), and the pentons in HSV-1 
(Zhou et al., 1999). The capsid itself is constructed around a scaffold consisting of the 
HCMV assembly protein (pUL80A), and three other scaffold proteins that are all 
generated by auto-proteolytically cleaved pUL80, which contains protease activity in the 
amino-terminal half. Following construction of the capsid, the scaffold proteins are 
cleaved in order to allow them to vacate the nucleocapsid, so that the genomic DNA can 
then be packaged (Gibson, 1996; Welch et al., 1991). 
1.2.2 The  envelope 
HCMV particles have a lipid bilayer envelope, which is derived from host intracellular 
membranes into which viral glycoproteins are embedded. The acquisition of the envelope 
is thought to occur in two separate stages, for which an envelopment-deenvelopment-
reenvelopment model has been proposed (Mettenleiter, 2002). The first envelopment stage 
occurs by budding of DNA containing HCMV C capsids at the inner nuclear membrane 
into the lamellar space, followed by deenvelopment by fusion with the outer nuclear 
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membrane and then release of the naked capsids into the cytoplasm (Buser et al., 2007). 
Tegument proteins are thought to be added to the capsid in the cytoplasm, although a few 
may be added earlier when in the nucleus. Most tegument proteins are thought to 
aggregate on the cytoplasmic surface of membranes derived from the trans-golgi network, 
and which also contain viral envelope glycoproteins. Budding of the naked virus particle 
into the vacuole generates the tegumented and enveloped virus particle contained within 
a transport vesicle (Sanchez et al., 2000). However, this model is not universally accepted 
as two diverse pathways have been identified in HSV-1 envelopment. The first pathway is 
based on the envelopment-deenvelopment-reenvelopment model as mentioned above. 
The second pathway involves direct access of the capsids from the nucleus to the 
cytoplasm through impaired nuclear pores, and the capsids are then enveloped by 
budding from membranes derived from the rough endoplasmic reticulum (RER), trans-
golgi apparatus, or large intracellular vacuoles (Leuzinger et al., 2005).  
Approximately 50 glycoproteins are thought to be encoded by HCMV, but the majority 
have not yet been studied, and it is not clear which are expressed on the host cell surface 
and/or in the virion envelope (Mocarski and Tan Courcelle, 2001). Three major 
glycoprotein complexes are found in HCMV particles. Glycoprotein B (gpUL55) is a type 
1 transmembrane protein that forms a homodimeric glycoprotein complex termed gcI. 
This complex binds to heparan sulphate proteoglycans to facilitate entry into host cells, 
and is also required for cell-to-cell spread of infection (Navarro et al., 1993; Boyle and 
Compton, 1998). Sequence analysis reveals that four gB subtypes exist, and that sequence 
variation is at its highest between codons 448 to 480 (Chou and Dennison, 1991). Such 
sequence variation is probably linked to immune evasion, as nearly all individuals 
develop anti-gB neutralising antibodies, reaching a neutralisation efficiency of 50 % at 
most (Speckner et al., 1999).  
Glycoprotein complex gcII is composed of gM (gpUL100) and gN (gpUL73), which forms 
a gM/gN disulphide linked dimer that exhibits heparin-binding activity, thus having a 
role in virus entry and membrane fusion (Kari et al., 1992; Mach et al., 2000). These genes 
are essential for HCMV replication in fibroblasts as expression of one without the other 
leads to altered glycosylation and/or distribution phenotypes, resulting in replication 
deficient viruses (Hobom et al., 2000; Mach et al., 2000). Recently, it was demonstrated 
that the disulphide bond between gM and gN molecules was not required for complex 
formation or translocation of the gCII complex into the assembly compartments (Mach et 
al., 2005). However, disruption of the C-terminal domain of gN led to a reduction of 
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secondary envelopment of HCMV capsids, suggesting a critical role for gN in mediating 
this process (Mach et al., 2007).  
Glycoprotein complex gcIII is composed of gH (gpUL75), gL (gpUL115) and gO 
(gpUL74), and is required for viral entry into host cells, since antibodies that mimic the 
gH/gL complex and bind to the same cell surface receptor as gCIII prevent HCMV from 
penetrating the cell membrane (Keay et al., 1991). Proteins that complex with gH/gL in 
EBV have cell tropism functions, and it is thought that HCMV gO might have a similar 
role (Mocarski and Tan Courcelle, 2001). Binding of gB or gH to cell surface receptors 
induces intracellular signalling that results in the expression of the cellular transcription 
factors SP1 and NF-κB (Yurochko et al., 1997).  
1.2.3  The tegument   
A recent assessment of the HCMV particle proteome identified 14 tegument proteins 
(Varnum et al., 2004). The tegument is a complex multifunctional structural component of 
the virus particle. Tegument proteins have a diverse range of functions that include: 
particle architecture, virus egress, trans-activation of immediate-early gene expression, 
and preparation of the cellular environment for lytic replication (see Table 1.1).  
The most abundant tegument proteins are pp65 (pUL83) and pp150 (pUL32), comprising 
~ 18 % and ~ 20 % of the total virion protein mass respectively (Irmiere and Gibson, 1983; 
Zipeto et al., 1993). Despite its abundance, pp65 is dispensable for growth in tissue culture 
(Schmolke et al., 1995). After infection, particle-delivered pp65 localises to the nucleus, but 
its function at this very early stage remains unknown. Expression of the UL83 (pp65) gene 
occurs at early-late times PI, and nascent pp65 is localised in the nucleus throughout the 
replication cycle, but at late times PI, is also accumulated in the cytoplasm (Hensel et al., 
1995). It has been shown that pp65 has serine/threonine protein kinase activity capable of 
both autophosphorylation and phosphorylation of IE1 (Gilbert et al., 1996). It was also 
reported that pp65 prevents cleavage of IE1, therefore inhibiting the presentation of IE1 
peptides via MHC class I (Gilbert et al., 1996). The association of pp65 with a cellular 
protein, Polo-like kinase (PIK1) might have effects on intracellular signalling, sub-cellular 
location and substrate specificity (Gallina et al., 1999).  
The basic-phosphoprotein, pp150 is an immunodominant protein for which 85 % to 90 % 
of HCMV seropositive individuals have antibodies (Mocarski and Tan Courcelle, 2001). 
pp150 is modified by O-linked N-acetylglucosamine, a modification associated with 
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nuclear localisation. Initial investigations reported that like pp65, pp150 was localised in 
the nucleus at early times PI, but was found in the cytoplasm only at late times PI (Hensel 
et al., 1995); however, other workers only detected pp150 exclusively in the cytoplasm 
(Sanchez et al., 2000). As pp150 binds the MCP (Baxter and Gibson, 2001), it is possible 
that pp150 is involved in tegument attachment.  
Other tegument proteins include the transactivators pp71 (pUL82), pUL69, pTRS1/pIRS1, 
which activate the virus immediate-early (IE) promoter/enhancer and other virus and 
cellular promoters. The tegument is also reported to contain multiple members of the 
US22 gene family: pUL23, pUL24, pUL43, pUS22 (Adair et al., 2002); pUL36, 
pTRS1/pIRS1 (Mocarski and Tan Courcelle, 2001); pUS23 and pUS24 (Varnum et al., 2004; 
Feng et al., 2006). pUL99 (pp28) is also a tegument protein and was reported to be 
essential for virus replication and envelopment of HCMV capsids (Silva et al., 2003). 
Together, these suggest a complex role for tegument proteins from initiating lytic 
infection, evading immune defences and/or modifying the cellular environment, to 
maturation and egress of virus particles.   
1.3  The HCMV genome and its coding potential 
HCMV is the largest member of the herpesvirus family with a linear double-stranded 
DNA genome of 235646 bp (strain Merlin; GenBank accession number AY446894). The 
genome is organised into two segments, designated UL and US, which are flanked by 
inverted repeat sequences (TRL/IRL and IRS/TRS) allowing the formation of four 
genome isomers: to date, two isomers have been shown to be viable (Mocarski and Tan 
Courcelle, 2001; Borst et al., 1999). HCMV gene predictions originally based on the AD169 
laboratory strain predicted 208 ORFs of more than 100 amino acids (Chee et al., 1990) 
These ORFs were given prefixes of TRL, UL, IRL, IRS, US or TRS depending on the 
location of the ORF within the genome. However, the AD169 and Towne strain genomes 
lack 15 kbp and 12 kbp of sequence respectively, which are present in the UL/b’ region of 
the genome in clinical isolates and the low passage Toledo strain. The 15 kb DNA 
sequence lacking in AD169 was reported to contain at least 19 ORFs. Moreover, the 
Toledo strain differs from clinical isolates, in that sequences from the Toledo UL/b’ region 
are present in inverted orientation (Cha et al., 1996). Some stocks of AD169 (i.e. the 
sequenced AD169 genotype published by Chee et al., (1990)) also lack 929 bp of additional 
sequence from the UL42/UL43 region that are present in other laboratory stocks 
worldwide (Dargan et al., 1997). DNA sequence comparison between HCMV (AD169 plus 
the missing 15 kb fragment from the Toledo strain) and the chimpanzee cytomegalovirus 
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(CCMV) was undertaken to assess the number of HCMV protein coding ORFs. This study 
discounted 51 ORFs, predicted 10 new ORFs and modified the coding of a further 24 
ORFs. It was therefore predicted that HCMV clinical isolates (i.e. wild-type), encodes 165 
ORFs (Davison et al., 2003). It was later demonstrated that the low passage HCMV strain 
Merlin accurately reflected the wild-type complement of 165 genes, except for a point 
mutation in gene UL128 leading to a truncated protein (Dolan et al., 2004). Thirteen 
different gene families arising from gene duplication events during evolution have been 
identified: RL11, UL25, US1, GPCR (G-protein coupled receptor), UL14, UL82, US2, UL18, 
UL120, US6, US22, UL146 and US12. In addition, 40 herpesvirus-common ‘core’ genes are 
located centrally within UL, and have homologues in all members of the herpesviruses 
(Davison et al., 2003). A detailed map of the HCMV strain Merlin genome is shown in Fig. 
1.1. Note that the genes are colour-coded in accordance with their respective gene family 
etc.  A table of the Merlin ORFs, their known or predicted function and their homologues 
in CCMV and MCMV is shown in Table 1.1. 
A different analysis of AD169 coding potential was undertaken using an in silico based 
approach. The Bio-Dictionary Gene Finder (BDGF) algorithm was used to interrogate the 
AD169 genome and the additional 15 kb sequence present in the Toledo strain. This 
analysis discounted 37 ORFs predicted by Chee et al. (1990) and identified a further 12 
new ORFs (Table 1.2). It was therefore estimated that wild-type HCMV isolates encode 
192 unique ORFs (Murphy et al., 2003a). Murphy et al. then set out to compare the coding 
potential of clinical and laboratory strains of HCMV. They sequenced the genomes of six 
HCMV isolates that had been cloned in the form of bacterial artificial chromosomes 
(BAC), two of which were from the laboratory strains (AD169 and Towne), one from the 
low passage laboratory strain (Toledo), while the others were prepared from clinical 
isolates (designated as PH, TR and FIX). A database was generated for the ORFs in the six 
HCMV genomes that encode polypeptides of ≥ 80 amino acids. The BLASTp algorithm 
was used to identify ORFs in all four clinical isolates that had not been previously 
recognised, and subjected them to additional filters: the presence of an AUG start codon, 
and an overlap of < 396 bp. This method identified 29 previously unrecognised ORFs 
(Murphy et al., 2003b) (Table 1.2). However, there is no evidence to suggest that any of the 
novel ORFs proposed by Murphy et al. are protein coding.  
1.3.1  HCMV transcript mapping 
Like other herpesviruses, HCMV has a genome that is densely packed with ORFs, but 
contains relatively few polyadenylation signals required for transcription termination and 
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Figure 1.1. Gene map of the Merlin strain of HCMV (Modified from Dolan et al.,
2004) 
Gene families are grouped accordingly, those coloured red represent the
herpesvirus core genes (located centrally within the genome) and code for proteins
involved in DNA replication, and structural proteins. The terminal regions of the
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HCMV  Function  MCMV  CCMV 
RL1    RL1 
RL5A RL11  family    
RL6 RL11  family    
RL10 Virion  envelope  glycoprotein    RL10 
RL11  RL11 family; IgG Fc-binding membrane glycoprotein    RL11 
RL12  RL11 family; putative membrane glycoprotein    RL12 
RL13  RL11 family; putative membrane glycoprotein    RL13 
UL1  RL11 family; putative membrane glycoprotein     
UL2 Putative  membrane  protein    UL2 
UL4  RL11 family; virion glycoprotein    UL4 
UL5  RL11 family; putative membrane glycoprotein    UL5 
UL6  RL11 family; putative membrane glycoprotein    UL6 
UL7  RL11 family; putative membrane glycoprotein    UL7 
UL9  RL11 family; putative membrane glycoprotein    UL9 
UL10  RL11 family; putative membrane glycoprotein    UL10 
UL11  RL11 family; membrane glycoprotein    UL11 
UL13  Putative secreted protein     UL13 
UL14  UL14 family; putative membrane glycoprotein    UL14 
UL15A Putative  membrane  protein    UL15A 
UL16  Membrane glycoprotein; inhibits NK cell cytotoxicity    UL16 
UL17    UL17 
UL18  UL18 family; putative membrane glycoprotein; MHC-I homologue; possibly inhibits NK 
cell cytoxicity 
 UL18 
UL19    UL19 
UL20 Putative  membrane  glycoprotein    UL20 
UL21A    UL21A 
UL22A  Putative secreted glycoprotein     UL22A 
UL23  US22 family; tegument protein  M23  UL23 
UL24  US22 family; tegument protein  M24  UL24 
UL25  UL25 family; tegument phosphoprotein   M25  UL25 
UL26  US22 family; tegument protein; transcriptional activator of MIEP  M26  UL26 
UL27   M27 UL27 
UL28 US22  family  (spliced)  M28  UL28 
UL29 US22  family  M29 UL29 
UL30   M30 UL30 
UL31   M31 UL31 
UL32  Major tegument phopshoglycoprotein (pp150)l; very immunogenic; binds to capsids  M32  UL32 
UL33  GPCR family; membrane protein; putative chemokine receptor ; virion protein  M33  UL33 
UL34 Represses  US3  transcription  M34  UL34 
UL35  UL25 family; tegument phosphoprotein; interacts with UL82 protein  M35  UL35 
UL36  US22 family; immediate early tegument protein; inhibitor of caspase-8-induced apoptosis 
(vCIA) 
M36 UL36 
UL37  Immediate-early envelope glycoprotein; possible auxilliary role in DNA replication; exon 
1 product is mitochondrial inhibitor of apoptosis (vMIA) 
M37 UL37 
UL38   M38 UL38 
UL40  Putative membrane glycoprotein; inhibits NK cell cytotoxicity    UL40 
UL41A Putative  membrane  protein    UL41A 
UL42 Putative  membrane  protein    UL42 
UL43  US22 family; tegument protein   M43  UL43 
UL44  Processivity subunit of DNA polymerase (ICP36)  M44  UL44 
UL45  Large subunit of ribonucleotide reductase; tegument protein  M45  UL45 
UL46  Minor capsid-binding protein (mC-BP)  M46  UL46 
U47  Tegument protein; possible role in intracellular transport; binds to UL48 protein  M47  U47 
UL48  High molecular weight tegument protein; binds to UL47  M48  UL48 
UL48A  Small capsid protein (SCP)    UL48A 
UL49   M49 UL49 
UL50  Inner nuclear membrane protein; role in egress of capsids from nucleus  M50  UL50 
UL51  Role in DNA packaging  M51  UL51 
UL52  Role in DNA packaging   M52  UL52 
UL53  Nuclear matrix protein; tegument protein; role in egress  M53  UL53 
UL54  Catalytic subunit of DNA polymerase   M54  UL54 
UL55  Virion glycoprotein gB; component of gCI  M55  UL55 
UL56  Putative subunit of terminase; exhibits nuclease activity  M56  UL56 
UL57 Single-stranded  DNA-binding  protein  M57  UL57 
UL69 Regulatory  protein;  tegument  M69  UL69 
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HCMV  Function  MCMV  CCMV 
UL70  Component of DNA helicase-primase complex  M70  UL70 
UL71 Putative  membrane  protein  M71  UL71 
UL72  Derived from deoxyuridine triphosphatase; enzymatically inactive  M72  UL72 
UL73  Virion glycoprotein; gN; component of gCII  M73  UL73 
UL74  Virion glycoprotein; gO,; component of gCIII    UL74 
UL75  Virion glycoprotein; gH; component of gCIII  M75  UL75 
UL76  Virion-associated regulatory protein  M76  UL76 
UL77  Role in DNA packaging  M77  UL77 
UL78  GPCR family; putative chemokine receptor  M78  UL78 
UL79    M79 UL79 
UL80  Protease (N terminus) and minor capsids scaffold protein (C terminus)  M80  UL80 
UL80.5  Major capsids scaffold protein    UL80.5 
UL82  UL82 family; (pp71; upper matrix protein); transcriptional activator  M82  UL82 
UL83  UL82 family; tegument phosphoprotein (pp65; lower matrix protein) suppresses 
interferon response 
M83 UL83 
UL84  UL82 family; role in DNA replication; exhibits nucleocytoplasmic shuttling; 
transdominant inhibitor of IE transcription 
M83 UL83 
UL85  Minor capsid protein (mCP)  M85  UL85 
UL86  Major capsid protein (MCP)  M86  UL86 
UL87   M87 UL87 
UL88 Tegument  protein  M88 UL88 
UL89  Putative ATPase subunit of terminase  M89  UL89 
UL91   M91 UL91 
UL92   M92 UL92 
UL93  Role in DNA packaging; tegument protein  M93  UL93 
UL94  Tegument protein; binds single-stranded DNA  M94  UL94 
UL95   M95 UL95 
UL96 Tegument  protein  M96 UL96 
UL97  Serine-threonine protein kinase; tegument protein; roles in DNA synthesis, DNA 
packaging and nuclear egress; phosphorylates UL44 protein 
M97 UL97 
UL98 Deoxyribonuclease  M98 UL98 
UL99  Myristylated tegument phosphoprotein (pp28)  M99  UL99 
UL100  Virion glycoprotein; gM; component of gCII  M100  UL100 
UL102  Component of DNA helicase-primase complex  M102  UL102 
UL103 Tegument  protein  M103 UL103 
UL104  Portal protein; possibly interacts with terminase  M104  UL104 
UL105  Component of DNA helicase-primase complex; helicase  M105  UL105 
UL111A  Viral interleukin 10 (vIL-10)     
UL112  Role in transcriptional activation or organising DNA replication proteins  M112  UL112 
UL114  Uracil-DNA glycosylase; roles in excision of uracil from DNA and temporal regulation  M114  UL114 
UL115  Virion envelope glycoprotein; gL; component of gCIII  M115  UL115 
UL116 Putative  membrane  glycoprotein  M116  UL116 
UL117 CC  chemokine   UL117 
UL119  IgG Fc-binding membrane glycoprotein related to COX-2  M119  UL119 
UL120  UL120 family; putative membrane glycoprotein   M120  UL120 
UL121  UL120 family; putative membrane glycoprotein  M121  UL121 
UL122  Immediate-early transcriptional activator (IE2); interacts with basal transcription 
machinery and cellular transcription factors; specific DNA-binding protein 
M122 UL122 
UL123  Immediate-early transcriptional activator (IE1); enhances activation by IE2; interacts with 
basal transcriptional machinery; disrupts ND10 
M123 UL123 
UL124 Putative  membrane  glycoprotein    UL124 
UL128  Putative secreted protein; putative CC chemokine    UL128 
UL130  Putative secreted protein    UL130 
UL131A  Putative secreted protein    UL131A 
UL132 Putative  membrane  protein    UL132 
UL148 Putative  membrane  protein    UL148 
UL147A Putative  membrane  protein    UL147A 
UL147  UL146 family; putative secreted glycoprotein; putative CXC chemokine    UL147 
UL146  UL146 family; secreted glycoprotein; CXC chemokine    UL146 
UL145    UL145 
UL144  Putative membrane glycoprotein; TNF receptor homologue    UL144 
UL142  UL18 family; putative membrane glycoprotein; MHC-I homologue    UL142 
UL141  UL14 family; membrane glycoprotein; inhibits NK cell cytoxicity by downregulating 
CD155 
 UL141 
UL140 Putative  membrane  protein    UL140 
UL139 Putative  membrane  glycoprotein    UL139 
UL138 Putative  membrane  protein    UL138 
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HCMV  Function  MCMV  CCMV 
UL136 Putative  membrane  protein    UL136 
UL135  Putative secreted protein    UL135 
UL133  Putative membrane protein     UL133 
UL148A Putative  membrane  protein    UL148A 
UL148B Putative  membrane  protein    UL148B 
UL148C Putative  membrane  protein    UL148C 
UL148D Putative  membrane  protein    UL148D 
UL150  Putative secreted protein    UL150 
IRS1  US22 family; immediate early transcriptional activator; tegument protein; involved in 
shutoff of host protein synthesis 
 IRS1 
US1 US1  family   US1 
US2  US2 family; membrane glycoprotein; selective degradation of MHC-I and MHC-II    US2 
US3  US2 family; immediate-early gene; membrane glycoprotein; inhibits processing and 
transport of MHC-I and MHC-II 
 US3 
US6  US6 family; putative membrane glycoprotein; inhibits TAP-mediated peptide transport    US6 
US7  US6 family; membrane glycoprotein    US7 
US8  US6 family; membrane glycoprotein; binds to MHC-I    US8 
US9  US6 family; membrane glycoprotein    US9 
US10  US6 family; membrane glycoprotein; delays trafficking of MHC-I    US10 
US11  US6 family; membrane glycoprotein; selective degradation of MHC-I    US11 
US12  US12 family; putative multiple transmembrane protein    US12 
US13  US12 family; putative multiple transmembrane protein    US13 
US14  US12 family; putative multiple transmembrane protein    US14 
US15  US12 family; putative multiple transmembrane protein    US15 
US16  US12 family; putative multiple transmembrane protein    US16 
US17  US12 family; putative multiple transmembrane protein    US17 
US18  US12 family; putative multiple transmembrane protein    US18 
US19  US12 family; putative multiple transmembrane protein    US19 
US20  US12 family; putative multiple transmembrane protein    US20 
US21  US12 family; putative multiple transmembrane protein    US21 
US22  US22 family; tegument protein; released from cells  m128Ex3 
m139 
US22 
US23 US22  family  m140 
m143 
US23 
US24 US22  family  m141 US24 
US26 US22  family  m142 US26 
US27  GPCR family; membrane protein    US27 
US28  GPCR family; membrane protein; broad spectrum CC chemokine receptor; mediates 
cellular migration 
 US28 
US29 Putative  membrane  glycoprotein    US29 
US30 Putative  membrane  glycoprotein    US30 
US31 US1  family   US31 
US32 US1  family   US32 
US34  Putative secreted protein    US34 
US34A Putative  membrane  protein    US34A 
TRS1  US22 family; immediate-early transcriptional activator; tegument protein; involved in 
shutoff of host protein synthesis and capsids assembly 
 TRS1 
 
 
Table 1.1.  HCMV ORFs in strain Merlin, and associated homologues in MCMV and 
CCMV. 
The table shows the ORFs in HCMV strain Merlin (Dolan et al., 2004), with the associated 
homologues in MCMV (Rawlinson et al., 1996) and in CCMV (Davison et al., 2003). The 
MCMV genome is not yet fully annotated. 
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ORF  Merlin (Genome Position)  Strand  Reference 
ORF1 19446  19696  R 
ORF2   37178  37492  R 
ORF3 95417  95730  F 
ORF4 95470  95777  F 
ORF5 96843  97081  F 
ORF6 134719 135090  F 
ORF7 146369 146897  F 
ORF8 146369 146563  R 
ORF9 171496 172179  F 
ORF10 171872  172150  F 
ORF11 3729  3996  F 
ORF12 234784  234946  R 
Murphy et al.2003a 
C-ORF1 2103  2411  F 
C-ORF2 2505  2194  R 
C-ORF3 3656  3393  R 
C-ORF4   7647  7919  F 
C-ORF5 9143  8820  R 
C-ORF6 23893  23636  R 
C-ORF7 29239  29631  F 
C-ORF8 35007  35282  F 
C-ORF9 35626  36045  R 
C-ORF10 43175  43519  F 
C-ORF11 46367  46711  R 
C-ORF12 53935  54294  R 
C-ORF13 54728  54988  F 
C-ORF14 54901  55518  F 
C-ORF15 120492  120752  R 
C-ORF16 157314  157583  R 
C-ORF17 159230  159547  F 
C-ORF18 161724  161975  R 
C-ORF19      
C-ORF20 166444  166824  F 
C-ORF21 168066  168470  F 
C-ORF22 168531  168797  F 
C-ORF23 176123  176401  F 
C-ORF24 185685  185047  F 
C-ORF25 190448  190897  R 
C-ORF26 190553  191008  F 
C-ORF27      
C-ORF28 210088  210369  F 
C-ORF29 212116  212409  R 
Murphy et al.2003b 
RL3 3740 3933  F 
RL4 793  472  R 
RL5 4772 5006  F 
RL8 7757 8092  R 
RL9 7920 8348  F 
UL21 26832  27359  R 
UL41 54294  54719  R 
UL60 93829  94130  R 
UL61 94555  95277  R 
UL101 147662  148009  F 
US5 201445  201825  F 
US25 221325  221864  F 
J1S 235125  235262  R 
Chee et al., 1990 
 
 
Table 1.2. Additional ORFs that were contained in the HCMV microarray. 
The table shows the Merlin genome coordinates for novel putative ORFs, and previously 
described ORFs that are now considered to be non-protein coding. Note that the 
coordinates for C-ORF19 and C-ORF27 could not be identified. 
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the subsequent addition of a polyadenylate tail on the free 3’-end of mRNAs. 
Consequently, many spliced and non-spliced HCMV genes share polyadenylation signals, 
leading to the generation of 3’ co-terminal groups of genes within specific regions of the 
HCMV genome (Wing and Huang, 1995; Smuda et al., 1997; Guo and Huang, 1993). Some 
HCMV ORFs also overlap, e.g. UL146/UL147A (Lurain et al., 2006); while others are 
spliced, e.g. UL122/UL123 (Awasthi et al., 2004) and UL37 (Adair et al., 2003). To 
illustrate the point, a transcript map for HCMV ORFs is shown in Fig. 1.2. The data in the 
figure is partly obtained from published sources (green arrows), and partly speculative 
(black arrows), which does not take into account differential use of promoters and/or 
polyadenylation signals. A reference list for the mapped HCMV transcripts are shown in 
Table 1.3.  
1.4  The replication cycle 
1.4.1  The major stages of the HCMV replication cycle 
HCMV is able to infect a wide range of cell types in vivo including fibroblasts, epithelial 
cells, smooth muscle cells and endothelial cells (Sinzger et al., 1995). The virus is 
disseminated within the host via leukocytes (monocytes and neutrophils) in the 
peripheral blood (Sinzger and Jahn, 1996). The following description of the HCMV 
replication cycle has been deduced from studies of infected fibroblast cells. Recent studies 
with epithelial and endothelial cells have revealed differences in the mechanism of entry 
and in maturation and release of infectious progeny; the HCMV replication cycle in 
fibroblasts then serves only as a model system.  
 
Attachment of HCMV particles to heparan sulphate on the host cell surface precedes 
penetration via pH-independent fusion of the virion envelope and the host cell surface, 
releasing the viral nucleocapsid into the cytoplasm (Compton et al., 1992). HCMV capsids 
then associate with microtubules and are transported to the outer surface of the nucleus 
(Ogawa-Goto et al., 2003), with similar kinetics described for HSV-1 (Sodeik et al., 1997). 
Viral DNA is then deposited into the nucleus through a nuclear pore. The linear virus 
DNA circularises in the nucleus and replicates at intranuclear structures, which are 
associated with the periphery of promyelocytic protein (PML)-oncogenic domains (POD) 
(also known as ND10) (Penfold and Mocarski, 1997). The periphery of ND10 domains are 
also the site for the initiation of immediate-early gene expression. The particle delivered 
tegument protein pp71 (pUL82) and cellular hDaxx are reported to play an important role 
in HCMV genomic DNA deposition at the ND10 structures, and subsequent replication 
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Table 1.3. References for mapped HCMV transcripts. 
 
 
 
Leach and Mocarski, 1989  UL44 
Scott et al., 2002 US34 
Guo and Huang, 1993 US18, US19, US20 
Liu et al., 2002 US3 
Romanowski and Shenk, 1997  IRS1, TRS1
Rawlinson et al., 1993; Awasthi et al., 2004 UL122/UL123 
Leatham et al., 1991 UL115, UL116, UL117, UL119
Smith et al., 1996 UL105 
Scalzo et al., 1995 UL103, UL104 
Smith and Pari, 1995 UL102 
Wing et al., 1995 UL93, UL94, UL95, UL96,
UL97, UL98, UL99 
He et al., 1992 UL84, UL85, UL86 
Smuda et al., 1997; Kiehl et al., 2003  UL54, UL55, UL56, UL57
Hyun et al., 1999 UL47, UL48 
Adair et al., 2003 UL36, UL37, UL38 
Liu et al., 2002 UL35 
Biegalke et al., 2004 UL34 
Reference HCMV Genes  
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Figure 1.2. HCMV transcript map (Modified from Dolan et al., 2004). 
The arrows shown in black are predicted transcripts that are drawn from the start of the ORF to the
nearest proximal poly(A). The green arrows represent transcripts that have been mapped and
reported in the literature, references are given to these in Table 1.3.  
US3 
spliced 
180  
and onset of gene expression (Ishov et al., 1997; Ishov et al., 2002). However, the role of 
ND10 domains for HCMV DNA replication and the initiation of gene expression are 
controversial, since recent reports have suggested that ND10 domains form part of the 
cells intrinsic anti-viral defence mechanisms (Tavalai et al., 2006; Woodhall et al., 2006).  
 
The circular DNA genome is thought to replicate by a ‘rolling circle’ mechanism leading 
to the formation of concatemeric DNA, which is cleaved into unit length during 
packaging (LaFemina and Hayward, 1983; McVoy et al., 2000). Genes required for the 
replication of HCMV DNA are UL36-UL38, UL44, UL54, UL57, UL70, UL84, UL102, 
UL105, UL112-113, UL122(IE2)/UL123(IE1), TRS1/IRS1. Initiation of DNA replication 
occurs at the lytic-phase replicator (ori-Lyt), located centrally within the UL region of the 
genome. Herpesvirus core genes required for the formation of the core replication 
machinery are UL54 (DNA polymerase), UL44 (DNA polymerase processivity factor), 
UL57 (single stranded DNA binding protein), and UL70-UL102-UL105 (helicase-primase 
complex). The remaining genes listed above are presumed regulatory proteins, as IE1/IE2 
and TRS1/IRS1 are transactivators of gene expression. UL36-UL38 expression is also 
required for ori-Lyt dependent replication in human fibroblasts, but not in Vero cells, and 
UL36 and UL37 are known inhibitors of apoptosis (Goldmacher et al., 1999; Skaletskaya et 
al., 2001). UL84 is known to interact with IE2, and activate the ori-Lyt promoter in order 
initiate DNA replication, although the detailed mechanisms of this process at present 
remain unknown (Sarisky and Hayward, 1996; Xu et al., 2004a and b). pUL84 also 
functions as a transdominant inhibitor of IE2 transactivation (discussed in section 1.5.3.2). 
UL112-113 are thought to recruit replication-fork proteins (Ahn et al., 1999).  
 
Concatemeric virus DNA is cleaved into unit length by the viral terminase activity and 
packaged into capsids through a portal located at one unique vertex. The portal protein is 
coded by UL104, and acts as a dock for the terminase enzyme, itself composed of two 
subunits coded for by UL56 and UL89 (Dittmer et al., 2005). Packaging of the viral DNA 
into the capsids is a dynamic process that requires the ATPase activity of the terminase 
enzyme in order to ‘pump’ the DNA into the capsid. The ATPase activity of the HCMV 
terminase enzyme is reported to be exclusive to pUL56 (Hwang and Bogner, 2002). 
However, recent evidence suggests that pUL89 contains an ATPase catalytic site, ATPase 
motor motifs, a zinc finger, DNA cutting sites and portal binding sites (Champier et al., 
2007). Following packaging of the genomic DNA, capsids containing DNA are 
translocated from the nucleus into the cytoplasm. Tegumentation is thought to occur in 
the nucleus and in the cytoplasm; the capsids are then transported to the cell surface and 
released from the cell (see section 1.2).  
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1.4.2  Kinetic class of gene expression 
Herpesvirus genes are transcribed by host cell RNA polymerase II in a regulated temporal 
cascade; virus genes are subsequently classified into three kinetic classes: immediate-early 
(IE), early (E), or late (L). The first viral gene products to be made during the replication 
cycle are expressed in the absence of de novo protein synthesis from ~ 1 h PI, and include 
the major immediate-early transactivators UL123/UL122 (IE1/IE2), together with 
accessory proteins TRS1/IRS1, UL36-UL38, US3 and UL115-UL119. The major 
transactivator of HCMV gene expression is IE2 (86 kDa), which acts co-operatively with 
IE1 (72 kDa) and the accessory proteins to regulate the expression of the early and late 
genes. Cellular transcription factors such as NF-κB, SP-1, Elk-1, NF-Y and CREB are also 
utilised to regulate both viral and cellular gene expression (Mocarski and Tan Courcelle, 
2001).  
Expression of the early genes starts from 4–12 h PI and is dependent on the presence of 
the immediate-early proteins. The early genes tend to code for non-structural proteins 
required for DNA replication, packaging and maturation of virus particles. Inhibitors of 
DNA replication such as phosphonoacetic acid (PAA) or ganciclovir (GCV) do not affect 
the transcription of early genes, and these drugs can be used to assign genes to the early 
or late kinetic classes. The late genes code for structural proteins and can be sub-divided 
into early-late (E-L) and true-late (L) genes. True-late (L) protein synthesis is dependent 
on DNA replication, whereas proteins for early-late (E-L) genes are expressed in small 
amounts in the presence, but larger amounts in the absence of DNA synthesis inhibitors 
(Mocarski and Tan Courcelle, 2001).  
 
1.4.3  HCMV induced effects on intracellular signalling 
To date, the HCMV induced effects of intracellular signalling have been studied in 
fibroblasts only, therefore, the specific effects of HCMV particle binding to other cell types 
and their effects on intracellular signalling may differ. However, the stimulation of 
intracellular signalling pathways by HCMV infection of fibroblasts serves as a model. 
HCMV particles form transient attachments to the surface of host cells via heparin 
sulphate proteoglycans (HSPG), followed by stable interactions of HCMV glycoproteins 
gB, gH, and others (see section 1.2.2), to surface receptors such as the epidermal growth 
factor receptor (EGFR) tyrosine kinase, and possibly other receptor tyrosine kinases 
(RTK), or the tumour necrosis factor receptor (TNFR), and Toll-like receptor (TLR). Stable 
attachment of viral glycoproteins to cell surface receptors leads to the activation of the 
   36 
 
  
mitogen-activated protein kinase (MAPK) signalling pathway and the interferon-response 
pathway. Virus entry into the host cell is also mediated by the interaction of viral 
glycoproteins with the host cell surface receptors: pH independent membrane fusion 
(fibroblasts) or endocytosis (epithelial and endothelial cells) (Fortunato et al., 2000; Evers 
et al., 2004). A simplified diagram showing the HCMV induced effects on intracellular 
signalling in infected fibroblasts is shown in Fig 1.3.  
 
Stimulation of the MAPK/ERK signalling pathway occurs by the activation of epidermal 
growth factor receptor (EGFR) tyrosine kinase via binding of HCMV gB, resulting in the 
recruitment of phosphatidylinositol-3-kinase (PI3-K), which phosphorylates and converts 
PIP to PIP2. Activation of EGFR also stimulates phospholipase C (PLC-γ), which 
hydrolyses PIP2 to diacylglycerol (DG) and inositol-triphosphate (IP3). This in turn, leads 
to the activation of protein kinase C (PKC) via DG, and IP3  induced release of Ca2+, 
stimulating further second messenger activity (Evers et al., 2004). Protein kinase B (Akt) is 
also stimulated downstream of PI3-K signalling (Fig. 1.3), which in turn activates p70S6K 
(a serine/threonine kinase). Protein kinase B (Akt) and p70S6K both promote cell survival 
(anti-apoptosis) (Kandel and Hay, 1999). It has been reported that inhibition of PI3-K 
activity using drugs resulted in approximately 10,000 fold reduction in infectious virus 
progeny, suggesting an important role of PI3-K signalling for HCMV lytic infection 
(Johnson et al., 2001b).  
 
The activation of NF-κB occurs by PI3-K phosphorylation of IκB via IκB kinase (IKK), 
which results in IκB ubiquitin-mediated proteasomal degradation. Since IκB is an 
inhibitor of NF-κB, this is then free to translocate to the nucleus, where it activates cellular 
genes and induces the HCMV MIEP, and subsequent expression of HCMV early genes 
(Evers et al., 2004). Note that induction of NF-κB also occurs downstream of TNFR and 
TLR signalling. NF-κB activation leads to the expression of cytokines such as TNF-α and 
Il-1β, thus inducing the innate anti-viral defence programme. However, it has been shown 
that NF-κB signalling is transient, and at late times PI, HCMV late proteins are thought to 
inhibit the NF-κB signalling pathways (Montag et al., 2006). This is supported by the 
ability of HCMV to inhibit TNFR surface expression (Baillie et al., 2003), and down-
regulate interferon-response factor 3 (IRF3) activation of the interferon response (Abate et 
al., 2004). A diagram depicting the mutual regulation of HCMV and NF-κB is shown in 
Fig 1.4.  
 
Activation of extracellular-signal regulated kinases (ERK) ERK1/2 via MEK1/2 also 
occurs downstream of PI3-K signalling (Fig. 1.3). ERKs have been shown to phosphorylate  
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Figure 1.4. Diagram depicting the mutual regulation of HCMV and NF-κB (Modified
from Montag et al., 2006).  
(A) binding of HCMV activates NF-κB, which leads to the expression of immune response
genes (B) to establish anti-viral defence mechanisms (C). HCMV IE gene expression is co-
stimulated by NF-κB (D) along with viral accessory proteins and other cellular
transcription factors, possibly induced by virus/cell interactions e.g. via EGFR signalling
(E). In turn, it is suggested that HCMV IE proteins activate expression of NF-κB subunit
genes (F). HCMV IE proteins activate the expression of early/late genes (G), which in turn
recognise the cells anti-viral defence program (H), and turn it off (I).  
  
p90RSK (p90 ribosomal kinase), which upregulates CREB (cAMP-response elememt 
binding protein), but also inhibits MYT1, which is a CDC2/cyclin B regulatory kinase. 
Since HCMV infection arrests the cell cycle at the G1/S boundary, and because CREB 
plays a role in activation of the MIEP, this suggests a possible role for ERK activation in 
preparing the cellular environment for HCMV lytic replication (Fortunato et al., 2000). 
HCMV infection of human fibroblasts also induces p38 MAPK signalling at early times PI 
(Fig. 1.3), where HCMV inhibits dephosphorylation of p38. At later times PI, MKK3/6 are 
upregulated, thus stimulating further p38 MAPK signalling (Johnson et al., 2001a). 
Inhibition of p38 signalling using the drug FHPI (4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-
5-(4-pyridyl)1H-imidazole), showed that HCMV DNA replication and late gene 
expression were inhibited, thus demonstrating a critical role for p38 MAPK signalling 
during HCMV infection of fibroblasts (Johnson et al., 1999; Johnson et al., 2000a).  
 
Binding of HCMV gB to EGFR also activates a number of cellular interferon stimulated 
genes (ISGs), which are usually induced by IFN-α, which is a response normally 
associated with anti-viral defence (Navarro et al., 1998; Preston et al., 2001); however, 
different pathways are utilised by IFN-α and HCMV. IFN-α is a secreted cytokine that 
induces a signalling cascade via the JAK/STAT pathway, which leads to the nuclear 
localisation of ISGF3 (interferon stimulated growth factor-3), and activation of ISGs via 
binding of ISGF3 to the interferon-response element (ISRE). However, HCMV induced 
signalling via the interaction of gB/EGFR leads to the formation of a novel ISRE-binding 
protein complex, which contains interferon-regulatory factor 3 (IRF3) and CREB-binding 
protein, upregulating the expression of ISGs (Fortunato et al., 2000). As the infection 
progresses, cellular responses to IFN-α are diminished, thus disarming the anti-viral 
response. The HCMV tegument protein, pp65 (pUL83) has been shown to be an 
antagonist of ISG expression via inhibition of NF-κB, interferon-response factor-1 (IRF1) 
(Browne et al., 2003), and IRF3 (Abate et al., 2004). Interestingly, IE1 (72 kDa) has been 
reported to counteract STAT-mediated interferon signalling (Paulus et al., 2006). 
1.5  Transcriptional transactivation in HCMV infected cells 
1.5.1 Promoter  structure 
The major immediate-early promoter (MIEP) is composed of a promoter-enhancer region 
which spans from -500 to +1 bp (relative to the transcription start site) and is involved in 
the regulation of IE1/IE2 gene expression. A distal regulatory region spans from -1000 to -
500 bp and is thought to repress the MIE promoter-enhancer. The entire region is densely 
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packed with cellular transcription factor binding sites in order to regulate the expression 
of the IE1/IE2 genes. Differentially spliced IE1/IE2 transcripts give rise to four proteins: 
IE1 (72 kDa), IE2 (86 kDa), IE2 (60 kDa), and a true late protein IE2 (40 kDa). Repression of 
IE1/IE2 gene expression occurs via binding of p53 and YY1 at sites on the distal-enhancer, 
or by the binding of IE2 (40 kDa) or IE2 (86 kDa) at the cis repression signal (crs) just 
upstream of the transcription start site (Mocarski and Tan Courcelle, 2001). A diagram 
showing the structure of the IE1/IE2 promoter-enhancer and its subsequent regulation by 
IE1/IE2 spliced variants is shown in Fig. 1.5.  
Early genes have a promoter structure that consists of a TATA box and initiator elements 
just upstream of the transcription start site, and an upstream region spanning 100 to 200 
bp that contains cis-acting regulatory elements for trans-acting viral and cellular proteins. 
Early promoters (and some early-late promoters) also have CAAT or CCAAT boxes in the 
upstream region located between -50 to -100 that can bind cellular transcription factors. 
Transcription does not usually start at the +1 site as RNA polymerase II can begin 
synthesis of mRNA from up to 150 bp upstream of the +1 site; this is referred to as the 
transcript leader (Mocarksi and Tan Courcelle, 2001). A diagram depicting the general 
structure of an early gene promoter is shown in Fig. 1.6A. 
True-late genes have a very basic promoter structure that consists of a TATA box 
upstream of the transcription start site, and no upstream cis-acting regulatory signals. In 
HSV-1, true-late (γ-2) promoters may also have a downstream activation signal (DAS) at 
+20 to +44 (Costa et al., 1981). Expression of the true-late HCMV gene UL94 is reported to 
be fully activated from a promoter fragment from -45 to +1 in a transient expression assay; 
this is also the case for UL99 (pp28) where a fragment from -40 to +6 is sufficient for 
activation (Wing et al., 1998; Depto and Stenberg, 1992; Kohler et al., 1994). Because true-
late promoters lack cis-acting regulatory signals, true-late gene expression is dependent 
on the replication of viral genomic DNA. A diagram depicting the general structure of a 
true-late gene promoter is shown in Fig. 1.6B.  
1.5.2  Switch from immediate-early, to early, to late gene expression 
A UL122 (IE2) mutant Towne-BAC transfected into HFF cells failed to generate viral 
plaques, and mRNA for early genes could not be detected by RT-PCR. This confirmed 
that UL122 (IE2) is an essential gene for the growth of HCMV and is required for the 
switch from E to L gene expression (Marchini et al., 2001). Therefore, the main regulatory 
protein for the switch from IE to E to L gene expression is IE2 (86 kDa); however, IE2 
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(86kDa) transactivation of early and late genes is more efficient in the presence of IE1 (72 
kDa) (Mocarski et al., 1996). IE1 (72 kDa) also influences IE2 (86 kDa) transactivation in 
combination with TRS1/IRS1 ancillary regulators, and other viral IE proteins; US3, UL36, 
UL37 and UL69, which have accessory functions (Iskenderian et al., 1996). The expression 
of some genes is also influenced by the use of alternative promoters, which allows the 
production of both early and late transcripts from the same ORF. Transcripts are 
generated that have the same or related functions but differ in size because different 
promoters or polyadenylation signals are used, while their expression kinetics may also 
differ due to the operation of alternative posttranscriptional regulatory control 
mechanisms (Mocarski and Tan Courcelle, 2001).  
UL4 is an early gene that has three differentially regulated transcription start sites; two 
are expressed at early times, and the third at late times (Chang et al., 1989a and b). UL4 
expression is also influenced by the presence of cellular transcription factor binding sites 
for Elk-1 and NF-Y in an upstream element (Chen and Stinski, 2000). UL4 is one of the 
best characterised examples of posttranscriptional regulation in HCMV infected cells. UL4 
mRNA contains three short ORFs in the 5’ leader, which affect downstream translation of 
the UL4 mRNA. During translation, the second short ORF (uORF2) prevents the release of 
tRNA from the ribosome, thus stalling the translation machinery on the mRNA (Alderete 
et al., 1999). Mutation of the uORF2 initiation codon results in abundant early expression 
of UL4 (Alderete et al., 2001).  
UL44 (DNA polymerase processivity factor) also has three transcription start sites; the 
distal and proximal sites are active at early times, and the middle site is active at late 
times. It has been suggested that the early sites are responsive to the immediate-early 
regulatory proteins, while at late times, the middle site is induced by late-specific 
regulatory cis-acting sequences and TATA-binding transcription factors (Leach and 
Mocarski, 1989). HCMV viruses with mutated UL44 distal or middle TATA elements had 
lower levels of expression of UL44 and of late viral genes, which resulted in slower 
growth of the mutants compared to wild-type. Mutation of the UL44 distal site, but not 
the middle site, also resulted in a reduction in the level of viral DNA synthesis (Isomura et 
al., 2007).  
UL99 (pp28) is a true-late gene for which the promoter sequences from -40 to +6 (relative 
to the transcription start site) are sufficient to induce maximal activation of gene 
expression, therefore, specific upstream elements are not required (Depto et al., 1992; 
Kohler et al., 1994). This has also been observed for the expression of the late UL94 gene, 
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where a promoter fragment from -45 to +1 achieved full activation of UL94 in a transient 
expression assay (Wing et al., 1998). It is therefore probable that HCMV true-late gene 
expression is induced solely from a basic TATA element just upstream of the transcription 
start site. 
1.5.3  Regulatory activities of HCMV immediate-early proteins 
1.5.3.1  Role of IE1 in the transactivation of gene expression  
IE1 (72 kDa) is involved in regulating gene expression from the IE1/IE2 promoter-
enhancer, and also has a role in the efficient expression of early and late genes. IE1 (72 
kDa) is able to transactivate the MIEP indirectly by promoting the binding of NF-κB to the 
18 bp repeats that are distributed along the MIE promoter-enhancer (Cherrington and 
Mocarksi, 1989). UL123-null mutants are able to replicate when cells are infected at a high 
m.o.i., but exhibit a growth defect at a low m.o.i. (Mocarski et al., 1996; Greaves et al., 
1998). In transient transfection assays, the transactivation of viral promoters by IE2 (86 
kDa) alone or in combination with the ancillary regulators, pTRS1/pIRS1 is enhanced by 
the presence of IE1 (72 kDa) (Iskenderian et al., 1996). IE1 (72kDa) alone is a poor 
transactivator of heterologous promoters, but is shown to increase transcription of target 
promoters when co-expressed with IE86 (Hagemeier et al., 1992a; Klucher et al., 1993).  
Interaction of IE1 (72 kDa) with the CCAAT box binding protein, CTF1, induced 
expression from a TATA-less DNA polymerase α-promoter (Hayhurst et al., 1995), while 
IE1 (72 kDa) interaction with the E2F binding factor (E2F1) leads to the activation of the 
TATA-less dihydrofolate reductase (DHFR) receptor promoter (Margolis et al., 1995). 
Thus, the mechanism by which IE1 (72 kDa) influences gene expression from 
heterologous promoters occurs in a TATA box independent manner (Hagemeier et al., 
1992b). IE1 (72 kDa) is also reported to affect the acetylation status of core histone and 
other nuclear proteins in order to promote the expression of viral genes. The acetylation of 
core histone proteins results in chromotin modifications, exposing the DNA sequences 
and activating transcription. HCMV genomic DNA is complexed with histone proteins, 
and it was reported that IE1 (72 kDa) was able to antagonise the action of histone 
deacetylases (HDACs), resulting in the activation of viral gene expression (Nevels et al., 
2004).   
HCMV infection rapidly arrests the progression of the cell cycle at multiple points; G1 
phase, G2/M and G1/S boundaries (Lu and Shenk, 1996); a process that is mediated by 
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the actions of both IE1 (72 kDa) and IE2 (86 kDa). Direct interaction of IE1 (72 kDa) with 
the N-terminus of p107 (retinoblastoma family member protein), results in the 
displacement of p107 from cyclin E/cdk2 (Zhang et al., 2003), which allows cyclin E/cdk2 
to function as a kinase, and leads to the activation of E2F (family of transcription factors 
involved in cell proliferation) responsive promoters (Poma et al., 1996). Further cell cycle 
regulation occurs by IE1 (72 kDa) induction of activator protein (AP-1) gene expression 
via an interaction with a cellular protein kinase, MEKK1, itself a component of the 
MAPK/ERK signalling pathway (see section 1.4.3). AP-1 is composed to two subunits, c-
fos and c-jun, and is reported to be a cellular transcription factor with regulatory roles in 
cell proliferation and cell differentiation (Kim et al., 1999).  
1.5.3.2  Role of IE2 in the transactivation of gene expression 
It is known that IE2 (86 kDa) transactivates heterologous promoters by utilising cellular 
transcription factors to mediate the expression of viral and cellular genes (Lukac et al., 
1994; Kim et al., 2000a). It has been reported that IE2 (86 kDa) transactivation properties 
are based on the ability of IE2 (86 kDa) to act as an adaptor protein to stabilise 
transcription factor II D (TFIID) associated factors on the promoter. This is evidenced by 
the fact that IE1 (72 kDa) can interact with TFIID associated factors, TFII 130 and TFII 110, 
while IE2 (86 kDa) simultaneously binds TFII 130 and the TATA box binding protein 
(TBP), thereby bridging interactions between proteins of the basal transcription 
machinery (Caswell et al., 1993; Lukac et al., 1997; Kim et al., 2000b). The ability of IE2 (86 
kDa) to interact with target proteins is dependent on its phosphorylation status, and 
ERK2 (a MAPK family member), phosphorylates IE2 (86 kDa) at several different sites 
(Harel and Alwine, 1998). Sumoylation of IE2 (86 kDa) is also involved in regulation of its 
transactivation function, where interaction of IE2 (86 kDa) with SUMO-1 is suggested to 
provide IE86 with an additional cellular cofactor interaction motif (Hofmann and 
Stamminger, 2000; Ahn et al., 2001). The SUMO-1 modification of IE2 (86 kDa) is 
enhanced by an interaction with PIAS1 (protein inhibitor of STAT), which has SUMO E3 
ligase activity, thus enhancing sumoylation of target proteins. This may modulate IE2 (86 
kDa) transactivation of viral and cellular promoters (Lee et al., 2003).  
At late times PI, IE2 (86 kDa) and IE2 (40 kDa) function directly to switch off immediate-
early gene expression by binding to a cis-repression signal (crs) located between the 
TATA box and the +1 site at the start of the IE1/IE2 gene locus (Jenkins et al., 1994). It is 
suggested that the repression of US3 gene expression also occurs via binding of IE2 (86 
kDa) and IE2 (40 kDa) at a crs located just upstream of the +1 site (Lashmit et al., 1998), 
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and crs-like sequences have also been identified in the early UL112 and UL4 promoters 
(Arlt et al., 1994; Huang et al., 1995). DNA binding of IE2 (86 kDa) and IE2 (40 kDa) to the 
crs occurs via the C-termini of the two proteins (Schwartz et al., 1994), and is thought to 
inhibit expression by preventing the assembly of the RNA polymerase II transcription 
machinery on the MIE promoter (Lee et al., 1996). The core domain in the IE2 (86 kDa) C-
terminus required for interaction with the crs sequences consists of amino acids 450 to 544 
(Asmar et al., 2004). However, IE2 (86 kDa) transactivation function requires both amino 
and carboxy domains. The domain comprising amino acids 86 to 542 was reported to be 
required for protein/protein interactions with cellular transcription factors: NF-κB, AP-1, 
Sp1, Tef-1, c-jun, junB, ATF-2, protein kinase-A phosphorylated delta-CREB, p300, CBP, 
Nil-2A, CHD-1 and UBF (Spector, 1996).  
As with IE1 (72 kDa), IE2 (86 kDa) interacts with proteins that regulate cell proliferation. 
IE2 (86 kDa) binds the retinoblastoma protein (Rb) preventing Rb inhibition of the E2F 
cellular transcription factor family proteins, leading to the expression of genes associated 
with the S phase of the cell cycle e.g. cyclin E, cdk-2, B-myb, E2F-1, ribonucleotide 
reductase 1 (RR1), ribonucleotide reductase 2 (RR2), thymidilate synthetase (TS), MCM3 
and MCM7 (Hagemeier et al., 1994; Song and Stinski, 2002). The IE2 (86 kDa)/Rb complex 
also alleviates IE2 (86 kDa) repression of the MIEP, but suppresses IE2 (86 kDa) mediated 
transactivation of promoters. It was therefore suggested that Rb function may be a factor 
in the slow progression of the HCMV lytic cycle (Sommer et al., 1994; Choi et al., 1995).  
HCMV infection of fibroblasts, astrocytes and human umbilical vein endothelial cells 
(HUVEC) results in elevated steady-state levels of the tumour suppressor protein, p53 
(Muganda et al., 1994; Lokensgard et al., 1999; Kovacs et al., 1996). However, elevated 
levels of p53 are not associated with the activation of p53 responsive genes in HCMV 
infected cells, as evidenced by decreased levels of p21 (cyclin-dependent kinase inhibitor 
1A), as the expression of p21 is regulated by p53 (Chen et al., 2001). p53 transactivation of 
both viral and cellular promoters is repressed by an interaction of the C-terminal domain 
of IE2 (86 kDa) with p53 (Subler et al., 1992; Tsai et al., 1996), while increased levels of p53 
arise from an interaction of IE2 (86 kDa) with mdm2 (a negative regulator of p53 gene 
expression), leading to the proteasomal degradation of mdm2 by a mechanism not yet 
fully understood (Zhang et al., 2006). The affect of p53 on the replication of HCMV was 
examined in fibroblasts expressing wild-type p53, or in fibroblasts where p53 had been 
deleted. It was found that p53 is sequestered at viral replication centres in the nucleus, 
and that wild-type p53 enhanced the replication of HCMV. Furthermore, a delay in the 
release of infectious virus progeny was also observed in p53 negative fibroblasts 
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(Casavant et al., 2006). Similar delays in the accumulation and release of HCMV were also 
observed in the U373Mg cell line (although the data was not presented in the paper) 
(Casavant et al., 2006). The U373Mg astrocytoma cell line has a point mutation in p53 
codon 273, resulting in an Arg → His substitution, which abates normal p53 function (Van 
Meir et al., 1994). It is known that wild-type p53, unlike mutant p53, can inhibit the 
expression of c-fos, and repress expression from several other cellular and viral promoters 
(Ginsberg et al., 1991). The mutant (R → H) p53 (present in U373Mg cells), unlike wild-
type p53, can induce the expression from some cellular promoters, including the human 
multiple drug resistance gene, MDM1 (Chin et al., 1992). However, it remains unclear as 
to how mutant p53 functions, although interaction of mutant p53 with a constitutively 
expressed cellular heat shock protein (hsc70) was suggested to extend the half-life of 
mutant p53, enhancing the transformation of cells (Finlay et al., 1988). It has been shown 
that various p53 mutants (including the defective p53 protein present in U373Mg cells) 
activated viral and cellular promoters, requiring only the presence of a TATA box, while 
mutant p53 mediated expression was further enhanced by the presence of CREB binding 
sites in the promoter (Deb et al., 1992). It was also reported that HCMV early and late 
gene promoters are activated by IE2 (86 kDa) alone in transient transfection assays in 
U373Mg cells (Klucher et al., 1993; Wu et al., 1998; Wu et al., 2001). Therefore, the 
regulatory functions of mutant p53 are altered in U373Mg cells, leading to the activation 
of viral and cellular promoters, while the synergistic mechanisms of HCMV 
transactivation of early and late promoters by the viral immediate-early proteins may also 
be perturbed in this cell line.  
Although IE2 (86 kDa) is essential for the transactivation of viral promoters, high levels of 
IE2 (86 kDa) are reported to be cytotoxic. As a result, the MIEP is autoregulated by IE82 
(86 kDa) and IE2 (40 kDa) via a cis-repression sequence (crs) upstream of the transcription 
start site. pUL84 also binds to IE2 (86 kDa) in order to mediate the down-regulation of the 
MIEP. In addition, pUL84 is also responsible for the inhibition of IE2 (86 kDa) mediated 
transactivation of heterologous promoters (Gebert et al., 1997). 
1.6 Herpesvirus  tropism 
1.6.1 HCMV  cell  tropism 
During acute primary infection, HCMV infects a range of cell types and organs (Sinzger et 
al., 1995; Sinzger and Jahn, 1996); but the laboratory passage of the virus is generally 
undertaken in fibroblasts since virus yields are highest in this cell type. Unfortunately, 
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long term passage of HCMV in fibroblasts results in changes in the virus, both at the level 
of DNA sequence, and host-range phenotype. Mutations in virus tropism (host-range) 
genes limit the utility of fibroblast adapted HCMV as a research tool, and compromise its 
effectiveness as an in vitro model for viral infection in different cell types. This problem 
was highlighted following simultaneous parallel passage of a fresh HCMV isolate in 
human umbilical vein endothelial cells (HUVEC) or neonatal human dermal fibroblasts 
(NHDF); after the twentieth passage in NHDF, the isolate had lost its ability to induce 
cytopathic effects in HUVEC, and its ability to propagate in HUVEC had diminished 
greatly. However, the same isolate passaged in HUVEC retained natural endothelial and 
fibroblast cytopathogenicity and broad host-range cell tropism. This study demonstrated 
that HCMV encodes genes that confer cell type specific tropism, and that passage of 
HCMV in fibroblasts restricts the host cell range (Waldman et al., 1991).  
During acute primary infection, fibroblasts, smooth muscle cells and epithelial cells 
produce the highest yields of infectious progeny. Peripheral blood mononuclear 
lymphocytes (PBML) and endothelial cells are also infected, and play an important role in 
the dissemination of HCMV. Assessment of PBML cell populations during in vivo or in 
vitro HCMV infections have identified two PBML cell types (neutrophils and monocytes) 
as containing infectious virus, the latter being the predominant infected cell type. 
Monocytes and neutrophils are not permissive for HCMV but simply serve as vehicles for 
the transport of HCMV, where PBML-mediated transfer of virus to uninfected cells at a 
site distal to the original focus of infection is accomplished by transient microfusion 
events (Grundy et al., 1998; Revello et al., 1998; Gerna et al., 2000). Subsequent 
differentiation of monocytes into macrophages results in fully permissivity for HCMV. 
Neutrophils are not capable of further differentiation and replication in neutrophils is 
blocked at the immediate-early (IE) stage of infection (Sinzger et al., 1995). Compared to 
fibroblasts, the growth kinetics of HCMV in monocyte-derived macrophages (MDM) was 
delayed, and the virus was compartmentalised in vacuoles i n  t h e  c y t o p l a s m .  I t  w a s  
therefore inferred that the virus has evolved to replicate without causing lysis of MDM 
cells, thus allowing the virus to evade immune surveillance and spread infectivity by 
direct cell-to-cell contact (Fish et al., 1995).  
Monocytes may also differentiate into dendritic cells (DC), and monocyte-derived 
dendritic cells are also fully permissive for HCMV. Fibroblast adapted, but not HUVEC 
adapted HCMV, loses ability to infect and/or replicate in monocyte-derived DCs. 
Dendritic cells are located in tissues and organs, and present antigens, delivering them to 
the lymph tissue to initiate the process of NK cell destruction. Mature dendritic cells are 
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more active than immature dendritic cells. Thus, the ability of the virus to replicate in 
immature dendritic cells might be expected to interfere with the immune response to 
infection. In addition, the migration of infected dendritic cells to lymph tissues might 
facilitate virus transmission to other body sites (Riegler et al., 2000).  
Endothelial cell tropism has been genetically linked to the ability of HCMV isolates to 
transfer infectivity from infected fibroblasts or HUVEC cells to PMNL (monocytes and 
neutrophils) (Revello et al., 2001). Transfer of the HCMV isolates from HUVEC to PMNL 
is the function of a late viral gene product that appears to mediate microfusion events 
between the infected cell and PMNL cell plasma membranes, facilitating cell-to-cell 
transfer of cytoplasmic contents, including viral and cellular proteins, RNA, and virus 
particles. The infected PMNL cells serve as a transport vehicle for the haematological 
dissemination of virus. Virus transfer is mediated by subsequent microfusion events 
between the infected PMNL cells and uninfected cells, organs and tissues (Gerna et al., 
2000). Clinical isolates serially passaged in human embryonic lung fibroblasts (HELF) 
cells simultaneously lose both endothelial cell tropism and the ability to transfer to PMNL 
cells indicating that the same gene(s) are responsible for both phenotypes (Gerna et al., 
2000). Thus the ability of HCMV to transfer to PMNL can be considered to be a surrogate 
marker for its ability to replicate in endothelial cells, and hence pathogenicity of the virus. 
It follows then that, attenuation of the virus by long-term passage in fibroblast cell culture 
during vaccine production might be a consequence of the lack of transfer between these 
two cell types in vivo (Gerna et al., 2002).  
Latency and persistence are important features of the HCMV life cycle, as they are 
responsible for lifelong infection. HCMV latently infects myeloid progenitor cells of the 
monocyte lineage (Maciejewski et al., 1992; Kondo et al., 1994). It was also suggested that 
HCMV persistently infects aortic endothelial cells, which then serve as a further reservoir 
of virus (Fish et al., 1998). However, it was reported that the virus does not undergo a 
replicative cycle, and that viral infection does not affect the normal growth of aortic 
endothelial cells (Kahl et al., 2000). It must be noted that these observations are yet to be 
confirmed by others. In general, the laboratory strains of HCMV (AD169 and Towne) and 
the low passage clinical isolate (Toledo) are unable to propagate in endothelial cells 
(Bolovin-Fritts and Weideman, 2001).  
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1.6.2  HCMV sequence hypervariability and its effects on cell tropism 
Variation in the DNA sequences of some HCMV genes between different HCMV isolates 
has resulted in the recognition of different genotypes for the same gene e.g. there are four 
different genotypes of the gB gene (Chou and Dennison, 1991). Genotyping of such gene 
sequences can be utilised to identify strains of HCMV in the general population. There are 
a number of HCMV genes where the level of sequence variation is more extensive, 
referred to as variable or hypervariable genes (Dolan et al., 2004; see Fig. 2). The high 
amino acid variability is typically restricted to parts of the ORF, and is associated with 
ORFs that lie near the termini of the UL component of the HCMV genome, and is not a 
feature of the herpesvirus core genes. For the most part, hypervariable genes are thought 
to encode membrane proteins, and therefore, hypervariability might be expected to play a 
role in immune evasion. Although the number of genotypes coded by variable sequence is 
not yet known, it is clear from the high number of such genes that the potential number of 
different strains would be counted in thousands. It might be expected that differences in 
DNA sequence would result in HCMV strains with diffrerent pathogenicities, either 
through differences in immune evasion or cell tropism, though this hypothesis has yet to 
be studied.  
Gene UL55 encodes the essential glycoprotein, gB, required for cell entry and cell-to-cell 
spread (Navarro et al., 1993; Boyle and Compton, 1998). Sequence analysis reveals that 
four major subtypes exist, and that sequence variation is at its highest between codons 448 
to 480 (Chou and Dennison, 1991). Investigation of gB type 1 (gB1) reported this subtype 
to be generally associated with asymptomatic and non-fatal cases of HCMV infection, 
particularly in bone marrow recipients. Symptomatic HCMV infection among bone 
marrow recipients is thought to be associated with the gB type 2 (gB2) subtype (Fries et 
al., 1994). It was also reported that patients can be infected with two or more strains of 
HCMV, exhibiting different gB subtypes, and that the gB subtype did not correlate with 
prevalence in either the blood or urine from infected patients. However, it was reported 
that gB subtype may influence viral tropism in vivo since HCMV bearing either the gB2 or 
gB3 subtypes were able to infect T-lymphocytes, whereas virus with the gB1 subtype was 
not found to be associated with this cell type. It was concluded that gB subtype could 
influence the pathogenesis of HCMV in vivo and that it was linked to differences in viral 
tropism (Meyer-Konig et al., 1998).   
The HCMV UL144 gene has a highly variable DNA sequence and encodes a homologue of 
the human tumour necrosis factor receptor. Three main subtypes, A, B and C, and two 
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minor UL144 subtypes have been reported (Arav-Boger et al., 2001), with variability 
recorded as approximately 20 % over 172 amino acids (Lurain et al., 1999). 
Hypervariability in DNA sequence typically results in very high rates of amino acid 
substitutions. Gene UL146 codes a functional CXC-chemokine, with a role in the 
dissemination of HCMV via monocytes (Penfold et al., 1999). Analysis of UL146 
sequences revealed 14 subtypes, resulting from extensive sequence divergence, with 
amino acid substitutions at approximately 60 % (Dolan et al., 2004; Lurain et al., 2006). 
However, conserved regions include the core CXC motif, and also putative signal 
peptides and the spacing between the cysteine residues (Prichard et al., 2001). Such 
hypervariation and the presence of multiple UL146 subtypes could be a further 
determinant of HCMV virulence in the host.   
1.6.3  HCMV genes involved in cell tropism  
Viral tropism functions can operate at different stages in the replicative cycle of the virus. 
At the most basic level, the virus particle requires the appropriate receptor proteins to 
attach to, or to penetrate the plasma membranes of particular cell types. Binding of 
HCMV to cell surface receptors induces an anti-viral response e.g. interferon and/or cell 
apoptosis, and HCMV has evolved genes that interfere with these responses (Fortunato et 
al., 2000). If these viral functions operate more successfully in one cell type compared to 
another, these viral genes play a role in cell tropism.  
Immediately after entry, herpesvirus particles become associated with the cytoskeleton 
network and are transported from the cytoplasm to a nuclear pore where the capsid 
releases its DNA molecule to enter the nucleus and initiate IE gene expression and viral 
replication (see section 1.4). In the case of non-endothelial-tropic strains of HCMV, it has 
been reported that transport of particles to the nucleus is blocked in endothelial cells 
(Sinzger et al., 2000). HSV-1 viral tegument proteins (VP16, VP22 and US11) are required 
for binding of the particle to the motor protein complex on microtubules (Diefenbach et 
al., 2002). With respect to non-endothelial-tropic HCMV strains, it may be that genetic 
changes involving a tegument protein(s) might affect cell tropism, since it has been 
reported that HCMV capsids associate with the microtubule network (Ogawa-Goto et al., 
2003), and HCMV particles lacking the pUL47 and pUL48 tegument proteins have a post-
entry defect, resulting in abortive infection (Bechtel and Shenk, 2002).  
Apoptosis or programmed cell death is an innate property of many cell types, and can be 
induced when under viral attack. This suicide function operates to arrest viral replication 
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and prevent the spread of viral progeny in the host. The M45 gene of MCMV has strong 
anti-apoptotic function that confers endothelial cell tropism (Brune et al., 2001). The 
MCMV M45 homologue in HCMV is UL45; however, it was reported that pUL45 was not 
a determinant of HUVEC cell tropism, and although pUL45 exhibited a mild anti-
apoptotic effect, it was of a much lower potency than that of M45 (Hahn et al., 2002). 
HCMV encodes other genes whose products inhibit apoptosis. HCMV gene UL37 is 
contained within a highly-differentially-splice d  r e g i o n  o f  t h e  v i ru s  g e n o m e  w i t h i n  t h e 
gene locus UL36-UL38 (Adair et al., 2003). UL37 was found to have anti-apoptotic 
function, and was denoted vMIA (viral mitochondria-localised inhibitor of apoptosis). It 
was demonstrated that vMIA localised in the mitochondria and inhibited Fas-mediated 
apoptosis. No sequence similarity was detected between vMIA and the cellular 
equivalent, Bcl-2. It was therefore concluded that vMIA belongs to a new class of 
apoptosis inhibitors (Goldmacher et al., 1999). Further interrogation of UL37 identified 
two domains within exon 1, the first domain is required for trafficking of UL37 protein to 
the mitochondria, while the second domain prevents apoptosis by inhibiting the release of 
cytochrome c from the mitochondria (Hayajneh et al., 2001). It was later reported that a 
vMIA-Bax complex was formed, thus preventing Bax-induced mitochondrial membrane 
permeabilisation, and subsequent cell apoptosis (Arnoult et al., 2004). 
The UL36 gene also codes for an anti-apoptotic factor, which was denoted the vICA (viral 
inhibitor of caspase-8 induced apoptosis). It was reported that the vICA inhibits apoptosis 
by directly binding to and inactivating caspase-8, a protein intermediate of the Fas-
mediated apoptosis pathway. As with vMIA, no sequence similarity was detected 
between vICA and the cellular regulatory proteins of caspase-8 activity. It was concluded 
that vICA represents a novel class of viral apoptosis inhibitor (Skaletskaya et al., 2001). 
Murine cytomegalovirus (MCMV) gene M37 (a homologue of HCMV UL37) also localises 
in the mitochondria. A gene knockout of M37 severely diminishes the ability of MCMV to 
grow in vivo but not in vitro. Thus, M37 is a virulence factor and might be required for 
viral replication in vivo in certain cell types or tissues (Lee et al., 2000).  
The UL128 gene locus provides an important cell tropism function. All HCMV isolates 
adapted to growth in fibroblasts invariably acquired mutations in one or more of three 
adjacently located genes UL128, UL130 and UL131A (termed the UL128 gene locus). This 
gene locus is clearly detrimental for virus growth in fibroblasts, but is indispensable for 
growth in endothelial and epithelial cells, and also infection of PMNL cells (monocytes 
and macrophages) (Akter et al., 2003; Hahn et al., 2004; Wang and Shenk, 2005a), and 
monocyte-derived dendritic-cells (Gerna et al., 2005). It was reported that two 
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glycoprotein gH complexes are present in HCMV infected cells: gH-gL-gO, and gH-gL-
pUL128-pUL130. It was shown that the gH-gL-gO complex is sufficient for the entry of 
HCMV particles into fibroblasts, but the gH-gL-pUL128-pUL130 complex is also required 
for entry into epithelial and endothelial cells (Wang and Shenk, 2005b). Furthermore, the 
expression of pUL131A was reported to be required for the release of virus from 
endothelial cells; in contrast, wild-type pUL131A impaired the release of virus from 
infected fibroblasts (Adler et al., 2006).  
1.6.4  Role of viral determinants for cell tropism in non-human herpesviruses 
RhCMV gene Rh10 encodes an endothelial specific tropism factor, designated vCOX-2 
(Rue et al., 2004), that is a homologue of cellular cyclooxygenase-2 (COX-2) – an enzyme 
required for the synthesis of eicosanoids which function to mediate innate immunity, 
homeostasis, and inflammatory responses (Smith et al., 2000). It was found that a 
recombinant vCOX-2 deletion mutant (∆10RhCMV) was not able to replicate in 
endothelial cells (Rue et al., 2004). HCMV does not code a vCOX-2 homologue, but it has 
been shown that HCMV infection induces cellular COX-2 expression in infected cells, and 
that inhibition of cellular COX-2 resulted in decreased yield of HCMV, indicating an 
important role for COX-2 in HCMV replication, and suggesting that HCMV genes 
inducing up-regulation of COX-2 are involved in pathogenesis (Speir et al., 1998). 
Many HCMV genes not required for growth in tissue culture, but retained in clinical 
isolates, are presumed to have roles in pathogenesis, immune evasion or cell/tissue 
tropism in vivo (Cha et al., 1996; Dargan et al., 1997). Examples of such genes have been 
identified in other herpesviruses. VZV ORF47 (HSV-1 homologue of UL13) is dispensable 
for growth in vitro, but essential for VZV replication in T cells and skin cells, identifying 
t h i s  g e n e  a s  a n  e s s e ntial virulence factor in vivo (Moffat et al., 1998). VZV ORF10 
(homologous to HSV-1 VP16) encodes a tegument protein that is dispensable for growth 
in vitro, but is required for growth in vivo in epidermal and dermal cells (Che et al., 2006).  
Murine cytomegalovirus (MCMV) infection of mice resembles that of HCMV infection in 
humans in many aspects, including the ability to replicate in different cell types and 
organs. The characterisation of MCMV tropism factors that allow MCMV to replicate 
within different cell types is an area of focused research. The generation of transposon 
insertion MCMV mutants and their ability to replicate in vitro in NIH 3T3 cells, and in the 
lungs, liver, spleen, kidneys and salivary glands of BALB/c and SCID mice has been 
investigated. It was shown that a mutant in gene M43 (RvM43) was able to replicate to 
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high titres in NIH 3T3 cells and in all the tissues examined, except for salivary glands 
where it exhibited a growth defect. It was therefore suggested that gene M43 was a viral 
determinant of salivary gland tropism (Xiao et al., 2000). Other MCMV viral determinants 
of cell tropism include M83 and M84, which are homologues of the HCMV gene, UL83 
(pp65). It was shown that the MCMV M83 and M84 deletion mutants were able to 
replicate to wild-type levels in NIH 3T3 cells, but both mutants exhibited a growth defect 
in the spleen, liver and kidneys during in vivo infection. In addition, the M83 mutant was 
severely attenuated in the salivary glands (Morello et al., 1999). 
 Further MCMV determinants of cell tropism include the US22 family members (HCMV 
homologues are shown in backets): m142 (IRS1), m143 (TRS1), M36 (UL36), m139, m140, 
and m141. This study investigated the ability of MCMV transposon insertion mutants of 
the US22 gene family to replicate in fibroblasts, macrophages and endothelial cells. It was 
shown that M36, M43, m139, m140 and m141 were each viral determinants of macrophage 
tropism; m139, m141 and m141 proteins interact to provide the essential function. The 
tropism function of M36 was directly related to its anti-apoptotic function (Menard et al., 
2003).  
1.7  Application of microarray technology to the study of viruses 
DNA microarrays have proved a powerful tool for the first-step, global analysis of gene 
expression. Typically, a DNA microarray consists of DNA oligonucleotide molecules 
(probes) representing hundreds or thousands of ORFs arrayed onto a glass slide. In gene 
expression studies, the arrayed probe sequences interrogate labelled cDNA molecules 
prepared from mRNAs, which then hybridise to their cognate probes. Microarray 
experiments might compare the expression of transcripts from two different samples e.g. 
drug-treated or non-treated cells. The cDNAs prepared from the two samples are labelled 
with either Cy3- or Cy5-conjugated nucleotides. The labelled cDNAs are then hybridised 
to the array in equal concentration to allow binding to the oligonucleotide probes. 
Analysis of the intensity of Cy3- and Cy5-labelled cDNAs prepared from the mRNA 
extracted from cells grown under different conditions allows for comparative gene 
expression studies (Stekel, 2003).  
The applications of DNA microarrays include gene expression analysis, genotyping, 
diagnostics, and mapping of genomic libraries. Furthermore, tissue-based microarrays 
have also been designed in order to study gene expression from multiple tissues on one 
slide, and protein microarray chips have been developed to study nucleic acid-protein, 
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protein-protein, ligand-receptor, drug-protein targets, and also enzyme-substrate 
interactions. Like DNA microarrays, protein arrays are based on the attachment of 
capture molecules such as DNA, antibodies, enzyme substrates etc. to a glass slide, but 
with the hybridisation of fluorescently labelled protein molecules. This section provides 
an overview of microarray studies drawn mainly from herpesvirus literature, and is not a 
fully comprehensive review. However, microarrays for different herpesviruses that are 
novel and/or unique in their design have been selected for discussion in order to 
illustrate the application of this technology in virus research.  
1.7.1  Types of microarrays in current use 
Microarrays are generally printed on one of two solid supports; nylon membranes or 
glass slides. The solid support onto which the nucleic acid probes are printed influences 
the probe design and deposition, as well as the labelling strategy of the cDNA to be 
hybridised to the array. Nylon membrane arrays generally contain nucleic acid probes 
derived from PCR products of ~ 300 bp, and hybridised with cDNA that has been 
synthesised from RNA with direct incorporation of a radiolabelled dNTP. In contrast, 
arrays that are printed onto glass slides usually contain oligonucleotides (50– to 70-mers), 
which have been presynthesised prior to spotting, and hybridised with cDNA that has 
been synthesised and labelled directly or indirectly using fluorescent CyDye molecules 
(typically Cy3 or Cy5). On the other hand, the Affymetrix GeneChip is based on light 
directed  in situ synthesis of 25-mers directly onto glass slides, and hybridised with 
biotinylated-labelled antisense cRNA. For custom DNA microarrays, the deposition of the 
nucleic acid probes onto the solid support is achieved using a robot that contains pins to 
spot the probes. However, inkjet arrays have been utilised for the in situ synthesis of 
oligonucleotide probes directly onto the surface of glass slides, however, unlike 
Affymetrix GeneChips, the inkjet system is inefficient at producing large batches of 
identical arrays (Stekel, 2003). Attempts to optimise microarray data capture have been 
reported, in which alternative methods to label cDNA and detect spot signals have been 
used. The use of nano-sized gold and silver particles for the labelling of cDNA and 
detection of signals is based on the resonance light scattering (RLS) properties of these 
metallic particles. The RLS system is much more sensitive than CyDyes, and the metallic 
particles do not photobleach upon exposure to light, as is the case with fluorophores 
(Yguerabide and Yguerabide, 2001). The RLS system was tested for the HCMV microarray 
described in this thesis. Despite the advantage of requiring a small input of total RNA for 
cDNA synthesis and labelling, the HCMV microarrays gave a poor and uneven 
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background, which was considered detrimental for the capture of high quality spot 
signals (data not shown).  
While commercially available microarrays have been developed e.g. the Affymetrix 
GeneChip – these arrays are based on the cellular genomes of model organisms: Human, 
Arabidopsis, E. coli, C. elegans, mouse etc. To date, virus specific arrays are custom made, 
and have been developed using nylon membrane or glass slide based platforms, using a 
range of labelling and detection methods as discussed above. A HCMV microarray was 
first reported by Chambers et al., (1999) who designed an oligonucleotide array based on 
the AD169 mutant virus sequence, with additional sequences from the 15 kb fragment 
present in the Toledo strain (Chambers et al., 1999). However, this microarray has become 
dated due to recent assessments of the true coding potential of HCMV clinical isolates 
compared to AD169, and comparisons of the coding potential of HCMV with that of 
CCMV (Davison et al., 2003; Dolan et al., 2004; Murphy et al., 2003a and b). Since the 
development of the first HCMV microarray, virus-specific arrays have now been reported 
for other members of the herpesvirus family including: HSV-1 (Stingley et al., 2000), HSV-
2 (Aguilar et al., 2005), VZV (Kennedy et al., 2005), EBV (Li et al., 2006), HHV-6 
(Ohyashiki et al., 2005), KSHV (Jenner et al., 2001; Paulose-Murphy et al., 2001), MHV-68 
(Ahn et al., 2002; Ebrahimi et al., 2003), and MCMV (Tang et al., 2006). 
 
Microarrays have proven to be useful and robust tools for genomics studies, but each 
microarray system (i.e. Affymetrix or custom arrays based on nylon membranes or glass 
slides) is associated with specific advantages and disadvantages. The Affymetrix 
GeneChips can contain tens of thousands of different probes, which are standardised in 
design and manufacture; moreover, the system is also standardised for RNA preparation, 
cRNA synthesis/labelling, hybridisation, signal detection/data capture and 
normalisation. However, this system is not an open source, and there is an absolute 
requirement for the arrayed sequence to be known. This restricts the design of probes in 
regions of genomes that have yet to be fully sequenced and/or annotated. In contrast, 
custom made oligonucleotide based arrays are flexible in design, probes can be ORF- and 
strand-specific, while the system remains an open source. However, there are no 
standardised operating procedures with respect to the hybridisation of cDNA, or the 
subsequent data capture and analysis. These concerns have been addressed by microarray 
specialists through the introduction of MIAME (minimum information about a 
microarray experiment) and the development of public repositories for microarray data 
e.g. ArrayExpress hosted at the European Bioinformatics Institute (EBI) (Rocca-Serra et al., 
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2003). The HCMV microarray data reported in thesis is yet to be deposited into 
ArrayExpress.  
 
1.7.2  Microarrays used in transcriptome profiling of virus gene expression  
Virus-specific custom DNA microarrays have been designed for the following 
alphaherpesviruses: HSV-1 (Stingley et al., 2000), HSV-2 (Aguilar et al., 2005) and VZV 
(Kennedy et al., 2005); beteherpesviruses: HCMV (Chambers et al., 1999), HHV-6 
(Ohyashiki et al., 2005) and MCMV (Tang et al., 2006); gammaherpesviruses: EBV (Li et 
al., 2006), KSHV (Jenner et al., 2001; Paulose-Murphy et al., 2001), and MHV-68 (Ahn et 
al., 2002; Ebrahimi et al., 2003). For the HCMV, HSV-1, HHV-6, and the two MHV-68 
arrays, the kinetic class of virus transcripts were examined using drugs to limit the 
expression to the IE, early and late gene classes. In contrast, the MCMV and the two 
KSHV arrays examined virus gene expression kinetics over a time course. For the KSHV 
arrays, hierarchical clustering was applied to the data in order to identify the major gene 
expression groups (Jenner et al., 2001; Paulose-Murphy et al., 2001). For the MCMV array, 
virus gene expression was examined in fibroblasts (NIH 3T3), and transcripts from ORFs 
apparently not expressed in fibroblasts were then examined in macrophages by real-time 
PCR, thus identifying potential viral determinants of macrophage cell tropism (Tang et 
al., 2006). The VZV array compared virus gene expression at a single time point in two 
different cell lines (MeWo and SVG) (Kennedy et al., 2005). An EBV custom DNA 
microarray was used to profile the transcriptome of EBV in cell lines derived from NK/T-
cell lymphoproliferative disorders (LPD) in parallel with the examination of host cell gene 
expression using a human oligonucleotide array (Zhang et al., 2006).  
The total percentage (%) expression from the various herpesvirus genomes detected by 
each microarray was as follows: HCMV (75 %), HSV-1 (100 %), VZV (97 %), HHV-6 (61 
%), MCMV (84 %), MHV-68 (100 %; Ahn et al., 2002), MHV-68 (100 %; Ebrahimi et al., 
2003), KSHV (100 %, Jenner et al., 2001) KSHV (100 %, Paulose-Murphy et al., 2001), EBV 
(detection limit not reported). For arrays that examined the kinetic class of transcripts 
expressed (HCMV, HSV-1, HHV-6, and both MHV-68 arrays), the results were broadly 
similar irrespective of the virus, with the percentage of genes falling within each class as 
approximately: IE (6 %), early (34 %), and late (60 %). However, this approximation does 
not include the data for the HHV-6 array, where it was shown that the percentage genes 
within each kinetic class were: IE (2 %), E (12 %), and L (86 %). It seems likely that the 
differences may be caused by the incomplete annotation of the HHV-6 virus genome (only 
61 % of probes on the array detected a positive signal), and because the DNA synthesis 
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inhibitor used to define the early genes inhibited both viral and cellular DNA 
polymerases (Ohyashiki et al., 2005). Further difficulty in correlating data from different 
groups is caused by the introduction of a new E-L class. The HCMV (Chambers et al., 
1999) and MHV-68 arrays (Ebrahimi et al., 2003) reported the herpesvirus kinetic classes 
as IE, E, E-L and L. However, for the HSV-1 and MHV-68 (Ahn et al., 2002) arrays, the 
percentage of genes that could be split into E-L and L are likely to be similar to that of 
HCMV and MHV-68 (Ebrahimi et al., 2003). The KSHV arrays investigated changes in 
gene expression in a time course experiment, covering the switch from latently infected 
cells through to lytic replication, revealing four major gene expression groups (as assessed 
by hierarchical clustering), but which roughly corresponded to latency associated genes, 
and the three kinetic classes: IE, E and L (Jenner et al., 2001; Paulose-Murphy et al., 2001). 
Scrutiny of the data published by the various groups showed that in general, viral 
transactivators and anti-apoptotic factors were the first groups of viral genes expressed, 
then enzymes and some tegument proteins, and finally the remaining tegument and 
structural proteins. However, a gene belonging to the early kinetic class in one 
herpesvirus might not be expressed with the same kinetics in another virus. For example, 
the herpesvirus core gene gB, is reported to be expressed with early kinetics in HCMV, 
HSV-1, and KSHV, but is considered a late gene in MHV-68 (supported by both Ahn et 
al., 2002, and Ebrahimi et al., 2003). These studies have shown that although the general 
transcription programme is conserved between different members of the herpesvirus 
family, the kinetic class of expression of some genes may vary between different 
herpesviruses.  
1.7.3  Microarrays used in direct comparative studies of gene expression in 
different viruses  
A microarray was developed to detect both HSV-1 transcripts and the equivalent HSV-2 
homologues in order to compare the transcription profile of these two alphaherpesviruses 
during a lytic infection in a single cell line (NIH 3T3 cells). It was shown that the majority 
of transcripts from HSV-1 and HSV-2 belonged to the same kinetic class, although the 
level and accumulation of HSV-2 transcripts was generally lower than that of HSV-1 
transcripts. Differential gene expression of HSV-1/HSV-2 in NIH 3T3 was examined 
using the correlation function within the Microsoft Excel package to identify significant 
differences in the expression kinetics of individual viral genes over the time course. It was 
shown that the expression of UL4, UL30, UL29 and UL31 differed between these two 
viruses. These genes are all involved in nuclear organisation and viral genome replication, 
and it was suggested that their differential regulation was probably due to different 
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properties of viral replication compartments during infection with HSV-1 compared to 
HSV-2 (Aguilar et al., 2006). This work followed on from an earlier report of a HSV-2 
oligonucleotide microarray that had been applied to compare the global transcription 
programme of HSV-1/HSV-2, showing that the transcriptome profiles of these two 
viruses were very similar (Aguilar et al., 2005).  
 
The cellular response to the alphaherpesvirus members, HSV-1 and pseudorabies virus 
(PRV), during infection of a common permissive cell type (rat embryonic fibroblasts; REF) 
was examined using Affymetrix RGU34A arrays. Despite PRV and HSV-1 displaying 
similarities in genome structure, gene conservation, virion structure, and replication cycle, 
the cellular response to these viruses was diverse. Approximately 1500 cellular genes 
were increased or decreased > 3 fold following infection with HSV-1 and PRV, falling into 
24 different functional classes. However, only 500 of these cellular genes were increased 
or decreased in common, and the remaining cellular genes were expressed in a virus-
specific manner. Classes of genes that were affected during infection with the 
alphaherpesviruses HSV-1 or PRV included anti-viral defence, cell signalling, apoptosis, 
and the heat shock and oxidative stress pathways (Ray and Enquist, 2004).  
 
Similarly, the cellular response to the betaherpesvirus members, HCMV and RhCMV, was 
directly compared in a common permissive cell type (rhesus fibroblasts), in order to 
investigate the pathogenesis of these two viruses. As with the HSV-1/PRV study, it was 
found that there were similarities in the cellular response to HCMV/RhCMV, but virus-
specific expression of some cellular genes was detected for genes involved in metabolic 
and physiological processes,  or cell-cell communication. Surprisingly, the largest 
differences were observed for genes involved in the cellular innate immune response, and 
while HCMV induced expression of ISGs, proinflammatory cytokines etc., genes with 
these functions were not induced in cells infected with RhCMV. It was suggested that 
RhCMV particles have evolved to deter induction of these innate immune responses, in 
contrast to HCMV, which benefits from induction of these cellular responses during the 
early stages of infection (DeFilippis and Fruh, 2005).  
 
These results suggest that while there are shared cellular responses to different viruses 
from the same herpesvirus subfamily, the majority of changes in cellular gene expression 
are virus-specific. In contrast, regulation of expression of virus genes from members of the 
same herpesvirus subfamily are similar. These comparative studies allow virus replication 
to be dissected with respect to the differential regulation of virulence factors, coded by 
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related viruses in the same cellular environment, and also highlight common or diverse 
cellular responses to infection with different virus types.  
 
1.7.4  Microarrays used to determine the effect of herpesvirus infection on cellular 
gene expression 
The effect of herpesvirus infection on cellular gene expression has been examined in 
alphaherpesviruses: HSV-1 (Mossman et al., 2001), VZV (Jones and Arvin, 2003); 
betaherpesviruses: HCMV (Zhu et al., 1998; Browne et al., 2001), HHV-6 (Mayne et al., 
2001); and gammaherpesviruses: KSHV (Poole et al., 2002). These microarray studies have 
shown that the major classes of cellular genes that are modulated during a herpesvirus 
infection have roles in cell adhesion and structure, signal transduction/receptors, basal 
cell machinery (including synthesis, transport, and energy metabolism), immune and 
stress response, cell cycle, and apoptosis. Despite the commonality of functional classes of 
cellular genes affected, examples of virus-specific changes in the cellular transcription 
programme in response to infection with different herpesviruses have also been reported.  
 
HCMV infection results in the induction of interferon stimulated genes (ISG), which 
occurs via intracellular signalling induced by the binding of HCMV particles to the cell 
surface. Increased ISG expression was also maintained in the presence of HCMV gene 
expression during the early stages of infection (Browne et al., 2001). Similarly, HHV-6 and 
VZV induce the expression of ISGs and proinflammatory cytokines (Mayne et al., 2006; 
Jones and Arvin, 2003). In contrast, while HSV-1 infection can also induce ISGs, the 
induction of these genes requires penetration of HSV-1 particles into the host cell, and ISG 
expression is blocked when HSV-1 gene expression is inhibited (Mossman et al., 2001). It 
is likely that the innate anti-viral defence mechanism induced by the interferon response 
is beneficial to HCMV, VZV, HHV-6 and KSHV in the early stages of a lytic infection, but 
is detrimental to HSV-1 infection. This difference in cellular response could highlight a 
major difference in the pathogenesis of HSV-1 infection compared to that of other 
herpesviruses. Interestingly, the induction of ISGs seen in HCMV infected cells was not 
observed during an infection with RhCMV (see section 1.7.3) (DeFilippis and Fruh, 2005).  
 
Other examples of cellular genes that are modulated differently in response to virus 
infection include genes involved in apoptosis. It has been shown that VZV infection of T-
cells leads to the down-regulation of caspase-8 (Jones and Arvin, 2003), in contrast, HHV-
6 infection of T-cells leads to the up-regulation of caspase-8 (Mayne et al., 2001). It was 
suggested that this may reflect the need for VZV to inhibit apoptosis of T-cells to promote 
   61 
 
  
the transfer of virus from T-cells to skin cells, and person-to-person spread of this virus 
(Jones and Arvin, 2003). However, it was also suggested that the different caspase-8 
responses following infection of T-cells with VZV (Jones and Arvin, 2003) or HHV-6 
(Mayne et al., 2001), could be due to the use of primary T-cells (VZV), versus 
immortalised T-cells (HHV-6). A response that was unique to HHV-6 infection of T-cells 
was the induction of IL-18 expression. This cytokine is expressed in demyelinating lesions 
of multiple sclerosis (MS) brains, linking HHV-6 infection with the progression of MS, 
and possibly other auto-immune disorders (Mayne et al., 2001).  
 
It was reported that KSHV infection of human dermal microvascular endothelial cells 
(DMVEC) significantly induced the expression of tissue plasminogen activator (PLAT) 
and endothelial plasminogen activator inhibitor (PAI-1), and dysregulation of TSP1, 
angiopoietin 2, Cys-rich angiogenesis  inducer (IGFBP10), and thrombomodulin, all of 
which may contribute to the process of angiogenesis and the formation of KS lesions. 
Down-regulation of the angiogenesis inhibitor, thrombospondin-1 (TSP1), was also 
observed in KSHV infected DMVECs (Poole et al., 2002). Interestingly, TSP1 is also down-
regulated during HCMV infection in fibroblasts (Zhu et al., 1998) and human retinal glial 
cells (Cinatl et al., 2000), and in U373Mg cells stably expressing HCMV IE1 (72 kDa) (Lee 
et al., 2005). This may draw a common link between the pathogenesis of HCMV (in 
respect to retinitis and astrocyte malignancies), and KSHV with respect to the formation 
of KS lesions.  
1.7.5  Microarrays used to compare the effect of regulatory virus genes on viral 
or cellular transcription 
HSV-1 encodes an immediate-early protein, α27 (UL54), which is involved in the 
posttranscriptional regulation of viral RNA by inhibiting splicing and mediating the 
transport of viral transcripts from the nucleus into the cytoplasm. An HSV-1 mutant with 
a knockout mutation in UL54 was used to examine the regulatory activities of this protein 
with respect to viral gene expression, and also its effects on 57 cellular genes (Stingley et 
al., 2001; see section 1.7.2). The microarray was not able to fully resolve the effects of the 
UL54 knock-out mutant on the transcription programme of HSV-1, because some results 
were in conflict with previously reported observations e.g. the down-regulation of viral 
DNA polymerase (UL30) and helicase-primase (UL52) was not observed using the HSV-1 
array. However, it was shown that immediate-early transcripts such as α4, α47 (US12), 
and  α22 (US1) were increased, suggesting that α27 modulates their levels during 
infection. A HSV-1 gene that was down-regulated was that encoding ICP34.5, which has 
been reported to be a neurovirulence factor. The 57 cellular genes were generally 
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upregulated following infection with the HSV-1 UL54-KO mutant, suggesting that α27 
has a role in the decline of cellular mRNA during a normal HSV-1 infection (Stingley et 
al., 2001).  
 
It has been reported that HCMV IE2 (86 kDa) affects the cell cycle in infected cells by 
progressing quiescent (G0) cells to the G1/S boundary (Song and Stinski, 2005). The effect 
of IE2 (86 kDa) on the transcription programme of quiescent fibroblasts was examined in 
order to identify IE2 (86 kDa) induced cellular genes. This was achieved using 
transducing recombinant adenovirus vectors expressing IE2 (86 kDa) in quiescent 
fibroblasts, and examining the cellular transcriptome using an Affymetrix human genome 
GeneChip. This study showed that IE2 (86 kDa) induced the up-regulation of many E2F 
responsive genes including: myb, cyclin E, cdk-2, E2F-1, ribonucleotide reductase 1, 
ribonucleotide reductase 2, thymidylate synthetase, MCM3 and MCM7; all of which are 
involved in promoting G0/G1 phase transition to the S phase (Song and Stinski, 2002). In 
an analogous microarray study, the transcriptome of U373Mg cells stably expressing IE1 
(72 kDa) was examined in order to gain insight into the potential role of HCMV on the 
pathogenesis of malignant glioma, since a high percentage of malignant gliomas are 
infected with HCMV (Cobbs et al., 2002). It was found that 14 cellular genes were 
modulated, including the down-regulation of glial fibrillary acidic protein (GFAP), TSP-1 
and p53, and it was concluded that suppression of these anti-oncogenic genes contributed 
to the onset of glial tumourogenesis (Lee et al., 2005). These studies show that viral 
regulatory genes can modulate both viral and cellular transcription responses.  
 
1.7.6  Microarrays used to compare of viral gene expression during lytic and 
latent phases of infection 
Microarray studies into herpesvirus gene expression during latent and lytic phases of 
replication have been reported for KSHV (Jenner et al., 2001), and EBV (Li et al., 2006), 
while the changes in expression of cellular genes have been studied during HSV-1 latent 
and reactivation phases (Kent and Fraser, 2005). In the case of KSHV and EBV, a limited 
number of viral genes were expressed during latency (for KSHV: vFLIP, v-cyclin, and 
LANA-1; and EBV: EBNA1, EBNA2, EBER1 and EBER2). Reactivation of KSHV or EBV 
replication led to the expression of viral genes, subsequently defined in KSHV as primary, 
secondary and tertiary lytic genes. The expression of genes associated with an EBV lytic 
cycle were not identified according to the KSHV scheme (Jenner et al., 2001), and were 
reported only as expressed or not expressed (Li et al., 2006). However, both studies 
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revealed that the latency-associated genes were not expressed during the KSHV or EBV 
replication phase.  
 
The effect on the cellular transcriptome was examined during reactivation of HSV-1 from 
latently infected mouse trigeminal ganglia. During latency, 18 cellular genes were up- or 
down-regulated > 2.5 fold, which included immune response genes such as those 
encoding interferon-inducible protein 1, STAT1, and cytokine inducible SH2-containing 
protein 7. Reactivation of HSV-1 resulted in the modulation of 48 cellular genes, including 
many more immune response genes, genes involved in cell signalling (e.g. TNF receptor) 
and cell-to-cell spread of the virus (e.g. alpha 2 catenin) (Kent and Fraser, 2005).  
 
1.7.7  Microarrays used to compare viral gene expression in different cell types 
infected in culture  
Transcriptome profiling of VZV gene expression was compared in the human skin 
melanoma cell line (MeWo) and the human astrocytoma cell line (SVG), because of the 
clinical presentations as varicella or herpes zoster, and the neurotropic nature of the virus 
respectively. The VZV transcriptome was compared at one time point (72 h PI), at which 
maximal CPE was observed in both cell lines. The relative abundance of VZV transcripts 
was then compared in the two cell lines. For the astrocytoma SVG cells, only 20 out of 71 
VZV ORFs were significantly expressed, whereas 68 out of 71 VZV ORFs were 
significantly expressed in skin MeWo cells. Of the top six expressed ORFs in MeWo cells, 
only ORFs 49, 57 and 58 were also significantly expressed in SVG cells. Despite large 
differences in the transcription programme of VZV infection in skin (MeWo) and 
astrocyte (SVG) cells, analysis of differential expression of VZV genes was restricted 
because it was not possible to perform a synchronised high m.o.i. VZV infection of the 
two cell lines, and therefore the differential expression kinetics of viral genes could not be 
studied (Kennedy et al., 2005).  
 
Differential viral gene expression in a time course experiment has been investigated for a 
baculovirus (autographa californica multicapsid nucleopolyhedrovirus; AcMNPV) in a 
time course experiment in two different cell types. The transcriptome profile of AcMNPV 
was determined and compared in insect S. frugiperda (Sf-9) and T. ni (TnHigh-Five) cells. 
Six viral genes displayed differential expression kinetics and the functions of two of these 
are known; one gene, p35, is involved in virus-origin specific DNA replication and 
exhibits anti-apoptotic activity, and the second, gene p10, has a role in stabilisation and 
release of infectious progeny virus from cells at the end of infection. The function of the 
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remaining four differentially expressed genes (lef-6, lef-3, PK-2 and ORF150), are as yet 
unknown (Yamagishi et al., 2003).  
 
Together, the VZV and AcMNPV studies highlighted a number of points regarding the 
design of microarray experiments for differential analysis of viral gene expression in 
different cell types. Firstly, it is important to initiate a synchronised infection in each of 
the cell types studied, and to select time points that allow appropriate comparisons 
between virus gene expression profiles. Secondly, robust statistical analyses are required 
to extract significant and biologically relevant data.  
 
1.7.8  Microarrays designed for the simultaneous comparison of viral and 
cellular gene expression  
Microarrays that include both viral and cellular oligonucleotide probes have been 
reported for HSV-1 (Stingley et al., 2000) and MHV-68 (Ebrahimi et al., 2003), but the 
complement of probes representing cellular targets was limited (< 100). An EBV custom 
DNA mcroarray was used to profile the viral transcriptome in cell lines derived from 
NK/T-cell lymphomas in parallel to the examination of host cellular gene expression 
using a second human oligonucleotide array. Results indicated that EBV genes such as 
BARF-1 (a latency associated protein) was expressed in natural killer cells and T-cell 
lymphoproliferative disorders (NK/T-LPDs), thus supporting the data from earlier 
reports that BARF-1 is expressed in nasopharyngeal carcinoma (NPC) and gastric 
carcinomas. Several EBV lytic genes were also expressed including BKRF3, BDLF3, BFLF2, 
and BHRF1 (the homologue of human bcl-2 proto-oncogene). Cellular gene expression 
that was significantly upregulated included TNFRSF10D, which inhibits toll-like receptor 
(TRAIL) mediated apoptosis, CDK2, a key cell-cycle regulatory factor, and HSPCA, a heat 
shock protein associated with mantle-cell lymphoma (Zhang et al., 2006). While an 
attempt was made to define an EBV - NK/T-LPD molecular signature, the study was 
focused on the in vitro selection of EBV-infected NK or T-cells, and it was suggested that 
clinical samples would be required to clarify these findings. 
 
1.7.9  Viral diagnostic microarrays 
Microarrays have the potential to be ideal tools for viral diagnosis since they allow for the 
parallel screening of different human viruses; microarrays are fast, sensitive and specific, 
though expensive. However, in the case of HCMV at least, careful probe selection would 
be required because different strains of HCMV have different genotypes for some variable 
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sequence genes (see section 1.6.2). The development of viral diagnostic arrays is an 
interesting area of research, and the production of arrays that can detect human 
herpesviruses in human plasma and/or cell culture would be useful. An oligonucleotide 
based microarray that can differentiate between HSV-1, HSV-2, VZV, EBV, CMV and 
HHV-6 has already been developed (Foldes-Papp et al., 2004). The sensitivity (detection 
limit) of this diagnostic array was also enhanced by the use of fluorescently labelled 
dendrimers to optimise hybridisation signals (Striebal et al., 2004).  
Another herpesvirus microarray has been developed for the detection of eight human 
herpesviruses in samples from cerebrospinal fluid (CSF), whole blood, plasma and serum. 
Oligonucleotide probes were designed for the viral DNA polymerase or the DNA 
polymerase processivity factors for each virus: HSV-1 (UL42), HSV-2 (UL30), VZV 
(ORF28), HCMV (UL44), EBV (BALF5), HHV-6A (U38), HHV-6B (U38) and HHV-7 (U38). 
PCR primers were also designed for each virus gene and used for RT-qPCR experiments 
for a direct comparison with the microarray data. It was shown the PCR and microarray 
data were in agreement for 94 % of the tests. However, some negative results for PCR 
were found to be positive in the microarray, and it was thought that these represented 
false-positives, that had not been eliminated during analysis of the microarray data. While 
the PCR and microarray data were largely in agreement, it was reported that each system 
had advantages and disadvantages. Diagnostic PCR tests were performed sequentially 
and therefore could be quite expensive, whereas with the microarray, several viruses were 
detected in a single hybridisation reaction. However, it was noted that optimisation of 
microarray sensitivity was required in order to avoid false-positive detection of viruses 
(Jaaskelainen et al., 2006).   
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1.8  Aims of the thesis 
Human cytomegalovirus (HCMV) is the leading viral cause of neonatal abnormality and 
plays an important role in morbidity and mortality among immuno-compromised 
patients. During acute primary infection, HCMV is present in most organs, (heart, 
kidneys, lungs, spleen and liver), and replicates in many different cell types (fibroblasts, 
epithelial cells, endothelial cells, smooth muscle cells, macrophages and dendritic cells). 
The aims of this study were firstly to determine whether the pattern of HCMV gene 
expression was changed when the virus was grown in different cell types, and secondly to 
explore whether novel ORFs recently proposed by other workers are transcribed. A 
HCMV microarray platform was designed based on the Merlin strain of HCMV, since it 
contains a complete complement of intact ORFs, with the exception of UL128, which has a 
premature termination mutation. The microarray contains probes for all known and 
predicted ORFs. HCMV transcriptome activity was investigated in human foetal foreskin 
fibroblasts (HFFF), human retinal pigmented epithelial cells (RPE) and human astrocyte 
cells (U373Mg) at several time points post infection (PI). To summarise, the aims of this 
investigation were to: 
1.  Design and produce a custom DNA microarray based on the recent reassessment 
of HCMV coding potential. 
2.  Profile the expression of the low passage clinical isolate, Merlin, in permissive cell 
lines; human foetal foreskin fibroblasts (HFFF-2), human retinal pigmented 
epithelial cells (RPE), and human astrocytes (U373Mg).  
3.  Identify HCMV genes whose expression was differentially regulated in the 
different cell types.  
4.  Verify the microarray data using real-time PCR, northern and western blotting 
techniques.  
5.  To correlate virus growth characteristics in each cell type with the kinetics of viral 
gene expression.  
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2 MATERIALS  AND  METHODS 
2.1 Materials 
2.1.1 Chemicals 
All chemicals were molecular biology grade, unless stated otherwise, and were purchased 
from SIGMA-ALDRICH (UK). 
2.1.2 Radiochemicals   
All radiochemicals were purchased from Amersham Biosciences (UK).  
 
2.1.3 Restriction  Endonucleases 
All restriction endonucleases were purchased from New England Biolabs (UK) Ltd., and 
were supplied with their appropriate buffers.  
2.1.4 Antibodies 
 
Table 2.1. List of antibodies 
Antibody  Species  Isotype  Company 
Anti-HCMV US22  Mouse monoclonal  IgG2a Advanced  Biotechnologies 
Inc. 
Anti-HCMV UL83 
(pp65) 
Mouse monoclonal  IgG3  Capricorn Products LLC 
Anti-HCMV UL99 
(pp28) 
Mouse monoclonal  IgG3  Advanced Biotechnologies 
Inc. 
Anti-HCMV  
UL44/FITC 
Mouse monoclonal  IgG1  Dakocytomation 
Anti-HCMV IE1/IE2   Rabbit polyclonal (recognises all 
protein species from the IE1/IE2 
region) 
Kind gift of Dr E. Mocarski 
2.1.5  Composition of solutions and buffers 
Bacterial culture: 
L-broth    10 g/L NaCl, 10 g/L tryptone peptone (Becton Dickinson), 5 g/L  
      yeast extract (Becton Dickinson), pH 7.5 
L-broth agar    L-broth medium with 15 g/L agar (Becton Dickinson) 
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Eukaryotic cell culture: 
PBS      170 mM NaCl, 10 mM Na2HPO4, 3.4 mM KCl, 1.8 mM KH2PO4,  
   6.8  mM  CaCl2, 4.9 mM MgCl2, pH 7.5 
Trypsin  0.25 % trypsin in Tris saline pH 7.7 (140 mM NaCl, 0.7 mM 
Na2HPO4, 5.6 mM dextrose (D-glucose), 24.8 mM Tris-HCl, 2.5 mM 
KCl solution, containing 1 % (w/v) phenol red with 0.1 % (v/v) 
penicillin, 0.1 g/L streptomycin) 
Versene  0.6 mM EDTA containing 0.002 % (v/v) phenol red in PBS 
DNA extraction: 
DNA extraction  20 mM Tris-HCl pH7.5, 2 mM EDTA, containing 1.2 % (w/v) SDS      
buffer 
NTE buffer  140 mM NaCl, 10 mM Tris-HCl pH 7.5, 1 mM EDTA 
RSB buffer  10 mM Tris-HCl pH 7.5, 10 mM KCl, 1.5 mM MgCl2
TE buffer  10 mM Tris-HCl pH 7.4, 1 mM EDTA 
TBE buffer (10X)  1.25 M Tris, 27 mM EDTA, 0.4 M boric acid                                   
Microarray: 
BSA blocking    5 X SSC/0.1 % SDS (v/v), containing 1 % (w/v) BSA                                  
solution 
Northern blotting: 
Orange G (10X)   5 mM Orange G, 1.2 M Sucrose   
MOPS  (10X)    0.4 M MOPS, pH 7.0, 0.1 M sodium acetate, 10 mM EDTA                 
(SIGMA-ALDRICH) 
SSC (20X)    3 M NaCl, 0.3 M tri-sodium citrate 
 
 
SDS-PAGE and western immunoblotting 
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Resolving gel buffer  0.74 M Tris-HCl pH 8.9, containing 1 % (w/v) SDS 
 
Stacking gel buffer  0.122 M Tris-HCl pH 6.7, containing 0.1 % (w/v) SDS 
 
Gel running buffer  52 mM Tris, 53 mM glycine containing 0.1 % (w/v) SDS 
 
Sample buffer (2X)  100 mM Tris-HCl pH 6.7, containing 20 % (v/v) glycerol, 4 % (w/v)  
SDS, 2 % (v/v) β-mercaptoethanol, 0.2 % (v/v) bromophenol blue 
 
Towbins buffer  25 mM Tris, 192 mM glycine, containing 20 % (v/v) methanol 
 
2.1.6  Miscellaneous reagents and commercial kits 
DNA handling: 
 
Platinum Taq  p o l y m e r a s e          I n v i t r o g e n  
 
PureLink Quick Gel Extraction Kit       Invitrogen 
 
Rediprime II Random Prime Labelling System   Amersham Biosciences 
 
S Y B R   g r e e n   I        I n v i t r o g e n  
 
Taq p o l y m e r a s e       Q I A G E N  
 
QIAGEN large construct kit        QIAGEN  
  
RNA handling: 
 
Agarose (nuclease-free)     SIGMA-ALDRICH 
 
Amplification grade DNase I         Invitrogen   
 
Formaldehyde  (36.5-38 % in H2O)    SIGMA-ALDRICH 
 
NorthernMax Formaldehyde Load Dye     Ambion Inc. 
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O r a n g e   G          S I G M A - A L D R I C H  
 
RNA ladder (0.5 – 10 kb)        Invitrogen 
 
Superscript II Reverse Transcriptase     Invitrogen 
 
Tissue culture water (nuclease-free)    SIGMA-ALDRICH 
 
QIAGEN  RNeasy  kit      QIAGEN 
 
Protein handling: 
 
ECL  detection  reagents     Amersham  Biosciences 
 
Rainbow  markers  RPN756     Amersham  Biosciences 
 
Microarray specific materials: 
 
Centricon  columns      Millipore 
 
Hybridisation chamber (10 slide capacity)    GENETIX 
 
LifterSlip™ (25 mm × 20 mm)       Eerie Scientific Company, USA   
 
   
2.1.7  Miscellaneous materials and plastics 
Chromatography  paper  3MM   Whatman 
ECL nitrocellulose western blotting membranes  Amersham Biosciences 
Hybond-N+ nylon membrane      Amersham Biosciences 
Photographic  film      Kodak  Ltd 
Maximum recovery (nuclease-free) pipette tips  Axygen Scientific 
MaxiClear (nuclease-free) 1.5m ml microtubes  Axygen Scientific 
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2.1.8  Computer software and algorithms 
B L A S T n        N C B I  
GeneSpring  version  7.2     Agilent  Technologies 
GRAIL version 1.0          Oak Ridge National Laboratories 
Microsoft  Excel        Microsoft   
Oligo  6        Molecular  Biology  Insights 
ScanArray Express version 3.0      PerkinElmer Inc. 
SPSS  version  13.0      SPSS  Inc.      
Quantity One 1-D Analysis Software     Bio-Rad Laboratories  
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2.2 Methods 
2.2.1 Cell  culture 
Human Foetal Foreskin Fibroblasts (HFFF-2): Cat.# 86031405; European Collection of Cell 
Cultures (ECACC). 
hTERT immortalised Retinal Pigmented Epithelial (hTERT-RPE) cells: Gift of Dr J. Shay 
and Dr W. Wright, University of Texas, Southwestern Medical Centre. 
 U373Mg Astrocytoma cells: Cat.# 89081403; ECACC.  
2.2.1.1  Propagation of cell stocks 
HFFF-2 and U373Mg cell cultures were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10 % (v/v) FCS (DMEM/FCS) and 100 U of 
penicillin/streptomycin (GIBCO), and grown in 175 cm2 flasks incubated at 37 °C in a 
humidified atmosphere comprising 95 % (v/v) air and 5 % (v/v) carbon dioxide. Cultures 
of RPE cells were grown in Dulbecco’s Modified Eagle’s Medium Ham’s F-12 Mix 1:1 
(DMEM F-12) supplemented with 10 % (v/v) FCS in 175 cm2 flasks, and incubated as 
described for HFFF-2 and U373Mg cells. Confluent HFFF-2, RPE and U373Mg cell 
cultures were harvested by pouring off the medium, washing once with versene, and once 
with trypsin/versene solutions in a ratio 1:4. The cells were then resuspended in 10 ml of 
fresh medium and seeded into 175 cm2 flasks with a split ratio of 1:2, with 50 ml of fresh 
medium added per flask.  
2.2.1.2  Storage of cells in liquid nitrogen 
Cells were harvested as outlined above and then pelleted at 500 x g for 10 min at RT. The 
cell pellets were resuspended in storage medium at a density of 1 × 106 cells/ml and 2 ml 
aliquots dispensed into plastic cryovials, which were placed in a polystyrene box and 
frozen overnight to -70 °C. After overnight incubation, the frozen cells were transferred to 
long-term liquid nitrogen storage. Recovery of frozen cells was accomplished by quick 
thawing of cell aliquots at 37 ºC, resuspending in 25 ml of fresh medium and seeding of 
cells in 75 cm2 flasks.  
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2.2.2  Preparation of virus stocks 
HCMV strain Merlin was donated by Dr G. Wilkinson, University of Cardiff. HFFF-2 cells 
were seeded in 175 cm2 flasks containing 50 ml of DMEM/FCS and grown until 90 % 
confluent; the cells were infected with HCMV strain Merlin at a m.o.i. of 0.01 p.f.u./cell in 
an inoculum of 30 ml DMEM/FCS. As the CPE developed, the medium was removed and 
replaced with 14 ml of fresh medium, and the infected cells were incubated at 37 ºC until 
complete CPE was achieved at about 10-15 days PI. The cell supernate was clarified by 
pelleting detached cells at 500 x g for 10 min at RT. Cell debris was removed by 
centrifugation at 10000 x g for 20 min at 20 ºC in a Sorvall RC-5B superspeed centrifuge 
using the SLA-1500 rotor. The cell-released virus (CRV) was then pelleted by 
centrifugation at 40000 x g for 1 h at 20 ºC using the SS-34 rotor. The virus pellets were 
resuspended in fresh medium, pooled and dispensed, and then stored at -70 °C. Adherent 
infected cells were detached by tapping the culture flask and resuspension of the cells in 
either DMEM/FCS for cell-associated virus (CAV) stock preparations or resuspension in 
NTE buffer for DNA extraction. The cell suspension was sonicated to release the CAV and 
the preparation pelleted at low speed to clarify the virus preparation.  
2.2.2.1  Titration of virus stocks 
HCMV titres were determined by plaque-assay on HFFF-2 monolayers. Virus stocks were 
serially diluted in ten-fold steps, and 200 µl of each dilution plated on cell monolayers 
grown in 35 mm diameter tissue culture dishes. Virus was allowed 1 h at 37 ºC to adsorb 
to cells, with gentle shaking every 15 min. Following virus adsorption, cell monolayers 
were overlaid with 2.5 ml of DMEM/FCS. Infected cell monolayers were incubated at 37 
°C until visible plaques were observed (10-12 days PI). The medium was removed and 2 
ml of Giemsa stain was added, and incubated at RT for 3 h. After staining, the fixed cell 
layers were washed with water and the plaques counted using a dissection microscope.   
2.2.3  Extraction of HCMV genomic DNA  
HCMV infected HFFF-2 cells were used to extract HCMV whole genomic DNA. Infected 
cells were harvested into NTE buffer and pelleted by centrifugation at 500 x g for 10 min 
at RT, the supernatant was discarded and the cell pellet resuspended in RSB buffer 
(containing NP40) and incubated on ice for 5 min to lyse the cells, and then pelleted by 
centrifugation as before. The supernatant was considered to be the cytoplasmic fraction 
and was carefully removed. The pellet was resuspended in RSB buffer, then sonicated to 
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release virus particles and to shear cellular and non-encapsidated DNA; this was 
considered to be the nuclear fraction. The cytoplasmic and nuclear sonicate were treated 
with DNase I (200 µg/ml) and RNase A (10 µg/ml) and incubated at 37 °C for 3 h. To 
extract encapsidated DNA, an equal volume of DNA extraction buffer was added, and the 
NaCl concentration adjusted to 0.3 M. The samples were then incubated with proteinase K 
(1 mg/ml) at 55 °C for 1 h. An equal volume of TE buffered phenol was added and mixed, 
and the sample centrifuged at 500 x g for 10 min at RT. The upper phenol layer was 
removed and mixed with an equal volume of TE buffered phenol:chloroform 1:1 (v/v) 
and centrifuged as before. The upper phase was removed and mixed with an equal 
volume of chloroform and centrifuged as before. Finally, the upper phase was removed, 
transferred to sterile dialysis tubing and dialysed against TE buffer overnight at RT. When 
required, DNA was concentrated by the addition of NaCl (to 100 mM), followed by 
ethanol precipitation and pelleting of the DNA (13000 x g for 10 min at RT), washing of 
the pellet in 70 % ethanol, air drying (5 min at RT), and resuspension of the DNA pellet in 
a small volume of sterile distilled water.   
2.2.4  One step virus growth curve 
35 mm tissue culture dishes seeded with 5 × 105 cells/dish of HFFF-2, RPE or U373Mg 
were incubated at 37 ºC overnight. The cell monolayers were then infected with HCMV at 
a m.o.i. of 1 or 6 p.f.u./cell as previously described. After virus adsorption, the cell layers 
were washed twice with 1 ml of DMEM/FCS, and then overlaid with 2.5 ml of fresh 
medium, followed by incubation at 37 ºC. At 0, 24, 48, 72, 96, 120, 144, 168 h PI, infected 
cell cultures were harvested by scraping the cells followed by sonication of the infected 
cell suspension and storage of samples at -70 ºC, prior to titration of virus yield. 
For separate assessment of infectivity contained in the cell-released (CRV) and cell-
associated (CAV) virus fractions of the virus yield, the growth medium was pipetted off 
and pre-cleared by low speed centrifugation to provide the CRV fraction. Pelleted cell 
debris was resuspended in medium and this was used to harvest infected cells by 
scraping off the adherent cells into the medium, followed by sonication to provide the 
CAV fraction. The CAV and CRV virus preparations were then stored at -70 ºC. Virus 
infectivity was titrated on HFFF-2 cells, as previously described. 
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2.2.5  Preparation of mock-infected and HCMV infected total cellular RNA 
75 cm2 flasks containing 6 × 106 cells/flask of HFFF-2, RPE or U373Mg were incubated at 
37 ºC overnight. The cell monolayers were either mock-infected or infected with HCMV at 
a m.o.i. of 6 p.f.u./cell as previously described. After virus adsorption, the cells layers 
w e r e  w a s h e d  t w i c e  w i t h  5  m l  o f  D M E M / F CS ,  a n d  t h e n  o v e r l a i d  wi t h  2 5  m l  o f  f r e s h  
medium and incubated at 37 °C. Total RNA was harvested at 12, 24, 48, and 72 h PI, and 
at 72 h PI for MI cell cultures. The cell monolayers were washed and harvested as 
previously described. After centrifugation at 500 x g for 10 min at RT, the cell pellets were 
lysed using 1 ml of buffer RLT (supplied with the QIAGEN RNeasy kit), containing 1 % 
(v/v) β-mercaptoethanol. Cell lysates were passed through an 18-21 gauge needle 8-10 
times in order to shear cellular and viral genomic DNA. Total cellular RNA was extracted 
using a RNeasy kit (QIAGEN), according to the manufacturer’s instructions. RNA 
samples were quantitated by measuring the optical density at 260 nm, using an 
Eppendorf BioPhotometer. 
 
2.2.6  Assessment of RNA integrity 
The quality of RNA preparations were assessed by examining the integrity of the 28S and 
18S ribosomal bands. 0.2-0.5 µg of RNA was diluted with water (SIGMA) to give a total 
volume of 7 µl, and incubated at 65 °C for 10 min, and then snap-cooled on ice. 3 µl of 5X 
OrangeG loading dye was added to the RNA sample, followed by electrophoresis on a 1 
% agarose/TBE gel containing ethidium bromide. RNA was visualised using short-wave 
UV transillumination, and photographed using the BioRad Gel Doc system. High quality 
RNA exhibits a ribosomal band ratio for 28S and 18S rRNA of 2:1. If the 28S and 18S 
bands were smeared or deviated from the 2:1 ratio, the samples were discarded.  
2.2.7  DNase I treatment of total RNA 
RNA samples used for microarray or quantitative PCR analysis were treated with 
amplification grade DNase I (Invitrogen) to remove any contaminating cellular or viral 
genomic DNA. 80 µl of RNA sample was mixed with 10 µl of 10 X DNase I buffer, and 10 
U of DNase I, then incubated at 25 °C for 15 min. The reaction was terminated by 
treatment with 10 µl of EDTA (25 mM), followed by incubation at 65 °C for 10 min. The 
DNase I treated RNA preparation was then cleaned using QIAGEN RNeasy spin-
columns, according to the manufacturer’s instructions.  
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2.2.8  Synthesis of cDNA 
2.2.8.1  Synthesis of cDNA for microarray hybridisation 
For microarray analysis, CyDye-3 conjugated nucleotides were used to directly label 
cDNA. 25 µg of total RNA from mock-infected or HCMV infected cells was resuspended 
in water (SIGMA) to give a final volume of 9 µl. The two control bacterial spike mRNAs 
(from B.subtilis, see section 2.2.9.1) each prepared at a concentration of 50 ng/µl, were 
mixed in a ratio of 1:1, and 2 µl of the pooled spike mRNA then added to the total RNA 
sample. 4 µl of random hexamer primers (250 ng/µl) were added to the RNA sample, 
which was then incubated at 70 °C for 10 min, and then snap-cooled on ice for 5 min. The 
following reaction mix was added to each sample: 6 µl of 5 X first strand synthesis buffer, 
3 µl of DTT (10 mM), 0.6 µl of dNTP mix (dATP, dGTP, dTTP at 0.5 mM; dCTP at 0.3 mM) 
and 3 µl of Cy3-dCTP (0.1 mM) (Roche), and 400 U of Superscript II Reverse Transcriptase 
(Invitrogen). Samples were then incubated at 42 °C for 2 h, and the resulting labelled 
cDNA immediately stored at -20 °C.  
2.2.8.2  Synthesis of cDNA for quantitative PCR 
2 µg of total RNA from mock-infected or HCMV infected cells was mixed with 1 µl of 
random hexamer primers (250 ng/µl), 2 µl of dNTP mix (each at 5 mM), water (SIGMA) 
to a final volume of 13 µl, incubated at 65 °C for 5 min, and then snap-cooled on ice for 5 
min. 6 µl of 5X first strand synthesis buffer, and 2 µl of DTT (0.1 M) was added to the 
sample and then incubated at 42 °C for 2 min. 200 U of Superscript II Reverse 
Transcriptase was added followed by incubation at 25 °C for 10 min, 42 °C for 2 h, and 
then 70 °C for 15 min, and cDNA samples then stored at -20 °C.   
2.2.9 HCMV  Microarray 
The HCMV microarray work was performed under the guidance of our collaborator Dr. 
Bahram Ebrahimi (see Ebrahimi et al., 2003) of the Liverpool Microarray Facility. 
Protocols and the equipment for microarray hybridisations etc. were provided by Dr 
Ebrahimi during visits to the Liverpool Microarray Facility.  Protocols for the analysis of 
microarray data were decided following discussions with Dr Bahram Ebrahimi, Dr Brian 
Lane (Bioinformatician at the North-West Institute for Bio-Health Informatics (NIBHI)) 
and Dr Ewan Hunter (Senior Scientist at Agilent Technologies), and consultation with my 
supervisor Dr Derrick Dargan.  
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2.2.9.1  Probe design and microarray fabrication 
Microarray oligonucleotide probes were designed using Oligo6 software (Molecular 
Biology Insights). Viral ORFs were defined by 60-mer oligonucleotide probes based on the 
Merlin strain of HCMV (GenBank accession number AY446894), that shared the following 
properties: G+C content in the range of 40-60 %; melting temperature between 85-95 °C; 
lack of homo-oligomers or sequence repeats (Table 2.2). Probes were also selected either 
for regions of the genome that are now considered to be non-coding, or for regions 
containing proposed novel ORFs (Table 2.2). Normalisation control probes were also 
designed for two spiked B.subtilis genes; SpoOB (accession number M24537) and for the 
lys gene for diaminopimelate decarboxylase (accession number X17013) (Table 2.3).  
Probe sequences were interrogated with BLASTn searches against the following 
databases: nr (non-redundant), EST (expressed sequence tag), and HTGS (high-
throughput genomic sequences). Probes that scored an E-value < 0.1 were discarded, 
while those that showed little or no sequence similarity were selected for synthesis and 
microarray deposition. Viral sequences were not filtered out during the BLASTn searches, 
and sequence matches between the probe and the associated viral ORF were used to 
confirm the specifity of the 60-mer oligonucleotide sequence.  
All Merlin ORFs were represented by 3’- and 5’- proximal probes, unless stated otherwise. 
To investigate transcription from the regions now considered to be non-coding (Dolan et 
al., 2003), probes were made for several previously proposed ORFs (Chee et al., 1990). 
Recently proposed novel ORFs (Murphy et al., 2003(a) and (b)) were represented by only 
a 3’- proximal probe. Oligonucleotide probes were synthesised by MWG-Biotech (U.S.A.). 
Microarrays were printed at the Liverpool Microarray Facility by Dr Margaret Hughes. 
All viral oligonucleotide probes were printed in triplicate on Corning GAPS II microscope 
slides at a concentration of 40 pg /spot, using a BioRobotics Microgrid (Genomic 
Solutions). Control features were printed in forward (sense) and reverse (anti-sense) 
orientation (576 positive and 576 negative control features). A gene array list file (GAL) 
was generated during the printing process, to facilitate identification of probe features. 
After overnight incubation in a desiccator at RT, slides were briefly hydrated and snap 
dried on a 100 °C hot plate, and then UV cross-linked at 600 Jcm-2.  Slides were then stored 
in a desiccator at RT prior to hybridisation.  
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Table 2.2. List of HCMV microarray oligonucleotide sequences 
HCMV ORF  5’ or  3’ 
Probe 
Genome 
Position 
Strand  Oligonucleotide Seqeunce (60-mer) 
RL1 5’  1557  F  ACCTCTACGGTCAAACACAACCCCAACTACACGCATACCCCAACGCCAACCCACAGGAAA 
RL5A 5’  5539 R  TGGGAAACATGGGATGACGGTGGAGAGTCTCTATACGATGTGACTAATAATGGTACAACG 
RL6 5’  6148 R  ACGGGTATAGGTAATGCTACTGTGAATGGTAACGCAACTATTTGTGTGTCGAGCTGTGGT 
RL10 5’  8686 F  CCACCAACTGTCTCGTGAAAGCAGAAAATACCCACCTGACATGTAAGTGCAATCCGAATA 
RL11 5’  9162 F  CCTCACGCTTATCATAGTCACGTCGCTGTTTTTGTTCACAACTCAGGGAAGTTCATCGAA 
RL12 5’  10708 F  TCAGGCAGATATAGTCGACGGTGTTACAAAGAGTACAACCACGATGGACCACACGAGGAT 
RL13 5’  11426 F  GCAGCGTCGTCAACCATAATATCTCAAACCAACCGCAGTCATACGAGTAATGCTATCACA 
UL1 5’  12368 F  CCCCTGCAACTTTTCTAGTTACTGGAATCACAATAACTGCGAACTTTGCGGTTGGACACC 
UL2 5’  13283 R  TATCCGTCGTTCGGCAGCCTACCCGCCTCGCACGCTCAGTACGGCTTTCGACTGCTACGC 
UL4 5’  13918 F  CCGTGGAATGGAAGTCTCCCGACCGTCAGATTCCTATGAATATTACTTGCGCTAATTACT 
UL5 5’  14362 F  TTCTAGGCTACTCTGACTGTGTAGATCCCGGCCTTGCTGTGTATCGTGTATCTAGATCAC 
UL6 5’  15514 F  GTAATGACACCCACGCTGGTTACAAACTCCACATTCAGTGTGTCACTTGTTGCGTTGAGA 
UL7 5’  16197 F  CGGTCGTTACGGAGCAGAAGGTTTTACGAGAAGCGGCGAAAATGAAACGTTCCTGTGGTA 
UL8 5’  16713 F  TGCAGTCAACCTCAGCAACGCGACTACGGTCATCCCACAACCTGTAGAATACCCGGCTGG 
UL9 5’  17024 F  GACAATACCATGTACCCCTACAGTTGGATACGGCAGTCATAATATTAGCTTGCATCCGCT 
UL10 5’  18005 F  CCTACGACCCTCCTAAACCTGGTAGACAAAAGACAATGAAAACTACTCCGTTGCCATCAC 
UL11 5’  19076 F  CCCCACTACCACCACCAAAAAGCCCACTACGACTACGAGAACGACAACTACCACAACACA 
UL13 5’  20778 F  GAGAAGGGAATGATGGGAGCCGAGCAAGTGGAAACGACGAGAGAAGGAATAATGCGGGAA 
UL14 5’  21591 F  GCAGCGGCTGAGCCTCTCGTTTCGTCTCATCACCGAGACCGCGGGCACCTACACCTGCGT 
UL15A 5’  22225 F  ATGAAGCGGATGATTCGCAGTCACGGCAGGAAAACGGAGTGTCAGATGACGGGCGCCGGC 
UL16 5’  22774 F  GGTACCGCTGGGATGGGTGTTTTTTGTTCTTTGCTTATCTGCCTCTTCCCCGTGTGCTGT 
UL17 5’  23593 F  CGTCACTGTCGGTTGGAAATGTTGATTCTGGACGAACAGGTGTCTAAGAGATCCTGGGAC 
UL18 5’  24371 F  CCGGTTACGAGGGATTTGGGTGGGACGGGGAAACTTTAATGGAGCTCAAGGATAACCTGA 
UL19 5’  25162 F  GCACTCGTGATGGGTTCTGCGGTCGGTTGACGTCCATCGCCACGAATTCCCACTACACTA 
UL20 5’  26100 F  CGCTGGGAAATGAAACACGGTGCATGCTGCTCCCTAGACAGTATACTCTCAACGCCACGG 
UL21A 5’  27112 R  GGAGGTAGCCCTGTTCCCCAGCTCACCACCGTCACTCAAGGACTCATGCCATCTGTGCGC 
UL22A 5’  27710 F  GAGATGAAGATTACTCCGGGGGAGACTATGACGTTTTGATTACGGATACAGATGGAGGTA 
UL23 5’  28700 R  TACCTATGGACCGACCACATCTACTCTGACTCGTTGACCTTTGTGGCCGAGAGCATCACT 
UL24 5’  29451 R  CGCCCTTTCCTCACTTGCGCTGGCCCGTCGACCTTATCCCCATCGTCGTCGCCTATACCG 
UL25 5’  30911 F  CGAGGGCGATGAGTTTTCCTTCTGCGACAGCGACATCGAAGACTTTGAGCGCGAATGTTA 
UL26 5’  32915 R  ATACTGGAAGCTGCTGGTGGTGACCCAGGGTCAGTTGCGCGTCATCGGCACCATCGGACT 
UL27 5’  34801 R  AGTTTTGTCACCAGTTCCTGCGCGCCTACCTGACGCCGATTCGTAATCGACAGGAGGCTG 
UL28 5’  35873 R  CACGGCATCATGCTGGGCGACACTCAGTACTTTGGGGTGGTGCGCGATCACAAGACCTAC 
UL29 5’  37151 R  CTTGGCCGACCTGTGCGTGCGACGCGACTATGAGGGCCTGCGGCGTTACTTGCGGCGCTT 
UL30 5’  37605  R ACCCGGAGCCCATCCAGAGCGAGACGGAGGGGGAGAATAAACAGTTTACGGAGCACACAC 
UL31 5’  38530 F  CAGGAATGAGAGAAGAGAAAACAGGGAGGACGAAGGAGGGGAGACGAGGACGACGGGCAC 
UL32 5’  42492 R  ACACGCTGCTGGAGCTGCTCATCGAGGACTTTGACATCTACGTGGACAGCTTCCCGCAGT 
UL33 5’  43735 F  AACCCCCACCATCTACATGACCAACCTCTATTCCACCAACTTCCTCACGCTCACCGTACT 
UL34 5’  45141 F  ATGAACTTCATCATCACCACCCGAGACTTCTCCAACGACGATTCAGTCCTGCGAGCCGCC 
UL35 5’  47728 F  ACTTCCACGAAGGCAAGATCACCACCGAGACGTATCACCTCCAGCGCATCTATAGCATGA 
UL36 5’  50014 R  GGGACTTCAACGGTCTCAACGACTTTCTGGAGCAGGAATGCGGCACCCGGCTGCACGTGG 
UL37 5’  50871 R  GGCTGGTTTCCCCTGCGCATCCTGAACGAGAGCCGCGATATCAACGTCACCGAGGTCTAC 
UL38 5’  52350 R  GCAGATGGACGTGGGGGGACTGATCCAGGCGTCGGCGTTGGGCAAGGTGGCGCTTCGCTA 
UL41A 5’  NA NA 3'-oligonucleotide  only 
UL40 5’  53980 R  CGTGTACCACCAAGGCGACATGGTCCTCATGACGCTCGACGTGTACTGCTGCCGCCAGAC 
UL42 5’  54972 R  TTTCCACGCCACCGCCGCCACCACCCGACTGCAGCCCACCGCCCTATCGACCCCCGTACT 
UL43 5’  56059 R  GCTGTCGAGCTGGTCAACGAGACCTTCCGCTGCTCTGTCACCTCCGACGCCCGCAAGGAC 
UL44 5’  57553 R  ACAGCTCATGCCTCTACATCACTGACAAGTCGTTTCAGCCCAAGACCATTAACAATTCCA 
UL45 5’  58563 R  TCATGCGGTTAGGGTTCACGTACTTTGCCTCTTGGGACTTGATCGAGCGCATCTTTGAGC 
UL46 5’  61227 R  GCTGGGCTGCGTCAAGACCGTCTCGCTGGGCATCACCTCGTTGCTCACCTGCGTCATGCG 
UL47 5’  62436 F  GCCGTGGAGTTTCAAAACTACGTCAAGAACAGCGTGCGGCACATGAGCTCTTTCGTCAGT 
UL48 5’  65203 F  GCCCGCTTTCTACTATGAGGCCCTTTTTCTCTACATGCTGGATGTGGCGACCGTACCAGA 
UL49 5’  73130 R  GCAGCAGCTGGTGCATCACGTGCCACGTTCTTGCGTCCTTCATCTCTTCGTGACGGATAA 
UL50 5’  74395 R  TCTGTAAAAATCCCAATTACTCGGTGTGCGACGCCATGCTCAAGACAGACACGGTCTATT 
UL51 5’  74848 R  GCGGTGGGCTCGAGGGGGGAGGTGGTGACGACGAGGACGGTGAAGACGGACACGCGCTAC 
UL52 5’  75695 F  CGCCATCATCAGCATCTGCCTCAAACAGGACTGCGACCAGAGCTGGCTCCTCGAGTACAG 
UL53 5’  77342 F  TCACGGGCAAAGAGTCCATCTGCTTACCCTTCAATTTCCACTCGCACCGGCAGCACACCT 
UL54 5’  81424 R  GCGTCAACGTTTTCGGGCAGCGCAGCTACTTTTACTGTGAGTACAGCGACACCGATAGGC 
UL55 5’  84697 R  GTTAACTTGTGTATCGTCTGTCTGGGTGCTGCGGTTTCCTCATCTTCTACTCGTGGAACT 
UL56 5’  87024 R  GGAGATGCTGCTGAAGGCGCTGCACGAGGATACGGCTTTGCTGGATCGGGCGCTGATGGC 
UL57 5’  91311 R  ACGGCGGGGTGCTCACGAAAGTCACGTCCTTCTGTCCTTTTGCGCTCTACTTTCATCATA 
UL69 5’  101168 R  GCCGAGTTCCCAGTTGTCCTACGACTTTCGGTTCTTCTCACCCCTCCTCAGCCAATAATC 
UL70 5’  103725 R  ACCGAGCTGCTGGACGTCATGCAAAAATACTTCTCGCTCGACAACTTTCTACACGATTAC 
UL71 5’  105022 F  AATCGCAGCGTATCCTAGAGGCCCTGGACATTCTCATCCTCAAACTGGTGGTGGGCGAGT 
UL72 5’  106772 R  ACATTTACGCTGCCCCAATCGACCGAGGAGAAATACGACAAAGAGCAGCATCCGGGAGAG 
UL73 5’  107203 F  TACGGCGACAAGTACTTCATCGACGACTAGTGCCAAACCTGGTTCCACTACTCACGACCC 
UL74 5’  108669 R  AGACGTTCCTGGCCGTATACCGTGCTATCTTATCGAGGTAAAGAGATTCTGAAGAAACAG 
UL75 5’  111126 R  TTCCATATGCCTCGATGTCTTTTTGCGGGTCCTCTGGCGGAGCAGTTTCTGAACCAGGTA 
UL76 5’  112187  F  TGTACCGATTCTGTTCTGGACTATCTGGGACGGCGTCAGGATGAGTCTGTTGCACACCTT 
UL77 5’  112400 F  ACGGTATCTGCGTCAGGAGCTGAGGGATCTGGGTCACAGGGTACAGACTTACTGCGAGGA 
UL78 5’  114530 F  GCGCTCTAAATCTCAGCCTCTGTCGCTTAGTGCTCTTTGTCGACGACGTGGGCCTATATT 
UL79 5’  116168 R  GGACCACGCCGTGCTTAGTCGCAAGACGCCGCAACCCTACTGGCCTCATCTGTACCGCGA 
UL80,UL80.5 5’  118165 F  GCGGGTTCCAATCAGCAGCAGCAACAACGTTACGATGAACTGCGGGATGCCATTCACGAG 
UL82 5’  120179 R  AATCTCCGCACGACACCGTAGACCTGACCGACTTAAACATCAAGGGCCGCTGCGTGGTGG 
UL83 5’  121477 R  GCAACGGCTTTACGGTGTTGTGTCCCAAAAATATGATAATCAAACCGGGCAAGATCTCGC 
UL84 5’  123531 R  GCGCTGCATCTGCCAGAACTCACGTTCGAGCCGACGCTGGATATAAACAACGTAACGGAG 
UL85 5’  125182 R  GCCGTTGTGCCCATTCCGCAGCGTCTACATCTCATCAAGCACTACCAGCTGGGCCTACAC 
UL86 5’  128430 R  TTGCGGCGCGTCTACAAAAACACCGATACCAAAGATCCGCTAGAACGTAACGTGGACCTG 
UL87 5’  123032 F  CGTAAAAGCGGCGGTAGATACGTAACGTGTGCGAGTTTTTCAGCGTCAATTCGTAAGGGA 
UL88 5’  132631 F  CGTGTGTTACCGCCGCCGCCCGACGCCGAAGACGACGTGGTTTTTGCTTCCGAGCTGTGT 
UL89 5’  139141 R  CATCTTTTTTATAGCCGTGACCAAGATCCCCGTGCTGGCCAATCGCGTGCTGCAGTACCT 
UL91 5’  135171 F  ACTGGGGGTCGCGCACGCCACTACGGAGGATGTTTTTATCTTTGTCGACCGCCTCTTTCA 
UL92 5’  135664 F  TGTTGGAACCCATCGAGGAGGCCGCACTGGACGACGTCAACATCATCAGCGCCGTGCTCA 
UL93 5’  136290 F  GGCCTGTTTTCGTGTACTACCGCGCCCACTGGAGTTGCTCGATTACCTACGTCAAAGCGG 
UL94 5’  137939 F  CGCATCTGTCATTTACCTACCTTGTACCAACTGAGCTTCGGAGGTCCTTTGGGTCCAGCC 
UL95 5’  139707 F  GGCGGTGGTGCGAGCGGAGGTTAGGCGGCAGCGGCGAGAGGAGAGGAAAAAGATGGCGTC 
UL96 5’  141323 F  GGACGTGATGCGCGTCGACCTTGAGCGACAGCAGCATCAGTTTCTGCGGCGTACCTACGG 
UL97 5’  142736 F  CGTGCCCAAAGAGGACGATTTTTGCCACAAGATCTGTTATGCCGTGGACATGAGCGACGA 
UL98 5’  144089 F  GCCCCTCAGTCTCTTTCTCATGAACACCTTTTTGCTGCACCAGGAGGGCTTCCGTAATCT 
UL99 5’  145864 F  GGATGACGATAACGAGGAGCGGCAACAGAAGCTGCGGCTCTGCGGTAGTGGCTGCGGGGG 
UL100 5’  147366 R  TTGGTGTGCTACGCCGTGTTCATGCAGCTCGTCTTTTTAGCCGTGACCATCTACTACCTG 
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UL102 5’  149545 F  TGGTCTGGGGCGACGAGCGGTTGGTGGGTCCCTTCAACTTCTTCTACGGCAACGGCGGCG 
UL103 5’  151283 R  GCGTGCTGGAGGTCCATACGGATTTCACTAGACAGAATGTGATGATCATGGAGCCGCAAG 
UL104 5’  152874 R  TCCGCGACATTTTATATCAGTACGCCGATAACGACGACTATGGTCTCTACGTGGATTGGT 
UL105 5’  154295 F  AACAAGCGTTGCACCGACCTGGACTTTGGCGACCTGCTCAAGTACATGGAGTTCGGTATC 
UL111A 5’  161009 F  TCGGTGATGGTCTCTTCCTCTCTGGTCCTGATCGTCTTTTTTCTAGGCGCTTCCGAGGAG 
UL112 5’  162293 F  AGAACGGTAATTTGCAAGTGACTTACGTGCGGCATTACCTGAAAAACCATGGCGAATCCT 
UL114 5’  164777 R  ACCGCTGGAGCTATCTGTGTCCGCCCGAGCAGGTGCGCGTGGTGATCGTGGGCCAGGACC 
UL115 5’  165661 R  TGCCCCGAACTAACGCGCCGATGCTTGTTGGGTGAGGTGTTTGAGGGTGACAAGTATGAA 
UL116 5’  166428 R  ACCATCGGTACGAACGCTACTTCCCCCTCCTCTTCTGTATCCATACTTACCACCGTGACA 
UL117 5’  168003 R  CTCCCAGGACCACGTCCAGATCGTCTACGGCTCCACACGCATCTGCAAGTCCCTGGCCCC 
UL119 5’  169196 R  GGGAGTGAAAAGTAGCACCACAAGCGCCGTCACTTCCCCTAGTAATACCACCGTCACGTC 
UL120 5’  169858  R  TGGGACTCGGTGACGGTGGCAACTACAATTAGGGTAGGGTGGTGGTATGAACCTCAAGTA 
UL121 5’  170191 R  CACGCTACGGCTGCTGATACGAGATGGGATGTACGGGCGGGGGGAGAAAGAGTTGTGCAT 
UL122 5’  173721 R  CTTTGAACAAGTGACCGAGGATTGCAACGAGAACCCCGAAAAAGATGTCCTGACAGAACT 
UL123 5’  172481 R  ACAGTGATCAGGAAGAAAGTGAACAGAGTGATGAGGAACAGGAGGAGGGTGCTCAGGAGG 
UL124 5’  174205 F  TGCCCTCCACCGTTAACAGCACCGCAACAGGAGTTACCTCTGACTCTCAACAGAACACAA 
UL128 5’  176805 R  AGAAGAATGTTGCGAATTCATAAACGTCAACCACCCGCCGGAACGCTGTTACGATTTCAA 
UL130 5’  177491 R  CCGTGGTCGACGCTAACAGCAAACCAGAATCCGTCCCCGCCATGGTCTAAACTGACGTAT 
UL131A 5’  178086 R  TGCGGCTGTGTCGGGTGTGGCTGTCTGTTTGTCTGTGCGCCGTGGTGCTGGGTCAGTGCC 
UL132 5’  178771 R  ATGAAAGTGCTGGCTATCCTCTTCTACATCGTGACAGGCACCTCCATTTTCAGCTTCATA 
UL148 5’  179714 R  TTTCTAAGCTTTACGTGCCGCCTGCAGCTAGAACCCGTGGTGGAAAATGTTGGCCTCTAC 
UL147A 5’  180268 R  ACTAGTATCCTCGCAGAGATTAACGAAAATTCCTGCTCCTCATCTTCTGTGGACCACGAA 
UL147 5’  180722 R  TACTTGCCATATGTCCCATAGCCGTCCGTCTTTTAGAACTAGAAGATTACGACAAGCGGT 
UL146 5’  181177 R  AGTGCATGGAACGGAATTACGCTGCAAATGTCTTGATGGTAAAAAACTGCCGCCCAAAAC 
UL145 5’  181725 R  TGGCTACATCGCAAAGAAAGTCCCTAGTGTTACATCGATACAGTGCCGTGACAGCCGTGG 
UL144 5’  182559 R  TGGGACAAAGAGTTACTAAAGTATGCACGGAGCGTACCAGCGTAACGTGTACCCCTTGCC 
UL142 5’  184213 R  GGGAGCGAACGGTCATTATCCTATCGTTACCACCTGGAATCTAATTCATCTGCCAACGTG 
UL141 5’  185001 R  TCTCGCAGTTGCATCTCGGCCAAATATTCTCGCTGACTTTCAACGTATCGACGGACACGG 
UL140 5’  185957 R  GACGAGAGTCGTACTAACAGCGTGTCATCGTACGTTCTTTTATCACCCGCGTCCGATGGC 
UL139 5’  186786 R  GCATCGGCGAGTGAAACCACTACAGGTACCAGCTCTAATTCCAGTCAATCTACTTCTGCT 
UL138 5’  187855 R  ATCGGCGTGATGCTCGTGCTGATCGTGGCCATTCTCTGCTATCTAGCTTACCATTGGCAC 
UL136 5’  188662 R  CGTGGGACTTGGACGTTGGAAATAAATGGCGGCGTCGAAAGGTCCTGAGTCGCATTCACC 
UL135 5’  189443 R  TGTACGTCGCTCTACATAGGAGAGGATGGTCTGCCGATAGATAAACCCGAGTTTCCTCCG 
UL133 5’  190595 R  GATAACATGCGCGGCTTTAGGAATTTGGTGTTTGGCGGGATCGTCGGCGGATGTCTCTTC 
UL148A 5’  NA NA 3'-oligonucleotide  only 
UL148B 5’  191358 R  CTAGCGGGGCTGGCTATCTGCGTGGGTCTAGTCATGGGGGTTACCGTGATCGCGTCGTGC 
UL148C 5’  191545 F  GGCCGTGCTCTACCTCCTGGCGCTTGTCGTCTGGGTTGAGATGTTCTGCCTCGTCGCCGT 
UL148D 5’  192228 F  GGATCAGCGTTGCCATCGTCATCTTCATCGGAGTCTGTCTGGTGGCCCTGATGTACTTTA 
UL150 5’  193497 R  CGCCCCAACCTCACCTGCTGCGGCTACCACACATCGACTGTCGTTCCCTGAAGGATCGAG 
IRS1 5’  197707 F  GGTCTCGACCTCACCACCGTCATGACAGAGCGTCAAAGTCAATTGCCCGAAAAGTATATC 
US2 5’  199485 R  CTGGCTGCGTTGCGTCCCCGAACTGCGAGTGGATTACACGTCTAGCGCGTACATGTGGAA 
US3 5’  200716 R  GCTGGTTCCATATGGGCATGCTGTACTTCAAGGGGAGGATGTCGGGCAACTTCACCAAGA 
US6 5’  201862 R  GCCTAAAACGCACAAATCCCGTCCGAACGATAGGAACCTTGAGGGTAGGCTGACCTGTCA 
US7 5’  202855 R  CCCCCGCCGACATCGCTAAAGTACTCATCTCACTGAAACCCGTGCAATTGTCTTCTGGAC 
US8 5’  203652 R  CCCATGTGGTGCCAGCCTCGGTACCATATACGTTATTTCAGTTACGGGAATTCAGTGGAT 
US9 5’  204839  R  TCCCCGTCCACCTGTTCCTTCTTCTGGCACTGGTGTCTGATCGCAGTAAGTGTACTCTCG 
US10 5’  205722 R  GCCACGGAGGAGACGAGAGAACCTACCTACTTCACGTGCGGCTGTGTTATTCAGAACCAT 
US11 5’  206480 R  CGGTCGCGGGTAGTATGCCTGAATTATCCTTGACTCTTTTCGATGAACCTCCGCCCTTGG 
US12 5’  207507 R  TAAGAAAGAGAAACCCCCACCCGTGTCGCCGCCGTCACCACCGCCGATCCGTCGAGTCAC 
US13 5’  208224 R  TGTCAACATGAATCTTCCCCTCTGCTGCTGGTTTTTGCCCCCTCCCTTCTCTGGTGTTTG 
US14 5’  208814 R  ACTTACACCTGGTTGCATAAGACTCTGCTGTGTCTCTACACCGTGTTCGTGGGCTGCATC 
US15 5’  209901 R  TGCTTCACGTGCCGCCGTTGATCGTAATATGTCTCTGCCTGGACGGTACGTTGGTCATCT 
US16 5’  210769 R  GTCGTTTGTGCTCACGTTGGTCATCACCTTGCTCTGCGCGGAAGTAGTCTTCATCTGTCG 
US17 5’  211880 R  GCGCCTGCTCCTCCTCTACGCTGGTGACCTTCTCGGGCCTCTTGGCTTGCGTGCTTTTTA 
US18 5’  213053 R  TTTCGCCCACACACCACCAATTTTGCTCATCTCACAGTGGCGTGCTTGCTGATCAACACC 
US19 5’  213660 R  CGACGACGCTGTTGACGGTGACGCTGATGCTAATTCACGATCTGTCCCTGATCACCTGTC 
US20 5’  214680 R  AGTAGGTTCCTACGTGATGACCCTGGCGTTGTTTATCTCCTTTACGGGGCTGGCGTTTCT 
US21 5’  215708 R  GTCTGACGCTGTCTTGCTTAATGATCTCCATCGTGTGCCTAGGTCTGTTGCGTTGGGCCG 
US22 5’  217512 R  CGAACAGGCCGCTATCCCGCAGATTTACGCACGTTCTCTGGCCGCCGACTATCTCTGCTG 
US23 5’  218843 R  CCGTTTCTGTCGTTTTTACGTGGTAATCGTCAAGTCGCACCTGGACCGCTCGCCGCCCCT 
US24 5’  221160 R  CGACAAGTGTTGCGGGATTTTAAGGAACTGTTCTTTTGCCTGGAGCCAATGGAAATCACG 
US26 5’  223618 R  GCAGGACATCCGCCACTTAGTTCGTAGCTATGCTGATATGAACATTAGCCTTCCCGTTTC 
US27 5’  224293 F  TACCACCATCCTGTACTACCGTCGTAAGAAAAAATCTCCGAGCGATACCTACATCTGCAA 
US28 5’  225543 F  TGTTTCTGTACGGCGTTGTCTTTCTCTTCGGTTCCATCGGCAACTTCTTGGTGATCTTCA 
US29 5’  226666 F  GTGTTTCCGATGGTGGCTCTACAGTGGGTGGTGGTGGCTCACGTTTGGATGTGCTCGGAC 
US30 5’  228324 F  GACGCCAAGTACGGTATTCGTAACCAGCATTTGAGTATACGGTTAATGTATCCTGGGGAA 
US31 5’  229084 F  CGTGCGGTAACTGGCAAAGCCACGTTGAGATTCAGGACGAGGAGCCCAACTGCGAGCAGC 
US32 5’  229711 F  AGCACCTCTATTGTGTGTACGACAGCCATTTTCAGCGACGACCCACGACCCGAGCCGAAC 
US34 5’  230802 F  GGACTCGTTTATCGTGAGCTTCATGATTTCTACGGGTATCTGCAGCTGGACCTTCTGGGA 
TRS1 5’  233004 R  ACCCTAGCCACCAAACATCCGGTCATCTGTGCAAATGTGGAAGACTATCTGCAAGACGCC 
RL1 3’  2111  F  GCTCGGCCAGATCACACGCTCTTTCCTGTCCCTTCTACACCCTCAGCCACGGTTCACAAT 
RL5A 3’  5472 R  ATACAACAGCCTGTGTTTCAAGTTGTTCGCATACGTCGCTTGTGCTTTGCAATATGACGC 
RL6 3’  6025 R  TGGTTCGGTGAAAACATGGATGAATACAGTGGTGATGTGTGGCACTTGGAAGTCAGCTAA 
RL10 3’  8969 F  ACGCAAAAAGCTGGAACAACACGCGGCTAAAAAGCAGAACATCTACGAACGGATTCCATA 
RL11 3’  9786 F  GCTGCGGACGGACCTGGATACGGAACCTCTGTTGTTGACGGTGGACGGAGATTTGGAATA 
RL12 3’  10801 F  GACACTGACAATCATACCACCCCACTATGTCCCAGATACGTAGGAACACAATCAGAAGAA 
RL13 3’  11786 F  AGCCTCACGGTGATTTTTGCCAACACGACATCCATAGTCACCAACAGAACGTGTGATAGA 
UL1 3’  12705 F  GTAGCCACTCACGTTGGTTGGACAGCCACCGTGGTGATAATTATCTGCGTTTTAACTTAC 
UL2 3’  13211 R  ATCATGCTTGTCATTTGGACCGCAGTGTGGCTCAAGCTGCTTCGAGACGCTCTTTTGTAA 
UL4 3’  14148 F  TGTACCTATGACCGCCTGACGTTGCTGAATTTGACGACGGAAAACAGCGGAAAGTATTAT 
UL5 3’  14518 F  AGAGTAACAAGGCTATATCAAGGGACGAAGCAGCATTCACCTCCAGCGTGAGCACCCGTA 
UL6 3’  15689 F  GCGTTGCGATGCTGCTGTTTGCCGCCGTGATGGTGCTCGTTGATTTGGGTTTGCCTCAAT 
UL7 3’  16382 F  CACAACTACGTGCCGTCGCTGGATTCTCCCATCAGACGCCTTTGGAAAACAACACGCACC 
UL8 3’  16854 F  CTGTCTACGAGCACCTCGAAAAATCTACCATCACTGGAAAGACAGTAAACAGTACGGACA 
UL9 3’  17357 F  CCACCAAACACATTGCCATACAACTACATCATCCCTGTATCCACCTACATCTGTACACGA 
UL10 3’  18109 F  GTAAACGTCTCAGATCCCAGAAACTATTGCAGGCGAAAATGTCCACCAAAGGGTAACTGT 
UL11 3’  19158 F  ACCACCACCGCCAAGAAGACGACGATAAGCACTACCCATCATAAACACCCCAGTCCCAAA 
UL13 3’  20901 F  TGAATAGGAGGTCACAGGAGGAGAACGAGGAAGGTGGACCGTGTGAATCGCCGCCAATGA 
UL14 3’  21883 F  TGCGAGGAGGACGAGCGCGAACTGTGCGTGCCCTTCATCAGCCAGAGCATCGCGGACAAC 
UL15A 3’  22455 F  GGCGGACATTGGGCTGTGGTTCATGTTTCTGGTTTTTGGACTGTGTTCGTGGTTGGCGAT 
UL16 3’  23140 F  GGTCACTAATCTTACCGTGGGCCGCTATGACTGTTTACGCTGCGAGAACGGTACGATGAA 
UL17 3’  23770 F  CACGATTTGTGCTGGCTGTTTCGACGACTTTTCTTTCCTCGGGAGGACTCAGAGCCACTG 
UL18 3’  24915 F  TCACCCGACAGCTAACAAACGCTATAACACCATGACCATCAGCAGTGTCCTCCTAGCCCT 
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UL19 3’  25249 F  GCATCGAGCGACCGAGTCAGTCAGAAGTGGATTGCGCCAGTTTAATGGAAACGCTGAAGC 
UL20 3’  26562 F  CGTTGCCTCCACGACCTCCCCACTTAATAGAATTCCCGCCGTCTCCTCCGCCATCGCCTG 
UL21A 3’  26883 R  ACCGACCTCCGCAGCAACCCCTACCCAATCCGCTGGTGCTACTGCTGGACGATGTTCCCC 
UL22A 3’  27782 F  CACAAGAGAAGACCGACGAACACAAGGGAGAACACACCAAAGAAAATGAAAAGACCCAGT 
UL23 3’  28620 R  GCGACGCTGCAACTTCATCACCGTCCCAGAGGAGCTGCCGCACACCGCCTCGCTTAGAGC 
UL24 3’  29346 R  TGGGAGATAATCTCAACACGTTCATGTGTCTGGGACTTAACCTGCTGTTTGAAAACCGAC 
UL25 3’  31720 F  AGAGCATCTCGGAGCTGTGTTACCTCATCTATGTACAACTGCCGTCGTTGCGCGAAGACT 
UL26 3’  32574 R  TGACGCCGGGCAAGCAAGAAATCACCGACGCGATGTTCGAAGCCGGCAACGTGCCATCAG 
UL27 3’  33301 R  CGGACGCCGAGCTGAGCAACCACGCCAACCGCTGCCGCCGCAAGGCCCCGCTGGAACTCG 
UL28 3’  35549 R  CACACCTTTGCGGGCATGTACGAACTCTCCCAGATACTGCACGACCGCGCCAATCTGCTG 
UL29 3’  36334 R  CGCGTGGGGCTGGCGCTGCTCATCGACGACTTTCGCTACGAGAGCATCGGCCCCGTGGAC 
UL30 3’  37515 R  TCTTTGTATTTCCCTGTCTTGTGTTGCCCAACTGCTGTCAGGTCTCCGTAGATCGCTCCC 
UL31 3’  39443 F  GCGTCCAAAAACGTACAGTACGAATTCATGGGTCTCATTTTCACCGTCAACGTGGATTCA 
UL32 3’  41402 R  TCAGACGCCCGAGCAGTCGACGCCGTCCAGAATACGTAAAGCTAAGTTATCGTCTCCAAT 
UL33 3’  44540 F  CAGAATCAGCGAGCTACAGCGGAGACAAATCTAGCGGCTGGCAACAATTCACAATCAGTT 
UL34 3’  46295 F  GACCCCCTCACCTTCAGTCACCTCAGCCCTTACCCCCGTCACGTCCCCCATAACCCCGTT 
UL35 3’  48064 F  CTTCTTCTACCACGGGTCTCTTACTCTCCTCTTCTTCTTTGTCGGGGTCGCACGGCATTA 
UL36 3’  49139 R  GGCCGAGGACGTGGTTATGTTCACCTGCGTCATGGGAAAGAAGGGACACCGAAACCACCG 
UL37 3’  50500 R  TAACGTGACGTCGCTTCCCGAGTGGACACTACAACAATGCCAGGGGTGGAAATATTGGAC 
UL38 3’  51483 R  GAAGGATGTGATGTACACGGCCGGGGAGGGCGACGTGGTACAGATGGTGGTCGTGGTCTA 
UL41A 3’  54537 R  CGTCGACATGAACGTCTGCATCGGCATGATCGGCGTGGTTTGTTTCGTTTTCGGGGTCTT 
UL40 3’  53889 R  CATCCTGCCGATAACACGTTGCTGATCGAAGTGGGTAACAACACGCGTCGCCACGTAGAC 
UL42 3’  54743 R  CGTGGTGATTAACCGGGACAGTGCCAATATAACAACGGGGACGCAAGCATCATCGGGGTA 
UL43 3’  55571 R  GTGCATGAAGCGCGAGGGTTCTATCTTCAGCTGGCGAGACGGTAACGAGGCGCTGACGAC 
UL44 3’  56519 R  GCGAAAGAGGAGAGCGACAGCGAGGATTCTGTAACGTTCGAGTTCGTCCCTAACACCAAG 
UL45 3’  57553 R  ACAGCTCATGCCTCTACATCACTGACAAGTCGTTTCAGCCCAAGACCATTAACAATTCCA 
UL46 3’  60895 R  CTCTGTGTACCGGGGTCATACAAAAGCTGGGCTGGTGCCTGGCTGACGACATTCACACCT 
UL47 3’  64006 F  GCGTACGTCAGATCAGCAGCGACACAGAGGAAGTAAGCCGACACGCCAAGGGTCACCGCA 
UL48 3’  71227 F  GGTGCTCACGCAGAACGTCCTCAGTGCTCTAGAAATATTGCGACTAGTGCGATTGGACCT 
UL49 3’  71720 R  CCACGTCGGCGGCCACATTGTGCAGCAGGCGCGCGGCGGTTTAGCAGCGACGTCCTCCTC 
UL50 3’  73753 R  TGGCGGCGGGGTCGTGGCGGCTGTGTCGTTGTGAGGCCTGTATGGGACGATGCGGATGCG 
UL51 3’  74601 R  GCAACTATTAACGGCGATCGTCAGCAAGCTCATGGACATTAACGGAATCCTGGAGGGAAA 
UL52 3’  76526 F  CCGCGTCGTCTCGTACTGTCAGAACAATGTGAAGATGGTGGACCGCATTCAGCTGGTATT 
UL53 3’  78132 F  CCACCAGTCTCAGTCTCAGCAGCATCATCACCGTCCCCAGTCACCACCGCCGCCGCTGTT 
UL54 3’  78689 R  TCGTCGGTGCTTTCTAAGGACATCTCGTTGTACCGTCAATCTAACCTGCCGCACATTGCC 
UL55 3’  82146 R  AGCAGAACGGTACAGATTCTTTGGACGGACGGACTGGCACGCAGGACAAGGGACAGAAGC 
UL56 3’  84991 R  AGTCCAAAGATCTATATCTCCTCCTCTACAGGCATCTGTCCAGACCGGATGAGAGTGGCG 
UL57 3’  88286 R  GGATTGCGACCCCGAAGTGATGGCCGTGTACGAGATTTTGAGCGTGCGTGAGGAGATCCC 
UL69 3’  99671 R  CTTCTCACGGCGGCAGTCCACCCCAGGTTCCCCACAAGCAGCCCATCATCCCGGTGCAGT 
UL70 3’  101881 R  CACCAAAAAGTGTCACTCCAACGCCAAAAACGTCCACATTTCCATCAAAATCAGACCGCC 
UL71 3’  105147 F  CTGGTGGAGGTGCAGCGCGTTATGGGCCTGGTGGACATGGACTGTGAGAAAAGCGCGTAC 
UL72 3’  105913 R  TCGACGAGACAGAAGAAGATGAAAAGAGCTCCGACGCAGAAAGCCCTGTCAACACGAGTG 
UL73 3’  107345 F  TTTGCAGCCTGGTGGACTATGCTTAACGCTCTCATTCTGATGGGAGCTTTTTGTATCGTA 
UL74 3’  107756 R  ATCGGAATGAACCCTTTTGTAAACCAGACCGTAACCGTACCGCCGTGTCAGAATTTATGA 
UL75 3’  109364 R  TCGCCCTGGATCCCTACAACGAAGTGGTGGTCTCATCTCCGCGAACTCACTACCTCATGC 
UL76 3’  112404 F  TATCTGCGTCAGGAGCTGAGGGATCTGGGTCACAGGGTACAGACTTACTGCGAGGATCTC 
UL77 3’  113890 F  GCAAGAGCAACCCCGTGGCCGACTACATGTTCGCGCAGAGCTCCAAACAGTACGGCGATT 
UL78 3’  115228 F  AAGCGGGCTATGTATAGCGTGGAGCTGGCCGTGTGTTACTTTTCTACGTCCGTCCGAGAC 
UL79 3’  115956 R  TCCCCGAAGACCTGGCGCGCAACGGCAACATCCTCTTCTCCCTAGGCACGCTCTACGGAC 
UL80,UL80.5 3’  118302 F  CCCAACTACTACTACCGTGTGTACTCCCACCAGCGAGCTGACGAGTGGCGGAGGAGAAAC 
UL82 3’  118789 R  ACCCTCACCCATCAGCACCGCTTCCACTTCCAGCACCCCACGCAGTCGACCCCGCATCTA 
UL83 3’  121207 R  GCGGGCCTCAGTACAGCGAGCACCCCACCTTCACCAGCCAGTATCGCATCCAGGGCAAGC 
UL84 3’  123033 R  GTCCCTTACGAATTGACGCTGAAAAACTCGCACACGTTACGTATCTACCGCCGCTTTTAC 
UL85 3’  124763 R  GCAGCAGCTGCAGACCATTACTTTTCGCGACGCCACCTTCACCATCCCCGATCCGGTCAT 
UL86 3’  125722 R  CAACAAAACGCTCTTCAAAACCATCGACGAGTACCTGCTACGCGCCAAGGACTGCATCCG 
UL87 3’  132033 F  CACAGCGGGGTCTCTTTGACTACAGCAAGAACCTCACGGCGCACACCAAGATCAAGCACA 
UL88 3’  133332 F  TCTTTGTCAAGTCTGTCTTTACGAGTTGGACGAGGACGAGATGGGCGAGGAGATGCTGGG 
UL89 3’  133945 R  CTACATCAAAGCCTCGCAAGAGCTCGTCTCCTACACCATCAAGCTGAGCCACGACCCCAT 
UL91 3’  135363 F  CGTCGTGGAGACAAGCAACACCTGTCGTCCCTGCCCTTCTCCTGTTCCCTCCGCCCCCAA 
UL92 3’  135910 F  AGCTTATCATCGGTATCTACTCAAAGCAGACCAAGTACGACGCGTGTGTCATCAAGGTTA 
UL93 3’  137245 F  GCCTTGGCGCTCTGGATGGATCGGGCGGACGTGCGTAGCTGTATTATTAAGGCGCTAACG 
UL94 3’  138527 F  GCGGCGCAGGTCACACTGGGAGACGGCCTGGATTATCACATCGGTGTCAAGGATTCTGAG 
UL95 3’  140457 F  TACCTACGACGGCGAATTAATCTACGGCAGTTACCTGTTGTATCGCAAGGCTCACGTGGA 
UL96 3’  141535 F  GACAGCTGCAATCCGGTAACGTGGACGACGCGCTGGACTCTTTAACCGAGCTGAAGGACA 
UL97 3’  143108 F  CACGTTGGCCGACGCTATCAAATTTCTCAATCACCAGTGTCGTGTATGCCACTTTGATAT 
UL98 3’  145602 F  ATCGTCACGCCCGTGGTCTTTGACCCTCAGTTTACGCGCCATGCCGTCTCTACCGTGTTA 
UL99 3’  146183 F  CGGCCCGACACACCCAGGACTCCGCGCCAAAAGAAGATTTCACAACGTCCACCCACCCCC 
UL100 3’  146706 R  ACCGGCATCAGCTGGTCGTTCGGCATGCTCTTTTTCATATGGGCCATGTTTACGACGTGT 
UL102 3’  150120 F  TTGTCGTCCTCCACCGCTTCCACCACCACTTGTTCTTCTTCTTCCGTTCTCTCCTCCGCC 
UL103 3’  150637 R  AGACGTGCTCAACGCCAACTACCCCAATTTGCCCTCACCCCCCAAGCTGCCACCGCGCTG 
UL104 3’  151783 R  AACAGCTTCTTCTCGCAGTTCGTGCCCGGCACCGAGTCGCTGGAACGCTTCCTCACGCAG 
UL105 3’  155655 F  GCTACACCAGCGACAACGTGCTCAGTCTGCCCAGTGACCGCCACCGCATCCACCCCGAGG 
UL111A 3’  161574 F  TGATTAGTCGGCTGTCTCAGGAGGCGGAAAGGAAATCGGATAACGGCACGCGGAAAGGTC 
UL112 3’  163711 F  TCCCCGGCCCGTGTGTGAAATCAAGCCCTACGTGGTAAACCCCGTTGTCGCCACCGCCGC 
UL114 3’  164511 R  TCTCACCGTCACTTAGGCTGGCAGACGCTGAGTAACCATGTGATCCGGAGGCTGTCAGAG 
UL115 3’  165511 R  AACTCCGTGCTGTTGGACGAGGCTTTCCTGGACACTCTGGCCCTGCTGTACAACAATCCG 
UL116 3’  166195 R  AGACATTGCGGTGGATGAAGAAGAGCCAGAACTGGAGGACGACGACGAGTACGACGAACT 
UL117 3’  167026 R  CCGTAGCCACGTTCAAATTCTTTCACCAGGATCCCAACCGCGTTCTGGACTGCATCCGTC 
UL119 3’  168187 R  GAGACTGGAGGAGCCCGTTGAAGAAAAGAAACACCCGGTGCCCTACTTCAAGCAGTGGTA 
UL120 3’  169480 R  AACACATTCATCCACTTTGTCGAAGATAGTGAGCTGGTGGAGAATCCCGCATACTTTAGG 
UL121 3’  170090 R  TCGACGCCGACCTAGGACTCCTGTACGCCGTCTGTCTGATCCTGTCGTTCAGCATCGTCA 
UL122 3’  170935 R  ACCCACCAATTGTGCCCCCGCTCTTCTGATTACCGCAACATGATTATCCACGCTGCCACC 
UL123 3’  172428 R  CAGGAGGAGCGGGAGGACACTGTGTCTGTCAAGTCTGAGCCAGTGTCTGAGATAGAGGAA 
UL124 3’  174306 F  TCTGCGTCAGCGGTGCAAGCCCATTCCCCGAGCTCATTTTCAGACACATACCCTACCGCC 
UL128 3’  176542 R  GCGGGATCGTCACCACCATGACCCATTCATTGACACGCCAGGTCGTACACAACAAACTGA 
UL130 3’  177039 R  GAGCTGGGCTCACGTCTTCCGGGACTACAGCGTGTCTTTTCAGGTGCGATTGACGTTCAC 
UL131A 3’  177844 R  GGGAGCGAACGGTCATTATCCTATCGTTACCACCTGGAATCTAATTCATCTGCCAACGTG 
UL132 3’  178464 R  AACATGATCCTGAGAACGTCATCTATTTCAGAAAGGATGGCAACTTGGACACGTCGTTCG 
UL148 3’  179611 R  TTACACCGCAGGTAGACGTGGTACGCTTTGCTCTATATCTAGAAACGCTCTCCCGGATCG 
UL147A 3’  180160 R  GCTCTGCTGGCCTTTTCCCTAGTGATTTGCGGTACGCTCCTCGTCACTTGTGTGATCTGA 
UL147 3’  180391 R  AGCCTTTCTCTGGAAATACGCCAAGAAACTGAATTACCACTACTTTAGACTGCGCTGGTG 
UL146 3’  181019 R  GACCTGGAGTATGTTTATCGCCCCATCACCCTTTTTCAAAATGGCTAGACAAACGCAACG 
   81 
 
  
HCMV ORF  5’ or  3’ 
Probe 
Genome 
Position 
Strand  Oligonucleotide Seqeunce (60-mer) 
UL144 3’  182386 R  AAGAACCATACGTACTTTTCCACTCCAGGCGTCCAACATCACAAGCAACGACAGCAAAAT 
UL142 3’  184037 R  GTCATGGTTCACACCCTGGGTCCAAAATAAGAGTTACAGCAAACAACCCCTAAGTACCAC 
UL141 3’  184486 R  TTCACCGTATGTTTCCTATGCTACCTGTGTTACCTGCAGTGCTGTGGACGCTGGTGCCCC 
UL140 3’  185796 R  ACGCCGAGATTCGCAGCAACTGCTCATCGAGCTTCCGCCGGAGCCGCTCCCACCCGATGT 
UL139 3’  186633 R  AGCGGCTGGACATTATCTGGACTCCTTCTCATATTTACTTGCTGCCTTTGCTGTTTTTGG 
UL138 3’  187441 R  GGATCCGCGACGCAGTTCACCACCGTAGCCATGGTACATTATCATCAAGAATACACGTGA 
UL136 3’  188097 R  GACGTCGTCGAACGCGCTGCTGCCAGAATGGATGGATGCGGTACATGTGGCGGTCCAAGC 
UL135 3’  189131 R  AAGAACCTGAGCACGCCGCCCACCAAGAAAACACCGCCGCCCACGAAACCCAAGCCGGTC 
UL133 3’  190133 R  ACCGAAGAAAGGTAGGGCGAAAGACAAACCGAAGGGTAGACCGAAGAACAAACCTCCGTG 
UL148A 3’  190807 R  ACCGCCGGCCGAGCTGGAGATGGTGGAAGTGTCGGACGAGTGTTACTAGGAGATCGCCGC 
UL148B 3’  191298 R  GCGCTGCTGGTGTTTTATTATTGCGATGAGAGGGAGGATGGCCGTCCGTCGAAGCTGTTG 
UL148C   3’  NA NA 5'-oligonucleotide  only 
UL148D 3’  NA NA 5'-oligonucleotide  only 
UL150 3’  192511 R  CGGGGGGTGTGCGGGAGACGATTGGGGAGCGACAAGACAGGGACGTGGCGGACTCTGCGA 
IRS1 3’  198090 F  CGACCAACGCTTCACTACCGAAGGCCACCAGGTCATCCCGTTGTGCGCGTCCGAACCCGA 
US1 3’  198880 R  AGCCGACGACTCACACGACCTATGGTGTTGCTGTATGGACTGGAAGGCGCACGTTGAGTA 
US2 3’  199333 R  TCGTGTATGTGACTGTGGACTGTAACTTGTCTATGATGTGGATGCGGTTTTTCGTGTGCT 
US3 3’  200367 R  AACCCTGCTCGTATATCTGTTCTCTCTGGTTGTTCTTGTGCTCCTGACCGTAGGGGTGAG 
US6 3’  201684 R  CGACACGGATTCTTCGCTGTGACTTTGTATTTATGTTGCGGGATTACCCTGCTGGTTGTT 
US7 3’  202779  R  CCAATTACAACTACCCTGGGTTCCTCGACCGTCCTCATTCATGTACGACAGCTACAGGCT 
US8 3’  203591 R  ACCTGCGACGACTACACTATGAATACAGACACTTAGAGCTCGGGGTCGTGATCGCCATAC 
US9 3’  204425 R  CGACTCTCTTACGTGATGTTAACCGTTTACCCCTGCAGTGCCTGTAACCGGAGCGTGCTC 
US10 3’  205347 R  CTAGGCGACTATGGGGCAATACTAAAAATTTATTTCGGACTGTTCTGCGGGGCCTGCGTC 
US11 3’  205961 R  TGATGGTGGCAGTGATTCAAGTGTTTTGGGGGCTGTATGTGAAAGGTTGGCTGCACCGAC 
US12 3’  206812 R  ACCAAGTCATTATGTTTCTGCTCGTGGTAGTACCCCTGACGGCCCCCATCTGGTATCCAA 
US13 3’  208077 R  ACCTGGTGCTCCGACCTGCCCGCCATCCTCATCGACTACACACTGGTCCTCACGCTGTGG 
US14 3’  208680 R  GGTACTTTACGCCACCGAGACACTCATCTATCACACCACACTCCTGATGCTCACGCCCGT 
US15 3’  209699 R  GAGGCGTGGTTGGTCCTGGTGCTTTAAGATCGTCTTGTCCTTCAGCGTGCTCATTACCTG 
US16 3’  210440 R  GAATCCGCAACTGTCAGGACCTGCTGAGCGATCTACGTCTCTTAGAACTACCGTCGTCCG 
US17 3’  211595 R  AGGCCGACCTGCTCACCTTGTGTCTCTATGAGAACCTGGTGTACCTGTACCTGCTCATTC 
US18 3’  212685 R  TAAAAACAGCGTCTGTGTCAGCGTCGTGTTGTACACCATCGTCATGAGTCTCCTAAACAT 
US19 3’  213569 R  GCTACGCCTCTATGTCGAAAATGTGGCTTTATTCATCGGCATGTACCATCTTCTGAGGCT 
US20 3’  214445 R  ATGGTCATCTTTTTCTGCCCACCTAACCAATGCATCCGTCACGCCGTCTGTCTCTACCTG 
US21 3’  215591 R  TGGCTGTCACGGCGTCAGGCTTCCACTTTAGTCATCGTTCAGTCATTTATGCCATGGTGG 
US22 3’  216300 R  CCGTATAGGCGATACTCCAGAAACCCCGTGTAATAGCGAAAACGAGGACGACACGACGGT 
US23 3’  218100 R  AGGACACTGTCTTTGACCTCAAGGACGTAGACGAATGGTTTGAGCAACGGCGTTTGGCAG 
US24 3’  219816 R  TACTCGGACCCTTTTCCCTTAAAGAGCCTGACGGGTGTGCGCGAGTACATCCAGATTTGA 
US26 3’  221956 R  CCGCCCCACGCCCAAACCTACCATGCCTCATCCTGTTTCTTACTTGCCCTTTTGGATGTA 
US27 3’  225158 F  ACCAAACGTACCCATTATGACAGAAAACATGCACCTATGGAGTCCGGGGAGGAGGAATTT 
US28 3’  226268 F  CTCGCCTTTTGTCACTGTTGTCTCAATCCGCTGCTGTACGTCTTCGTGGGCACCAAGTTT 
US29 3’  227597 F  TTGGGTCTGCCGCCGCCACCGTCAGTCGCACCACCTGGGGAAAAGAAGGAGCTACCGGCT 
US30 3’  228729 F  GAAGGCAAACTGCAGGAAGAGAAGAAACGACAGTCTGCTCTGGTCTGGAACGTTGAGGCG 
US31 3’  229397 F  GTCTAACTGTGGGGAAAGTAGCACTAGCAGCGGCCAGAGTAGCGGTGACGAGAGTAACTG 
US32 3’  230112 F  CGCGTGGTGTTCCAGTTAGGGGGAGTACCTCCTCGCCGTCACCGGGAAACTTACGTGTAA 
US34 3’  231108 F  GCTAATGCCAGTTTTTTATCTCGCTTCAATGTCGGTGATTTTCACGGAGCGTCATGGGAA 
TRS1 3’  232450 R  TCCATCTGTGTACATGCCTCCCACCGTACCCTACCCCGACCCCGCTGCCAGATTGTGCCG 
C-ORF1 3’  2337 F  TTTCGCCGCCACGCTGCTTCACCGATATCCAATAAACCCATCCCCTCGCCACGACGTCTC 
C-ORF2 3’  2334 R  ACGTCGTGGCGAGGGGATGGGTTTATTGGATATCGGTGAAGCAGCGTGGCGGCGAAAGAC 
C-ORF3 3’  3397 R  TCCGTCGCCGTTCTGCACCATGATTCGATCAATAACAACATCATCATCGGAGACCATCTT 
C-ORF4 3’  7860 F  CTTCCAAACCATCTTGAGACCCGAGTAACGGTTTACAGGTCGCACGCCAGTCTCAGCTAA 
C-ORF5 3’  8969 R  TATGGAATCCGTTCGTAGATGTTCTGCTTTTTAGCCGCGTGTTGTTCCAGCTTTTTGCGT 
C-ORF6 3’  23771 R  TCAGTGGCTCTGAGTCCTCCCGAGGAAAGAAAAGTCGTCGAAACAGCCAGCACAAATCGT 
C-ORF7 3’  29346 F  GTCGGTTTTCAAACAGCAGGTTAAGTCCCAGACACATGAACGTGTTGAGATTATCTCCCA 
C-ORF8 3’  35184  F  GATGTATGGCTGCTCACCGGTTTCGCGGCAACGGTTGCGCTCGAGTCCAACGGCGAGAAG 
C-ORF9 3’  NA    No suitable probe could be identified 
C-ORF10 3’  43288 F  AAAGTTGACCAGGGCTACCACATCGCGCCGCTGTAGACCGATAAACTGCAAACTCATGCT 
C-ORF11 3’  46552 R  GCACGCCAAAGTTGAGCAGCCCCACAAAGTTGGAGCAGCCCTGGGTCAACATCTCGAGCA 
C-ORF12 3’  NA    No suitable probe could be identified 
C-ORF13 3’  54728 F  ATGCTCTATCCCCGTTACCCCGATGATGCTTGCGTCCCCGTTGTTATATTGGCACTGTCC 
C-ORF14 3’  55105 F  CGGCGTGGGCTCCATGTCGGTGGCAGTGACGGCGACGGTGGTAACTGTGGTGGAGACGGT 
C-ORF15 3’  120571 R  ACGACTCTATAAAAACCCACGTCCACTCAGACACGCAACTTTTGGCCGCCACACCTGTCA 
C-ORF16 3’  157339 R  GCGCTTTCTCTGGCTCGACACAATGATCACACCGCACGCTATAGACACGTCGTCATGGAC 
C-ORF17 3’  159486 F  CATACGTCGTCACCGTCCTCTGGAGGAGGCACGGCGGCGCTGTTTGTTGTTTGGATGCTT 
C-ORF18 3’  161781 R  CGAACCCCGTCGCAGACTCTATTTATACATCATCTTTCCAGCCCGCCTAGCAACACCCAC 
C-ORF19 3’  NA    No suitable probe could be identified 
C-ORF20 3’  166588 F  GTGGTGGGAGTGGTGACGGTGTTACTCGTGGTTGAAGTGACGTTAGGGGAGGTAGTAGTG 
C-ORF21 3’  168368 F  TCTTGATAAACACGTAGGTGGTGGTAAAACTTCGGCCCGCGATCTGGACGTGGAGACGCA 
C-ORF22 3’  168687 F  GTTGTGATGGCGGCCCCAGCTGAAGAAAGAGCACGTGTACTCAGTGGTCTCCTGCGGCCT 
C-ORF23 3’  176265 F  AGGCCCACGATCCGGGTTATCTTGTCGTATTCCAGATTGATCCATCAATAGGGAACGCTG 
C-ORF24 3’  185172 F  CGCGAATGGAAACCATGGGCCAGGAGTGTGTCATGACCGTGCAGGGGATGGTAACTTGCT 
C-ORF25 3’  190735 R  CCGGCGGACGTGACTCGGCAGCCGCTGTAGAGATAAATAGTGCGATGGCGTTTGTGGGAG 
C-ORF26 3’  190605 F  CCGCCGACGATCCCGCCAAACACCAAATTCCTAAAGCCGCGCATGTTATCCAGGCCACAA 
C-ORF27 3’      No suitable probe could be identified 
C-ORF28 3’  210280 F  TACTTGAAACCCTTTTTCTCTTCTCATGGTGCGCTGCGTTCTCTGGAAACGGCTGCTCTG 
C-ORF29 3’  212325 R  ACGGTGATTATATTACACTCTATAAACGGTTCTCATACGCGCCTTTTGATAGCCACCGCC 
ORF1 3’  19594 R  TTGGTCTTTCTAGGGCCGGTCAACAGCTTTATGAAGGGAATCAGGGACGTCGGCTTTGGA 
ORF2 3’  37357 R  GGTCGCCGAGACTACTACTGCTTCTGCTTTTTTGTCTCCTGTGGATCGTCGCGGACTGCC 
ORF3 3’  NA    No suitable probe could be identified 
ORF4 3’  95473   GGCCCGGCAGGTCACCCAACGTTGGTTCAGGCCCAGTCGAGTTTTTCCCCGGCACGAACG 
ORF5 3’  96898 F  CGTCTGAATTTTTGCTTGATAGACACGTGTTTGGAACTCTGTCCCCCCACGTTTTCACTG 
ORF6 3’  134825 F  CCAGAATGGTGTTGAAGGCCTCTTTCTTGATGAAGTGCGCCTCGTCCACCAGCAGCAAAT 
ORF7 3’  146707 F  CACGTCGTAAACATGGCCCATATGAAAAAGAGCATGCCGAACGACCAGCTGATGCCGGTG 
ORF8 3’  146381 R  TTATCTGTTCTTCCACCAGCTACTTTACGTGTTTCAAACAGCACATTAGACACACGGGGG 
ORF9 3’  171789 F  TCTCGACTTCTTCACCCTGTTCTTCCTCGCTATCAGAGATCACGATACAGCCGGCGGTAT 
ORF10 3’  171872 F  ATGGTAAAGTCGGGCTCGGGCTTGATGTCTTCCTGTTTGATGAGGGGCAGCATGATAGGC 
ORF11 3’  3933 F  ATAAAAACTCATGGACGTGAAATCTGGCTTGGTTGTGGTGATTTCATTCTCATTATTGTT 
ORF12 3’  234784 R  ACGGAGCCGTCCGCGTGTGTAAACGGCGTGGTCGCTGACGCGGGTTTGCTTCCTATATAG 
RL3 3’  3831  F  TATACATCTAAGATTGGAGTACTAGTAGTCGTTTGTGGTTTCTATTTTTTTTTTATATTT 
RL4 3’  304 R  CGGGGTGTGTCAGGGGTGTGTCGGGGTGTGTTGGCGGGCCGTGTCTGCGTGTGTCCTCGA 
RL5 3’  4772 F  AGATTCGACCAGACAGAAGAGAAGGACCGGGGCTTGGCGACCCTTCCACGACTGCTGTTG 
RL8 3’  7870 R  TCCGCTGTTTTTAGCTGAGACTGGCGTGCGACCTGTAAACCGTTACTCGGGTCTCAAGAT 
RL9 3’  8229 F  CGTCAGGGGCCGGGGTTCTTATTAGAGAAACAGCACGTAGGTCAGGATCCAGATGCTAAT 
US5 3’  201540 F  CGCGACAGAAAAAATACCGTTCGTAGAGAATGCCGTGTTGAAGGAACGCGCTTTTATTGA 
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US25 3’  221716 F  GGTGCCCGACCGTGAAGAGCCCTCATCCACCTGAACAGACCGCTAACCGAAGGACCCCGA 
J1S 3’  235125 R  CCCACCGCAGCACACGCAACTAGTCGCCGTCGCCGTCCACACACGCAACTCCAAATTTCA 
UL61 3’  95055 R  AGAGGGGGGAGGGGAGCCCAACCGGAGCCGCCGAGAGGGAGCCGCCGCGAGACCCGGAAG 
UL21 3’  27215 R  AACATGACGCGTTCGGGACGAAAGACGACGTCAGGGGATTCACGGTATTTAGCCATGCAG 
UL41 3’  54339 R  GAAGCCATAAAAATATGGGAATTCCCCTGCCTACGTCTTCATGACGGGCGCCTTTTTCTT 
UL60 3’  93693 R  TCGTAGAACGTTTCGTTAGAAGAATTATGCTATATAGGGTATGCATCCTAGGGGTGGAAG 
UL101 3’  147689 F  GGGGGCGCGCCGATGACGACAGGCTCGCGGGTCGTTAAATACTACGATGGGAGCCGCCGC 
 
 
Table 2.2. List of HCMV microarray oligonucleotide probe sequences. 
The table lists the 60-mer oligonucleotide sequences together with their genome position, and the 
strand that they represent, either the forward or reverse strand. Note that all viral probes 
sequences represented the sense strand of each ORF.  
 
 
 
 
 
 
 
 
Bacterial Spike 
Control  
Oligonucleotide Probe Sequence (60-mer) 
X17013  
(Sense) 
GGATCGAACCGGGCCGTTCTCTCGTGGGAGACGCAGGCACAACTCTTTATACGGTTGGCT 
X17013  
(Anti-Sense) 
CCTAGCTTGGCCCGGCAAGAGAGCACCCTCTGCGTCCGTGTTGAGAAATATGCCAACCGA 
M24537  
(Sense) 
GAAAGCGTTTGATGATGTATTGATTCCAGGGGCCATGCAGGAGCTTGAAGCACTCGGCTG 
M24537  
(Anti-Sense) 
CTTTCGCAAACTACTACATAACTAAGGTCCCCGGTACGTCCTCGAACTTCGTGAGCCGAC 
 
Table 2.3. Bacterial spike control probe sequences. 
Bacterial spike control probes were printed in forward (sense) and reverse (anti-sense) orientation, 
thus serving as positive and negative control elements.  
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2.2.9.2 Microarray  hybridisation 
2.2.9.2.1  Preparation of cDNA 
 
cDNA was fragmented by adding 15 µl of 0.1 M NaOH to the 30 µl cDNA sample (see 
2.2.8.1) and incubating at 70 °C for 10 min, and then neutralised by addition of 15 µl of 0.1 
M HCl. 20 µg of COT I human DNA was added to the cDNA preparation, and the 
unincorporated nucleotides etc. removed with water (SIGMA) by centrifugation in a 
Centricon column at 13000 x g for 5 min at RT. The flow-through was discarded and ~ 0.5 
ml of water (SIGMA) was added to the column. The column was then centrifuged at 
13000 x g until the volume of sample in the column was reduced to < 8 µl. The column 
was transferred to a clean collection tube by inversion of the Centricon column, and 
centrifugation at 13000 x g for 1 min at RT. The sample volume was then increased to 12 µl 
by the addition of water (SIGMA). The cleaned labelled cDNA was prepared for 
hybridisation by adding 2.6 µl of 20 X SSC and 0.44 µl of 10 % SDS (3.5 X SSC/0.3 % SDS 
(v/v)), and incubating at 95 °C for 2 min followed by 37 °C for 30 min.  
2.2.9.2.2  Pre-hybridisation of microarray slides 
 
Microarray slides were re-hydrated prior to pre-hybridisation. The slides were placed 
array face down in a chamber in an atmosphere of 1 X SCC for 2 min at RT, and then 
placed array face up on a 70 °C hot plate for 20 sec. The slides were then pre-hybridised 
with BSA blocking solution at 42 °C for 45 min, then rinsed with water and dehydrated in 
isopropanol, followed by cleaning under a stream of filtered compressed air. The array 
area was carefully covered by a LifterSlip 25 mm × 20 mm (Eerie Scientific Company, 
U.S.A.), previously prepared by washing in absolute ethanol, and drying under a stream 
of filtered compressed air.  
2.2.9.2.3  Hybridisation and stringency washes 
 
The cDNA sample was carefully applied to the array area under the LifterSlip by capillary 
attraction, so as to avoid the formation of air bubbles. The array slides were then 
hybridised in a humidified GENETIX hybridisation chamber, which was incubated in a 
dry oven at 65 °C for 16-20 h.  Following hybridisation, LifterSlips were removed without 
mechanical interference by briefly immersing the slides in 1 X SSC/0.2 % SDS (v/v) at 65 
°C. The subsequent array washes described below were performed at RT in staining jars, 
in which solutions were continuously mixed using a magnetic stirrer. The slides were 
washed in 1 X SSC/0.2 % SDS (v/v) for 5 min, 0.1 X SSC/0.2 % SDS (v/v) for 5 min, then 
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plunged 5 times in 0.1 X SSC in order to remove residual SDS. The slides were then dried 
by centrifugation (array face out) at 500 x g for 1 min at RT. The dry slides were then 
placed in a darkened box, and stored in a desiccator at RT.  
2.2.9.2.4  Scanning and quantitation of microarrays 
 
Microarrays were scanned and quantitated using Perkin-Elmer ScanArray Express 
hardware and associated software. Slides were scanned at a laser wavelength of 543 nm, 
with laser power set at 100 %, and a pixel resolution of 10 µm.  The slides were each 
scanned 4 times at photomultiplier tube (PMT) gain settings of 40, 50, 60, and 70 %. 
Scanning of slides with increasing PMT gain was performed in order to identify array 
images whose hybridisation signals lay within a linear dynamic range, in the absence of 
signal saturation. Microarray images were saved as both greyscale TIFF and colour JPEG 
files before proceeding with filtration of poorly defined spots and quantitation of spot 
signal intensities. A flow-diagram depicting the stages of microarray data analysis is 
shown in Fig. 2.1. 
Microarray hybridisation signals were quantitated using the ‘ScanArray Express new fast 
spot-finding algorithm’, on the TIFF image files. The spot-finding algorithm uses the GAL 
file to determine the position of each feature on the array. The spots were then quantitated 
by adaptive circle feature extraction; this places a circle over each spot and estimates the 
diameter for each spot individually (maximum diameter set at 100 µm), to optimise data 
capture. The spot-finding algorithm then defines background correction values and signal 
values (i.e. median and mean values), which are calculated for each spot. Visual 
inspection of the array grids was undertaken in order to confirm correct alignment, and to 
manually check the integrity of features (e.g. misshapen spots, smears or artefacts). The 
quantitation data was used to generate a spreadsheet listing signal intensities for each 
spot on the microarray (median minus background, and mean minus background), which 
was subsequently exported and saved as a Microsoft Excel file. This process was 
undertaken for each PMT gain setting (listed above), so that four Excel datasets were 
generated per microarray. 
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Figure 2.1:. Analysis procedure for the HCMV microarray data 
The flow-diagram represents the steps taken to analyse the HCMV gene expression data. This
procedure starts  with the raw gene expression  signal intensities, which are processed in a series
of steps in order to determine linearality, signal cutoff points, and normalisation. The data is
imported into GeneSpring and an experiment is created, followed by analysis such as filtering and
clustering, and then identification of differential gene expression using 1-way ANOVA tests.   
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2.2.9.3  Data Processing  
2.2.9.3.1  Determination of linear dynamic range and assessment of signal distribution  
 
Each microarray slide was scanned four times at PMT gain settings of 40, 50, 60, and 70 %, 
generating four datasets per microarray. The signal intensity values of all probes on the 
microarray were extracted, and the ‘mean minus background’ signal values were selected 
for data processing and analysis. In order to determine the dataset with a linear dynamic 
range, scatterplots were drawn in Excel of PMT gain 40 vs 50, 50 vs 60, and 60 vs 70. The 
dataset giving signal values with optimum scatter in the absence of signal saturation and 
falling within a linear range (assessed by least-square fit analysis), were chosen for further 
analysis.  
The signal distributions of the selected datasets were further assessed by drawing Box-
Plots (SPSS statistical analysis software). Linear signal intensity data is ‘right-skewed’ 
when assessed by histograms. In order to transform the linear signal intensity data so that 
it follows a symmetrical distribution (a common assumption for many statistical tests, and 
a requirement for those employed here for analysing HCMV microarray data), the 
microarray data was log2 transformed. Box-plots were then drawn to ensure that the 
datasets were symmetrical. Datasets that fulfilled the requirements for both linear and 
symmetrical data were selected for Receiver Operating Characteristic (ROC) analysis.  
2.2.9.3.2  Receiver operating characteristic analysis 
 
An essential requirement in all microarray analyses is to determine a signal threshold 
cutoff point that discriminates between true-positive hybridisation signals and false-
positive signals arising from non-specific binding. Unlike commercially available 
microarray technologies, where algorithms are designed to make such decisions with little 
user input, no such algorithms are applied to custom microarrays. Other workers have 
selected fairly arbitrary cutoff points, which do not take into account the sensitivity and 
specificity of such signal thresholds, and which can lead to elevated false-positive rates 
(Bilban et al., 2002). Receiver Operating Characteristic (ROC) analysis was performed to 
address this issue. ROC analysis determines signal thresholds that give optimum 
specificity (i.e. true-negative rate), without compromising the sensitivity (i.e. true-positive 
rate) of the microarray.  
ROC analysis (contained in SPSS) was performed on the positive and negative control 
signal values for selected linear datasets (2.2.9.3.1). ROC analysis ranks the values for 
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positive and negative signals, then establishes a series of signal thresholds and measures 
the likelihood of type I (i.e. false-positive) and type II (i.e. false-negative) errors for such 
cutoff points. A ROC curve is drawn representing the relationship between false-positive 
and false-negative rates for every possible cutoff point; it is then possible to select a signal 
threshold for the whole array that gives optimum sensitivity and specificity. For all 
control signal datasets analysed, a signal threshold that gave a false positive rate of 5 % 
was selected. All signal values that fell below this cutoff point were assigned a signal 
value of 0.01.  
2.2.9.3.3 Normalisation 
 
Linear datasets were normalised against positive control signals generated from the in 
vitro transcribed spike mRNA of known concentration, in order to control for differences 
in the efficiencies of cDNA synthesis, hybridisation and scanning. The 75th percentile was 
calculated from the positive control signal values for each array dataset. An array chosen 
at random served as a reference against which all other array datasets, irrespective of cell 
type, were scaled. The following calculation was used to define a correction value for each 
dataset, allowing global normalisation against the reference.  
 
Array)   (Test    Signals   Control   Positive   of   Percentile 75th 
  Array)   (Reference   Signals   Control   Positive   of   Percentile 75th 
     (CF)   Factor   Correction =  
A normalisation correction factor (CF) in the range 0.5 to 4 was deemed acceptable. Most 
of the HCMV array CF values fell within the range 0.75 to 2 (see table 4.2, results II). All 
probe signals in a particular dataset were then normalised by multiplying against the 
determined CF for that array. This allowed normalisation across all microarray datasets 
for all cell types.  
2.2.9.3.4  Data flagging and preparation for import into GeneSpring 
 
Following normalisation of the array datasets, signals were flagged as present (P), or 
absent (A). Signal values of 0.01 were flagged as absent (based on the ROC analysis, see 
2.2.9.3.2). The normalised flagged data were transferred to new Excel files, which 
contained three data columns (Gene Name; Signal Value (log2); Flag). The new Excel files 
were then saved as ‘tab delimited text files’; the format required for import into the 
expression analysis software, GeneSpring.  
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2.2.9.4  Analysis of data in GeneSpring  
2.2.9.4.1  Preparation of the GeneSpring software and import of microarray data 
 
In order to analyse HCMV gene expression data, the annotated HCMV (Merlin) genome 
file (acc. no. AY446894) was downloaded from GenBank (NCBI) into the GeneSpring 
software (Agilent Technologies).  Annotations for regions of the genome now considered 
to be non-coding and the novel ORFs recently proposed by Murphy et al., (2003a and b) 
were added, creating a genome within GeneSpring that represented the full complement 
of probes on the microarray. The log2 datasets (tab delimited text files; see 2.2.9.3.4) were 
imported into GeneSpring using the software import wizard. This process had several 
stages:  
1.  Import data files and create an ‘experiment’. 
2.  Describe the data contained within each data file (i.e. gene name; signal value; 
flag). 
3. Transform  log2 data to linear data (as GeneSpring uses the natural logarithm of 
linear data for its statistical analyses). 
4.  Further normalisation; per gene, normalise to the median. This normalisation step 
controls for differences in the detection efficiency between spots and was 
performed so that the relative change in gene expression could be compared for all 
genes between each cell type. This was calculated as follows: 
 
type   cell each    from   A   gene   for   ts measuremen   all   of Median 
A   gene   of strength    Signal
  Median    the   to   Normalise   : Gene   Per =
5.  Define the experiment parameters i.e. cell type and time. 
6.  Define the experiment interpretation and display options (i.e. calculate the 
arithmetic mean of the expression data for each gene).  
The microarray data for each gene was displayed in the form of three separate “gene 
expression profile” graphs (one for each cell type), with time (h PI) on the x-axis, and 
normalised signal on the y-axis.  
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2.2.9.4.2  Examination of present and absent flags 
 
All probes in each dataset had been flagged as present (P) or absent (A) prior to import 
into GeneSpring. Genes that failed to pass the cutoff points determined by the ROC 
analysis were assigned a value of 0.01, and flagged as absent (A). Examination of the 
number of datasets containing present/absent flags for each gene was undertaken in 
GeneSpring using the filtering tool. All genes from each cell type were assigned a value of 
from 0 to 12 (as there were 12 datasets per cell type), so genes that were not expressed 
could easily be identified, and to allow basic quality control analysis to be undertaken. 
2.2.9.4.3  Quality control based on clustering 
 
Condition trees were then assembled for each cell type, in order to confirm that the array 
datasets for each time point clustered together, and that there were no obvious anomalies 
(e.g. a 12 h dataset clustering with a 72 h dataset). The condition trees were drawn using 
the clustering tool within GeneSpring, and based on Spearman’s correlation (rank 
analysis) in which the null hypothesis (no relationship between the array datasets) was 
tested in order to determine the clustering. This analysis was peformed for each cell type 
independently. Note that the ‘per gene: normalise to the median’ was removed prior to 
clustering so that comparisons could be made independently from one another. Mock-
infected cell datasets were excluded from this analysis. 
2.2.9.4.4  Differential gene expression 
 
In order to identify genes whose expression were differentially regulated in different cell 
types, combined statistical tests (Student’s t-test; Welch’s t-test; and Wilcoxon-Mann 
Whitney test) were performed independently between HFFF-2 vs RPE, and HFFF-2 vs 
U373Mg. The statistical tests were performed on the mean expression value for each gene 
from all data points over the time course, giving a single expression value for each gene in 
each cell type. The statistical tests then compared the expression values for individual 
HCMV genes in HFFF-2 against the corresponding expression values for individual 
HCMV genes in RPE or U373Mg cells. The null hypothesis (no difference in the mean 
gene expression intensities in HFFF-2 and RPE or U373Mg cells) was tested. Significant 
differences in the mean expression of individual genes in HFFF-2 and RPE or U373Mg 
cells were identified at the 95 % significance level (p <  0.05).  
In order to adjust the p-values derived from the statistical tests to correct for the 
occurrence of false positives, a multiple testing correction (MTC) was applied. We 
selected the Benjamini and Hochberg False Discovery Rate as this provides a good 
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balance between the limitation of false positive data and the discovery of statistically 
significant differences. The Benjamini and Hochberg MTC was based on an error rate of 5 
%, therefore 5 % of genes considered significantly different would pass the MTC 
restriction by chance.  The MTC ranks the p-values derived from the statistical tests from 
smallest to largest; the largest p-value remains as it is. The second largest p-value is 
corrected by: 
Corrected p-value = p-value × (n/n-1) 
n = the total number of genes tested in the gene list. 
n-1 = the rank of the gene whose p-value is being adjusted. 
The third largest p-value is then corrected by multiplying the p-value by (n/n-2), and so 
on. The test becomes more stringent as the rank of the p-value decreases. Genes whose p-
values remain < 0.05 following the application of the MTC are considered significantly 
different, but note that 5 % of these genes will have passed this test by chance.  
2.2.10 PCR   
All PCR reactions were performed in a total volume of 50 µl and contained 100-500 ng of 
template DNA, using Taq polymerase (QIAGEN). Thermo-cycling conditions were; a hot 
start at 95 °C for 10 min; 35 cycles at 94 °C for 30 s; 55 °C for 20; 72 °C for 45 s; and finally a 
hold at 4 °C.  
2.2.11  Agarose gel electrophoresis 
All DNA fragments generated by PCR or restriction endonuclease digests were analysed 
on 1 % agarose/TBE gels containing ethidium bromide. DNA samples were diluted to 
give a final concentration of 1 X OrangeG (v/v), and electrophoresed at 100 V for 3 h. The 
gels were then visualised using short-wave or long-wave UV transillumination, as 
appropriate, and photographed using the BioRad Gel Doc system.  
2.2.12  Recovery of DNA fragments 
DNA fragments were separated on 1 % agarose/TBE gels at 100 V for 3 h. The DNA 
fragments were visualised using long-wave UV transillumination, and the bands excised. 
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DNA fragments were extracted from agarose gel slices using the PureLink Quick Gel 
Extraction Kit (Invitrogen), according to the manufacturer’s instructions.  
2.2.13 Restriction  endonuclease  digests 
Digest reactions typically contained 10 U of enzyme, ~ 500 ng of DNA, prepared in a 
buffer solution compatible with the restriction enzyme. Total reaction volume was 20 µl, 
with incubation at 37 ºC for 3 h.  
2.2.14  Preparation of FIX-BAC DNA 
The HCMV bacterial artificial chromosome FIX-BAC derived from the clinical VR1814 
strain of HCMV was the kind gift of Dr G. Hahn (see Gerna et al., 2003). FIX-BAC DNA 
was isolated from E.coli DH12 bacteria using the QIAGEN large construct kit, according to 
the manufacturer’s instructions.  
2.2.15  Real-time PCR  
Real-time PCR (RT-PCR) analyses were undertaken using an Applied Biosystems 7500 
Fast Real-Time PCR machine and associated software.  The PCR reaction mix contained 2 
µl of 10 X PCR buffer (200 mM Tris.HCl, 500 mM KCl), 1 µl of 10 X MgCl2 (50 mM), 1 µl 
each of forward and reverse primers (10 µM), 1 µl of 10 X SYBR green I, 2 µl of 10 X dNTP 
mix (each at 2 mM), 0.2 µl of Platinum Taq polymerase (5 U/µl) (Invitrogen), and 8 µl of 
template DNA (12.5 ng of cDNA; or 150 ng genomic DNA). Thermo-cycling conditions 
were; hot start at 95 °C for 10 min, then 35 cycles at 94 °C for 10 sec; 60 °C for 20 sec; 72 °C 
for 25 sec (with read plate); followed by dissociation analysis from 65-95 °C, with plate 
read every 0.2 °C increment; and hold at 4 ºC. 
2.2.16 Northern  Blotting 
2.2.16.1   Formaldehyde-agarose gel electrophoresis 
In order to avoid RNase contamination, disposable plastic-ware was used whenever 
possible. Glassware was autoclaved and baked twice in the dry oven; gel tanks and other 
re-useable plastic-ware were washed with RNaseZap (SIGMA), rinsed in distilled water 
and allowed to drip-dry; nuclease-free and/or distilled water, nuclease-free eppendorf 
tubes and pipette tips were used throughout. 
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To prepare the gel, 1 g of agarose was dissolved by boiling in 85 ml of water (SIGMA), 
and cooling to 55 °C. 5.8 ml of formaldehyde and 10 ml of 10 X MOPS were pre-heated to 
55 °C, added to the 1 % agarose (w/v), mixed and poured into a gel-casting tray and left 
to set at RT. The gel was pre-electrophoresed at 80 V for 10 min in 1 X MOPS buffer.   
10 µg of total RNA in 5 µl of water (SIGMA), was mixed with 3 volumes of NorthernMax 
Formaldehyde Load Dye (Ambion Inc.), and incubated at 65 °C for 15 min. The RNA 
ladder (0.5-10 kb) (Invitrogen) was similarly prepared by adding 9 µl of Loading Dye to 3 
µl of the RNA ladder and incubating at 65 °C for 15 min. The RNA samples and ladder 
were then snap cooled on ice for 5 min, and 0.25 µg of ethidium bromide added. RNA 
samples were electrophoresed at 50 V for 6 h, and the RNA bands briefly visualised and 
photographed using short-wave UV transillumination with the BioRad Gel Doc system. 
The intensities of the 28S and 18S rRNA bands across the gel tracks confirmed equal 
loading of the RNA samples.  
2.2.16.2   RNA transfer by capillary blotting 
RNA transfer from the gel to a nylon membrane (Hybond N+, Amersham Biosciences) 
was accomplished by capillary blotting (Southern, 1975). The gel was washed in distilled 
water for 10 min followed by washing in 10 X SSC for 15 min. The nylon membrane was 
washed in distilled water for 5 min followed by washing in 20 X SSC for 20 min. 
Whatman 3MM paper was washed in 2 X SSC for 20 min.  
The gel was placed on Whatman 3MM paper that functioned as a wick descending from a 
raised platform into a reservoir of 20 X SSC. The nylon membrane was placed on top of 
the gel, followed by Whatman 3 MM paper soaked in 2 X SSC, and a stack of dry paper 
towels with a weight on top. After overnight transfer of RNA, the membrane was washed 
in 10 X SSC for 1 min (no shaking) and the RNA cross-linked to the membrane using a 
Stratagene UV cross-linker operating at ‘auto-crosslink’ (12000 Jcm-2). The membranes 
were then wrapped in clingfilm and stored at 4 °C, prior to nucleic acid hybridisation. 
2.2.16.3   Preparation of DNA probes  
32P-radiolabelled DNA probes were prepared from PCR fragments (250-400 bp) amplified 
using HCMV (Merlin) genomic DNA (see 2.2.3). Radiolabelled DNA probes for the 
cellular housekeeping gene, glyceraldehyde 3’-phosphate de-hydrogenase (GAPDH) were 
prepared from DECAtemplate GAPDH-mouse (905 bp) (Ambion Inc.). The Rediprime II 
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Random Prime Labelling System (Amersham Biosciences) was used to synthesise the 
probes (using 100 ng of template DNA and 50 µCi of α-32P-dCTP), according to the 
manufacturer’s instructions. The radiolabelled probes were then purified by 
acetate/ethanol precipitation using 150 µg/ml of GlycoBlue (Ambion Inc.) to facilitate 
DNA recovery. The DNA was precipitated with 6 µl of ammonium acetate (5 M) and 3 
volumes of absolute ethanol -20 ºC. The DNA probe was incubated at -20 °C for 1 h, then 
the DNA pelleted by centrifugation at 13000 x g for 10 min at 4 ºC.  The DNA was washed 
with 70 % ethanol 4 ºC, followed by centrifugation as before. The DNA pellet was air 
dried for 5 min, before resuspension in 50 µl of water (SIGMA). The radiolabelled DNA 
probe was prepared for hybridisation by boiling for 10 min, cooled on ice for 5 min, and 
then added to the hybridisation reaction.  
2.2.16.4   Nucleic acid hybridisation 
Hybridisations were performed in glass hybridisation tubes (Hybaid) that were incubated 
in a Hybaid minioven MKII. Nylon membranes (Hybond N+) containing the cross-linked 
RNA fragments were prepared for hybridisation by washing in 20 ml of 1 X SSC/0.1 % 
SDS (v/v) at 68 °C for 1 h. The membranes were then pre-hybridised with 15 ml of Rapid-
Hyb Buffer (Amersham Biosciences) at 68 °C for 2 h. Denatured radiolabelled DNA probe 
was then added and hybridisation continued at 68 °C overnight. Hybridised membranes 
were then washed with 20 ml of 2 X SSC/0.1 % SDS (v/v) at 68 °C for 20 min, and washed 
twice with 20 ml of 0.1 X SSC/0.1 % SDS (v/v) at 68 °C for 10 min. The radiolabelled 
membranes were then wrapped in clingfilm and exposed to a BioRad phosphorimager 
screen. 
2.2.16.5   Phosphorimager analysis  
The radiolabelled membranes were exposed to a phosphorimager screen for 3 h, after 
which the membrane was removed and the screen placed on the BioRad Personal FX 
phosphorimager. Radiolabelled bands on the northern blot were imaged using the 
Quantity One program.  
2.2.17 Western  Blotting 
2.2.17.1   Preparation of mock-infected and HCMV infected cellular protein 
35 mm tissue culture dishes containing 5 x 105 cells/dish of HFFF-2, RPE and U373Mg 
were incubated at 37 ºC overnight. The cell monolayers were mock-infected or infected 
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with HCMV at a m.o.i. of 6 p.f.u./cell as previously described. After virus adsorption, the 
cell layers were washed twice with 1 ml of DMEM/FCS, and then overlaid with 2.5 ml of 
fresh medium followed by incubation at 37 ºC. At 0, 12, 24, 48, and 72 h PI, and at 72 h PI 
for MI cell cultures, the medium was removed and the layers washed twice with 1 ml of 
PBS, and lysed with 200 µl of SDS-PAGE sample buffer, and stored at -20 ºC prior to SDS-
PAGE. 
2.2.17.2   SDS-PAGE electrophoresis 
The Bio-Rad mini-protean II cell apparatus was used for the preparation of SDS-PAGE 
gels. A 10 % SDS-PAGE gel was prepared; 5 ml of resolving gel buffer, 8 ml of distilled 
water, 7 ml of 30 % acrylamide/BIS (37.5:1), 20 µl of TEMED, and 80 µl of 25 % (w/v) 
ammonium persulphate. The stacking gel contained 3 ml of stacking gel buffer, 7 ml of 
distilled water, 2 ml of 30 % acrylamide/BIS, 20 µl of TEMED and 80 µl of 25 % (w/v) 
ammonium persulphate. 25 µl of each protein sample were loaded onto each gel slot, 3 µl 
of rainbow protein marker (Amersham Biosciences), and electrophoresed at 120 V.  
2.2.17.3   Western immunoblotting 
The Bio-Rad mini trans-blot apparatus was used to transfer proteins to ECL nitrocellulose 
membranes. SDS-PAGE gel and membrane were sandwiched between two layers of 3MM 
paper pre-soaked in Towbins buffer. The sandwich was immersed in a tank of Towbins 
buffer and transfer was accomplished by electrophoresis at 50 V for 2-3 h. The membranes 
were retrieved from the apparatus and incubated with blocking solution (PBS with 
0.00005 % Tween 20 (PBS/T) and 5 % (w/v) ‘Marvel’ milk powder at 4 °C overnight, then 
washed 3 times with PBS/T for 15 min. Primary antibody (typically a 1:500 dilution in 
PBS/T containing 1 % BSA (w/v)) was incubated with the membrane at 37 °C for 2 h, 
followed by washes with PBS/T as previously described. Secondary antibody (typically 
1:1000 dilution in PBS/T with 1 % BSA (w/v)) was then incubated with the membrane at 
37 °C for 1 h, then washed 3 times with PBS for 15 min. The membrane was then treated 
with ECL reagents (Amersham Biosciences) for 1 min at RT, according to the 
manufacturer’s instructions, and then exposed to photographic film prior to developing 
the image using the Konica SRX 101A film processor. 
2.2.18 Immunofluorescence 
13 mm sterile glass coverslips containing 1 × 104 cells/coverslip of HFFF-2, RPE and 
U373Mg were incubated at 37 °C overnight. Monolayers were infected with HCMV at 
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varying m.o.i. as previously described. The infected cultures were incubated at 37 °C for 
48 h, after which the medium was removed and the cells fixed (5 % (v/v) formaldehyde, 2 
% (w/v) sucrose in PBS) for 10 min at RT. The cells were then permeabilised by treatment 
with 0.5 % (v/v) NP40, 10 % (w/v) sucrose in PBS, for 5 min at RT, and the cells washed 3 
times with PBS. Cells were then treated with primary antibody (anti-UL44 clone:CCH2 
pre-conjugated to FITC; diluted 1:500) for 1 h at RT, after which the coverslips were 
washed 3 times with PBS. The coverlsips were set on glass microscope slides using 
mounting medium and sealed by the application of clear nail varnish around the sides of 
the coverslip. The coverslips were examined under UV illumination using the Zeiss 
Axioplan 2 microscope wavelength LSM512 imaging system, operating with the 488 nm 
wavelength laser. Fluorescent cells expressing the HCMV UL44 early gene product were 
counted from 2 representative fields of view for each coverslip.   
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3 RESULTS  I 
3.1  Characterisation of HCMV strain Merlin replication in different cell types 
It is important to compare the replication kinetics of HCMV strain Merlin in HFFF-2, RPE 
and U373Mg cells prior to an interpretation of global HCMV gene expression data in 
these cell types. There are several stages in the virus lytic cycle that could be affected by 
growth in different cell types. Virus attachment and entry into host cells might be more 
efficient in one cell type compared to another. The kinetics of the viral transcription 
and/or protein expression cascade might vary in different cell types as a consequence of 
differences in the levels of specific cellular factors. The kinetics of viral DNA replication 
might also differ between cell types. Any one or more of these factors might affect the 
production and release of mature infectious particles.  
 
3.2  One step virus growth curves  
One step HCMV growth curves were obtained for HFFF-2, RPE and U373Mg cells 
infected at a m.o.i. of 1 p.f.u./cell. Samples were harvested every 24 h over a 7 day period 
for estimation of total infectious virus yield (Fig. 3.1). HCMV replication was most 
efficient in the HFFF-2 cell line. Exit from the viral eclipse phase of the growth curve 
occurred at 48 h PI in the case of HFFF-2 cells but was delayed by 24 h (i.e. at 72 h PI) in 
both RPE and U373Mg infected cultures. The rate of virus growth over the period 48 h to 
96 h PI was similar in all of these cell types, although the final virus titres obtained varied 
widely. The curve obtained with HFFF-2 plateaus at 144 h PI with a maximum titre just 
over 105 p.f.u./ml. The maximum titre obtained from the RPE culture was 10 fold lower at 
104 p.f.u./ml, although it should be noted that the curve has not reached a plateau; the 
maximum titre obtained from the U373Mg culture were 1000 fold lower than that 
obtained for HFFF-2, at 102 p.f.u./ml, and the curve plateaus after only 96 h PI. 
 
The one step virus growth curves were then repeated at a m.o.i. of 6 p.f.u./cell, but in this 
experiment, the total yield was fractioned into cell-associated virus (CAV) and cell-
released virus (CRV) yields. Fig. 3.2 shows the curves obtained for the CRV fraction. In 
HFFF-2 cells, released infectivity was first detected at 72 h PI, rising steadily to plateau at 
144 h PI, with a yield of 106  p.f.u./ml. In RPE and U373Mg cell cultures, release of 
infectivity was first detected at 120 h PI (i.e. 48 h after HFFF-2), and the rate of 
accumulation of released infectivity was much slower, and failed to plateau over the 7 day 
period. Yield for RPE cultures was 100 fold less than that for HFFF-2 cultures, and for 
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U373Mg cultures, 1000 fold less. Fig. 3.3 shows the curves for the CAV fraction. In HFFF-2 
cultures, exit from the viral eclipse phase occurred at 48 h PI, as before, RPE and U373Mg 
are relatively delayed by 24 h (i.e. at 72 h PI). The rate of accumulation of CAV is similar 
in HFFF-2 and RPE cultures, but slightly slower in U373Mg cultures. All three curves 
plateau at 96 h PI, with HFFF-2 and RPE having a similar titre at 104 p.f.u./ml, while the 
titre from U373Mg cultures is ~ 100 fold less at  102 p.f.u./ml.  
Taken together, Fig. 3.1, 3.2 and 3.3 shows that accumulation of mature infectious virus is 
delayed by ~ 24 h in RPE and U373Mg infected cells compared to infected HFFF-2 cells. 
The rate of growth is similar in HFFF-2 and RPE infected cells and similar amounts of 
CAV are made. In contrast, replication of virus is limited both temporally and in 
infectious titre in U373Mg cells. Release of infectivity to the extracellular medium is both 
delayed (by 48 h) and accumulates more slowly from RPE and U373Mg cells compared to 
infected HFFF-2 cells.  
3.3  Efficiency of HCMV infection in HFFF-2, RPE and U373Mg cells 
In order to determine whether differences in the final virus yield were due to differences 
in the efficiency of HCMV infection of the different cell types, immunofluorescence 
experiments were performed at a m.o.i. of 3, 6 and 10 p.f.u./cell for each type. Infected 
cells were incubated for 48 h prior to fixing and staining with anti-UL44 antibody (CCH2 
pre-conjugated to FITC). The HCMV UL44 is an early gene coding for the DNA 
polymerase processivity factor, and is used here as a marker for infection of the cells. 
Fluorescently labelled cells expressing UL44 were counted from 2 representative fields of 
view for each cell type (Fig. 3.4). No significant differences were seen in the numbers of 
cells infected for the different cell types. It was concluded that the observed differences in 
the final virus yields were not due to disproportionate numbers of cells infected for the 
different cell types.  
 
3.4  Expression kinetics of known HCMV immediate-early, early and late proteins 
Delays observed in the production of mature infectious particles and their subsequent 
release from RPE and U373Mg cells (Fig. 3.1, 3.2 and 3.3) could be due to delays in the 
onset of the gene expression cascade. The expression kinetics of representative known 
immediate-early (IE) (IE1/IE2), early (E) (US22; pUS22) and late (L) (UL99; pp28) proteins 
were examined in each cell type. Equal numbers of cells were seeded in 30 mm dishes and 
either mock-infected or infected with HCMV at a m.o.i. of 6 p.f.u./cell, and cell protein
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harvested in 200 µl/dish of SDS-PAGE sample buffer at 0, 12, 24, 48 and 72 h PI (and 72 h 
PI only for MI cell cultures). Equal volumes of protein samples were loaded into each gel 
slot and then separated by electrophoresis on SDS-polyacrylamide gels, transferred to a 
nylon membrane, then probed for IE1/IE2, pUS22 and pp28 using antibodies specifically 
directed against these target proteins.   
The western blot for IE1/IE2 (Fig. 3.5) detected IE1 (72 kDa) expression from 12 h PI in 
each of the three cell types, reaching an apparent steady state level of expression between 
12 and 24 h PI over the time course. IE2 (86 kDa) is similarly detected from 12 h PI in each 
cell type, but in contrast to IE1, IE2 gradually accumulates over the period 12 to 72 h PI. 
An early 60 kDa splice variant of IE2 is detected at 48 h PI in HFFF-2 cells and 
accumulates through to 72 h PI. This protein is also detected at 72 h PI in RPE infected 
cells, but not in U373Mg cells. The late IE2 (40 kDa) product is expressed from a transcript 
arising from an internal transcription start site within exon 4 of IE2 (Jenkins et al., 1994). 
Expression of IE2 (40 kDa) can be detected from 12 h PI in infected HFFF-2 cells but 
accumulates rapidly from 48 h PI through to 72 h PI in each cell type. No difference in the 
kinetics of expression of major IE transactivating proteins IE1 (72 kDa), IE2 (86 kDa) and 
the late IE2 (40 kDa) spliced product were detected in HFFF-2, RPE and U373Mg cells, 
although gross amounts differed between the cell types. In contrast, the IE2 (60 kDa) 
spliced product was not detected in U373Mg cells.  
US22 is an early expressing gene, expressing pUS22 (76 kDa) a component of the virus 
tegument. The western blot for the pUS22 protein (Fig. 3.6) shows expression from 12 h PI 
in each of the three cell types, accumulating with time PI. As with the IE1 (72 kDa) and 
IE2 (86 kDa) proteins, there was no apparent delay in the onset of expression for this early 
protein in HFFF-2, RPE and U373Mg cells, although the amounts made, especially at 12 h 
and 24 h PI, was very much less in RPE and U373Mg cells. 
 
Western blots for the late UL99 gene (Fig. 3.7) detected expression of pp28 (28 kDa) from 
24 h PI in each cell type, that increases sharply at 48 h PI and 72 h PI. Again, no difference 
in the onset of pp28 expression is detected in HFFF-2, RPE and U373Mg cells, although 
amounts of the protein made at each time point varies between the cell types. It should be 
noted that both pUS22 and pp28 are components of the virus tegument, and bands for 
both proteins can be detected in the 0 h PI sample due to its presence in the input virus.  
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3.5 Discussion 
Human foreskin fibroblast (HFF) cells have been used extensively in HCMV research 
because of the high yields of virus produced. Consequently, the HFFF-2 cell line was used 
here as a reference cell line for the microarray work. The biological studies have shown 
that there was no significant difference in the ability of HCMV to enter and initiate 
infection in the three cell types. However, the growth curves did reveal differential 
replication kinetics.  
For the growth curve performed at a m.o.i. of 1 p.f.u./cell (Fig. 3.1), there was a delay of 
24 h in the exit from the eclipse phase in RPE and U373Mg cells compared to HFFF-2 cells. 
The rate of replication from 48 to 96 h PI was similar in each cell type; however, the 
replication of HCMV plateaus at 96 h PI in U373Mg cells and at 144 h PI in HFFF-2 cells, 
while replication in RPE cells continues to increase up to 168 h PI. For the growth curves 
performed at a m.o.i. of 6 p.f.u./cell, the virus yield was fractionated into cell-released 
virus (CRV) (Fig. 3.3) and cell-associated virus (CAV) (Fig. 3.2) yields. As with the growth 
curve in Fig. 3.1, the CRV and CAV growth curves revealed differential replication 
kinetics with respect to the duration of the eclipse phase, delayed by a further 24 h in RPE 
and U373Mg cells compared to HFFF-2 cells, and also the release of CRV to the medium, 
and to a lesser extent, the accumulation of CAV. The accumulation of CAV was similar in 
HFFF-2 and RPE cells, but limited in amount and duration in U373Mg cells. When 
compared to HFFF-2 cells, the release of CRV to the medium was both delayed and 
occurred more slowly in RPE and U373Mg cells. The growth curves (Fig. 3.1 to 3.3) 
showed that the rate of replication in U373Mg cells was slower and shorter in duration 
compared to HFFF-2 and RPE cells, while the release of virus to the medium was delayed 
and slower in RPE and U373Mg cells when compared to HFFF-2 cells (Fig. 3.2). In the 
growth curve performed at a m.o.i of 1 p.f.u./cell (Fig. 3.1), the final virus yields were 
approximately 10 and 1000 fold lower in RPE and U373Mg cells respectively compared to 
HFFF-2 cells, while the CRV (Fig. 3.2) and CAV (Fig. 3.3) curves gave a final combined 
CRV/CAV virus yield that was approximately 25 and 1500 fold lower in RPE and 
U373Mg cells respectively when compared to HFFF-2 cells (data not shown). However, 
the growth curves were in agreement with respect to the duration of the eclipse phase in 
RPE and U373Mg cells, and the short duration of replication in U373Mg cells, when 
compared to HFFF-2 cells. The curves (Fig. 3.2 and 3.3) suggest impaired release of 
infectious virus from RPE cells and restricted production of infectious virus in U373Mg 
cells.  
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The differential replication kinetics were not due to a delay in the onset or progression 
through the virus gene expression cascade as evidenced by IE, E and L protein expression, 
though it may be explained by lower levels of viral protein made in RPE and U373Mg 
cells compared to HFFF-2 cells. Smaller amounts of protein feed through into lower 
numbers of infectious virions produced, especially during the early stages of infection 
(exit from the eclipse phase). The low yields of CAV obtained from U373Mg cells argues 
for some impairment of particle maturation into infectious progeny since protein 
synthesis appeared less affected than that in RPE cells (Fig. 3.5, 3.6 and 3.7).  
The implications for the microarray work are that: 1. when cells are infected at a m.o.i. of 6 
p.f.u./cell, equal numbers of cells are infected in all three cell types; 2. the temporal 
kinetics of transcription are the same in each of the three cells types; 3. but, based on 
protein expression data, there may be a general lower level of transcript abundance in 
RPE and U373Mg cells compared to HFFF-2 cells. It is concluded then that, despite some 
differences in viral growth kinetics and final virus yields, a valid comparison of the 
HCMV temporal kinetics of transcriptome expression can be made at the same time 
points using these three cell types.   
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4 RESULTS  II 
4.1  HCMV microarray validation 
The main objectives of HCMV microarray validation were to assess the specificity of the 
viral oligonucleotide probes, and to optimise the conditions for cDNA synthesis and 
hybridisation to the array. A flow-diagram depicting the major steps in the validation 
procedure is shown in Fig. 4.1.  
 
4.1.1  HCMV microarray print designs 
Microarrays were printed onto Corning GAPSII microscope slides using a BioRobotics 
Microgrid (see methods, 2.2.9.1). Microarrays were printed in single batches, with 45 
slides printed/batch. The first batch of arrays contained only HCMV probes, and were 
used in the validation hybridisations described in sections 4.1.2 (Fig. 4.3) and 0 (Fig. 4.4). 
The second batch contained both HCMV probes and bacterial control probes, which were 
used in the validation hybridisations described in sections 4.1.3 (Fig. 4.5) and 4.1.4 (Fig. 
4.6). The subsequent batches of microarrays were used for transcriptome profiling of 
HCMV in different human cell types, section 4.2 (Fig. 4.8). Fig. 4.2 shows the print design 
of the first two batches of arrays used for microarray validation, batch P1 and P2 
respectively, while Fig. 4.7 shows the print designs of the microarrays used for the 
profiling of HCMV gene expression in different cell types.  
4.1.2  Assessment of the specificity of viral oligonucleotide probes 
5’- and 3’- oligonucleotide probes were designed for HCMV ORFs or proposed ORFs as 
detailed in methods 2.8.1. The initial hybridisation experiments tested the specificity of 
the viral 60-mer oligonucleotide probes; this was achieved by hybridising mock-infected 
or HCMV-infected cell RNA to the array. At 96 h PI, total RNA was extracted from mock-
infected or HCMV-infected HFFF-2 cells. Labelled cDNA was produced in a reaction 
containing 25 µg of DNase I treated total RNA, and labelled with Cy3-dCTP. Mock-
infected or HCMV-infected labelled cDNAs were hybridised to separate arrays, each of 
which contained only HCMV probes, in order to test probe specificity (Fig. 4.3A and B). 
Hybridisation of HCMV-infected cell RNA showed that the spot morphology was 
uniform across the array, and triplicate spots gave consistent signal intensities, with low 
background (Fig. 4.3A). Hybridisation of mock-infected cell RNA confirmed the absence 
of cellular cDNA binding to the viral probes (Fig. 4.3B). 
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A .                   B .  
Figure 4.3. Assessment of probe specificity 
(A) hybridisation of infected cell RNA to the array. (B) hybridisation of mock-infected cell RNA to
the array. 
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4.1.3  The effect of hybridisation temperature on the specificity of the microarray 
Varying the hybridisation temperature influences the binding efficiency and/or 
specificity of target cDNA molecules to cognate probes on the array. Optimising the 
temperature of hybridisation facilitates true-positive hybridisation and reduces non-
specific (false-positive) hybridisation (Stekel, 2003). The hybridisations shown in Fig. 4.3 
were performed at 65 ºC, as described for the MHV-68 array (Ebrahimi et al., 2003). In 
order to investigate the effect of an alternative hybridisation temperature, two separate 
cDNA synthesis reactions were prepared using the same sample of HCMV-infected cell 
RNA. One cDNA preparation was hybridised to an array at 55 ºC, and the second to 
another array at 65 ºC. A mock-infected cDNA preparation was also hybridised to a third 
array at 55 ºC. Following hybridisation, the three arrays were scanned at the same PMT 
gain setting (PMT50), so that a direct comparison could be made (Fig. 4.4A, B and C). The 
images clearly show that the hybridisation performed at 55 ºC gave stronger and more 
abundant signals when compared with the hybridisation performed at 65 ºC, the overall 
intensity of spots in (Fig. 4.4B) is higher than in (Fig. 4.4A), and some spots absent in (Fig. 
4.4A) can be detected in (Fig. 4.4B). Assessment of the HCMV probe signal intensities of 
the two arrays hybridised at 55 °C (Fig. 4.4B) and 65 °C (Fig. 4.4A) showed that the 
median signal intensity increased by 1.3 fold for the array hybridised at 55 °C compared 
to the array hybridised at 65 °C (Table 4.1). The number of HCMV probes detecting a 
positive signal (an arbitrary signal cutoff point of 300 was selected) also increased when 
hybridised at 55 °C (Table 4.1). However, in contrast to hybridisations at 65 ºC (Fig. 4.3B), 
hybridisation of mock-infected cDNA to the array at 55 ºC resulted in a low level of non-
specific binding to some viral probes on the array (Fig. 4.4C). To maintain probe 
specificity, all subsequent arrays were therefore hybridised at 65 ºC. 
4.1.3  Comparison of cDNA synthesis methods on the specificity of the microarray 
cDNA was labelled by the direct incorporation of CyDye conjugated nucleotides during 
first strand synthesis of cDNA. We selected this strategy because labelled cDNA is 
generated easily and rapidly, and no further downstream processing is required other 
than cleaning the cDNA prior to hybridisation. However, there are some disadvantages in 
using this method: incorporation of large CyDye conjugated nucleotides can result in the 
premature termination of cDNA synthesis, yielding truncated cDNA copies of mRNAs 
(personal communication; Dr Tom Freeman, Sanger Institute). Because some regions of 
the HCMV genome code for 3’ co-terminal transcripts spanning several kb, it is important 
that the cDNA generated represents the full length mRNA.  
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A.                 B.                           C.  
  
Figure 4.4. Confirmation of different temperatures on specificity of the microarray 
 
(A) HCMV infected cDNA was hybridised at 65 ºC. (B) HCMV infected cDNA hybridised at 55
ºC. (C) Mock-infected cDNA hybridised to the microarray at 55 ºC.  
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Table 4.2. Assessment of median signal intensities for bacterial control probes. 
The signal intensities were generated from bacterial control RNA (X17013 and M24537)
each spiked into the cDNA synthesis reaction each at 50 ng. Note that control probes
were printed on the microarray in a 2:1 ratio (M24537:X17013) which accounts for the
doulbing of the median signal intensity of M24537 compared to X17013 when assessing
the positive control signals (sense probes).  
Table 4.1. Assessment of microarray signal intensities during hybridisation of
HCMV-infected HFFF-2 RNA under different experimental conditions. 
Hybridisations were performed with HCMV-infected HFFF-2 RNA at 55 °C and 65
°C, for which the median signal intensity was calculated from the HCMV microarray
probes. The table also shows the fold difference of the median signals between the
conditions tested, and also the number of HCMV probes that gave signals > 300.  
2  1238 M24537 
5510  X17013 
Median signal
intensity 
Bacterial control
probes  
903  5247  Oligo-dT 
1008  1.25  6579  Random 
Priming 
1042   7652  55 °C 
925  1.3  5883  65 °C 
Number of 
a signal inte
probes with
nsity > 300  
Total no. 1152 
Fold 
difference 
Median signal
intensity 
Experiment 
condition  
The cDNA synthesis and labelling strategy selected could skew or otherwise compromise 
the microarray data obtained. Priming cDNA synthesis reactions with oligo-dT (i.e. 3’ 
orientated) might result in truncated cDNA copies of mRNAs, whereas priming the 
cDNA synthesis reactions with random hexamers should result in the synthesis of cDNAs 
that represent the full-length transcripts. To investigate the effect of cDNAs synthesised 
using random hexamers or oligo-dT on the efficiency and/or specificity of detection of 
array probes, two cDNA synthesis reactions were prepared from the same sample of 
HCMV-infected cell RNA: one reaction was primed using random hexamers, the other 
using oligo-dT primers. The two cDNA samples were then hybridised to separate arrays 
at 65 ºC. Following hybridisation, the slides were scanned at the same PMT gain setting 
(PMT50), to allow direct comparison of the array images (Fig. 4.5A and B). While intra-
array triplicate hybridisation signals appear evenly labelled in both (Fig. 4.5A) and (Fig. 
4.5B), there is a greater sensitivity with cDNA synthesised using random hexamers (Fig 
4.5B). Assessment of the HCMV probe signal intensities of the two arrays hybridised with 
cDNA synthesis primed with random primers  (Fig. 4.5B) and oligo-dT (Fig. 4.5A) showed 
that the median signal intensity increased by 1.25 fold for the array hybridised with 
cDNA synthesised using random primers compared to the array hybridised with cDNA 
synthesised using oligo-dT (Table 4.1). The number of HCMV probes detecting positive 
signal intensities (> 300; see 1.1.1) also increased when hybridised with cDNA synthesis 
primed with random hexamer primers (Table 4.1). Consequently, all subsequent cDNA 
synthesis reactions were performed using the random hexamer priming method.  
4.1.4  Specificity of the microarray for the detection of control features 
In order to check the specificity of bacterial control probes (see 2.1.10.1), hybridisations 
were performed using the ‘spiked in’ control mRNA. cDNAs were synthesised and 
labelled using ~ 1 µg each of X17013 and M24537 mRNA in separate reaction tubes, then 
hybridised to separate arrays (that contained the full complement of viral and control 
probes). Scanning of the arrays (PMT50) showed that only the bacterial probes on the 
array were detected, thus confirming the specificity of the two control probes (Fig. 4.6A 
and B). Because the data in Fig. 4.6A and B was obtained with cDNA synthesised with 
control mRNA in excess (~ 1 µg), the experiment was repeated using 50 ng each of X17013 
and M24537, with cDNA synthesis and labelling performed in the same reaction tube. The 
labelled cDNAs were then hybridised to the array and scanned as before (Fig. 4.6C). Since 
the array shows equal hybridisation levels, without evidence of signal saturation, poorly 
defined signals, or non-specific binding, 50 ng each of the bacterial control mRNAs was 
selected for subsequent spiked controls in cDNA synthesis reactions. Hybridisation of 
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 A.                   B.  
Figure 4.5. Hybridisation of cDNA that had been synthesised using (A) oligo-dT; or (B)
random hexamer primers. 
cDNA was synthesised using the same sample of HCMV infected HFFF-2 RNA (96 h PI) using
(A) oligo-dT, or (B) random hexamer primers. 
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 A.                            B.                            C.  
Figure 4.6. Hybridisation of control ‘spiked in’ RNA. 
(A) Hybridisation of spike mRNA 1 (X17013); (B) hybridisation of spike mRNA 2 (M24537); and
(C) hybridisation of the spike RNA (X17013 and M23547) each at 50 ng.   
mock-infected HFFF-2 RNA containing the bacterial spike control RNA (each spiked in at 
50 ng) was also performed. The median signal intensities from the X17013 sense probes 
and M24537 sense probes generated from this hybridisation are shown in Table 4.2 (pg. 
109).   
4.2  Transcriptome profiling of HCMV in fibroblasts, epithelial cells and astrocytes 
The HCMV microarray was employed to investigate the temporal pattern of global virus 
gene expression during replication in three different cell types (HFFF-2, human foetal 
foreskin fibroblasts; RPE, human retinal pigmented epithelial cells; and U373Mg, human 
astrocytes), with the specific aim of identifying viral genes that are differentially 
regulated. Because of the complexity of the experiment (i.e. a time course experiment in 
multiple cell types), single colour arrays were used. The microarray print design is shown 
in Fig. 4.7. The details of the experiment hybridisations and the associated results for the 
normalisation, ROC analysis etc. are shown in Table 4.3. A flow-diagram depicting the 
stages of microarray analysis is shown in Fig. 2.1 (see methods, 2.2.9).  
4.2.1  HCMV microarray hybridisations 
Total RNA samples were prepared from three biological replicates of mock-infected cells 
or HCMV-infected HFFF-2, RPE and U373Mg cell cultures. 25 µg each of total RNA 
sample (DNase I treated) was then spiked with 50 ng each of B.subtilis X17013 and M24537 
mRNA (‘spiked in’ control RNA). cDNA was then synthesised using random primers and 
direct incorporation of Cy3-dCTP. The labelled cDNA preparations were then hybridised 
to separate HCMV microarrays at 65 ºC and scanned using the Perkin-Elmer ScanArray 
Express scanner, at PMT gain settings of 40, 50, 60 and 70 %. To monitor progression 
through the HCMV global gene expression cascade, total RNA was prepared from three 
biological replicates at 12, 24, 48 and 72 h PI for infected cells, and at 72 h PI for MI control 
cell cultures. Time points prior to 12 h PI were excluded due to the low level of viral gene 
expression (personal communication; Dr Bahram Ebrahimi). Representative images (1 of 3 
biological replicates for each cell type) of scanned arrays for each infected cell type from 
12, 24, 48, and 72 h PI samples respectively are shown in Fig. 4.8. The microarrays from 
these experiments produced high quality data, with excellent spot morphology and low 
background noise.  
Low numbers of virus specific signals were detected in infected HFFF-2 and RPE cells at 
12 h PI (Fig. 4.8) but the intensity and abundance of signals continued to increase with 
time as the HCMV genome became more transcriptionally active. In the case of infected
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Array 
Number 
Cell 
Type 
Time 
Point 
R2  
Value 
ROC 
Cutoff 
Correction 
Factor (C.F.) 
1 HFFF-2  12  0.988  10.423  3.744 
2  HFFF-2 12  0.964 9.074 1.146 
3  HFFF-2 12  0.941 7.185 3.584 
4  HFFF-2 24  0.977 9.944 1.190 
5  HFFF-2 24  0.911 9.350 1.014 
6  HFFF-2 24  0.938 8.258 1.076 
7  HFFF-2 48  0.997 8.384 1.111 
8  HFFF-2 48  0.979 8.423 1.388 
9  HFFF-2 48  0.998 9.343 1.069 
10  HFFF-2 72  0.998 7.472 0.954 
11  HFFF-2 72  0.998 7.833 1.262 
12  HFFF-2 72  0.997 7.234 1.015 
13  RPE  12  0.996 8.922 1.012 
14  RPE  12  0.996 8.545 0.935 
15  RPE  12  0.997 8.447 0.737 
16  RPE  24  0.996 9.013 0.618 
17  RPE  24  0.994 8.904 0.586 
18  RPE  24  0.989 8.071 0.811 
19  RPE  48  0.997 8.187 0.896 
20  RPE  48  0.998 8.872 0.637 
21  RPE  48  0.998 8.101 0.591 
22  RPE  72  0.983 9.568 0.899 
23  RPE  72  0.995 8.585 1.362 
24  RPE  72  0.995 8.545 1.181 
25  U373Mg  12  0.997 7.662 0.712 
26  U373Mg  12  0.999 7.472 0.666 
27  U373Mg  12  0.998 7.752 0.686 
28  U373Mg  24  0.997 7.448 0.859 
29  U373Mg  24  0.998 6.889 1 
30  U373Mg  24  0.998 6.577 1.022 
31  U373Mg  48  0.998 7.326 1.262 
32  U373Mg  48  0.998 7.271 0.854 
33  U373Mg  48  0.998 6.676 0.840 
34  U373Mg  72  0.956 7.353 1.096 
35  U373Mg  72  0.997 7.422 0.740 
36  U373Mg  72  0.998 6.679 0.837 
 
 
Table 4.3. Microarray data analysis determining selection cutoff points and correction 
factors.  
The table lists the array number, cell type and time points, together with the associated 
data generated during assessment of the linear dynamic range, defining cutoff points 
using ROC analysis, and the calculated correction factors for data normalisation (scaling). 
The reference array (no. 29) values are in shown in red. 
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U373Mg cells, it was apparent that a large proportion of viral genes were expressed as 
early as 12 h PI (Fig. 4.8). As expected, the strength of signals for U373Mg cells increased 
with time, but the incremental range over the period 12 h PI through to 72 h PI was not as 
large as seen with the HFFF-2 and RPE infected cells. The finding that the greater part of 
the HCMV transcriptome was active as early as 12 h PI in U373Mg cells was unexpected 
and contrasts with more strictly regulated activity seen with infected HFFF-2 and RPE 
cells. Consequently, the HCMV transcriptome profiling in U373Mg cells was repeated. 
Triplicate HCMV infections of fresh U373Mg cell cultures were performed and a second 
set of RNA samples were prepared at 12, 24, 48 and 72 h PI. Hybridisations were then 
repeated, and the expression profile analysed. Surprisingly, no difference could be found 
in the HCMV gene expression profiles obtained from the first and second set of U373Mg 
microarray data, confirming the unusually early transcription profile of HCMV in 
U373Mg cells (data not shown). Mock-infected cell RNA hybridisations for each cell type 
are also shown in Fig. 4.8, confirming the specificity of the virus probes.  
4.2.2  Determining the optimum PMT settings  
(Fig. 2.1, stage 1, step 1) 
In order to determine the optimum gain settings, spot intensities were plotted at a series 
of PMT settings. Non-linearity indicates sub-optimal PMT since no linear increase in spot 
intensity is possible at that setting. The optimal PMT occurs at the highest PMT values 
where a linear range is obtained. The scatterplots were examined by R2 least square fit 
analysis, and datasets exhibiting the optimum scatter were selected for further analysis.  
Fig. 4.9 shows the scatterplots of a representative microarray dataset. Scatterplot C (PMT 
60 vs 70) shows deviation from the linear range and saturation of the microarray data at 
signal intensities > 60000. Scatterplot B (PMT 50 vs 60) also deviates from the linear range 
and also exhibits signal saturation, though at a lower level than scatterplot C. Finally, 
scatterplot A (PMT 40 vs 50) gives linear signal intensity data with a dynamic range 
between 0 to 45000 in the absence of saturation, and yielding a R2 value of 0.9983. The 
dataset generated with PMT gain setting of 50 % was therefore selected for further 
analysis. The R2 values for selected linear HCMV microarray datasets are shown in Table 
4.3. 
Raw signal intensity microarray data was right-skewed (when assessed by histograms, 
see Fig. 4.10), it is important therefore to log2 transform the data so that it assumes a 
normal distribution for subsequent statistical analysis. This is firstly because many 
statistical tests (used to analyse microarray data) are based on the assumption that the 
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data is symmetrically distributed, and secondly, because taking the logarithm of linear 
expression data limits the numerical range, and reduces the computational power 
required when performing statistical tests.  
4.2.3  Assessment of signal distributions  
(Fig. 2.1, stage 1, step 2) 
Following base 2 logarithmic transformation of the raw signal intensity data, box-plots 
were drawn in order to ensure that the data followed a normal distribution before 
proceeding with further analysis. The box-plots for the entire HCMV microarray dataset 
for infected HFFF-2, RPE and U373Mg cells are shown in Fig.  4.11.  The central line 
represents the median of the data, and the surrounding box represents the 25th and 75th 
percentiles, and the whiskers show the spread of the data. The box-plots confirm that 
following log2 transformation, the linear HCMV microarray datasets for each cell type are 
symmetrical. Box-plots were also drawn after the data was scaled (Fig. 4.11.1), and 
following normalisation in GeneSpring (Fig. 4.11.2) to ensure that the patterns of gene 
expression were not skewed following these analysis procedures.  
4.2.4  Receiver operating characteristic analysis  
(Fig. 2.1, stage 1, step 3) 
Datasets that were linear and symmetrical were then subject to ROC analysis. Table 4.4 
shows an example of ROC analysis for a representative microarray dataset. The table lists 
various cutoff points and their calculated false-positive and true-positive rates. The data 
can be plotted as a curve (Fig. 4.12A and B) of false-positive values against true-positive 
values for each cutoff point. A curve that lies toward the top left hand corner of the graph 
represents good discrimination between true-positive and true-negative signals, because 
the true-positive rate remains high while the false-positive rate is reduced with increasing 
signal cutoff thresholds. A curve that is linear represents data where no distinction can be 
made between true-positive and true-negative signals. Table 4.3 shows the ROC analysis 
cutoff points that were selected for the HCMV microarray datasets. This analysis was 
performed on the positive and negative control signals for all linear datasets, and cutoff 
points that gave a false-positive rate of 5 % were selected. Data that fell below the cutoff 
point was assigned a value of 0.01.  
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4.2.5 Normalisation 
(Fig. 2.1, stage 1, step 4) 
Datasets were normalised against a reference array (see methods, 2.2.9.3.3), so that 
fluorescent signals were scaled against the 75th percentile of the positive control signals. 
This allowed normalisation across all microarrays irrespective of the cell type. The scaling 
correction factors (CF) are shown for all microarray datasets are shown in Table 4.3. 
4.2.6  Data flagging and preparation for import into GeneSpring 
 (Fig. 2.1, stage 1, step 5) 
The microarray data for individual probes were flagged as present (P) or absent (A), 
based on the cutoff points selected from the ROC analysis (Table 4.3). Data points falling 
below the cutoff point (assigned as 0.01) following ROC analysis were defined as absent 
(A). The data was then saved as tab delimited text files prior to import into GeneSpring.  
4.2.7  Microarry analysis using GeneSpring 
(Fig. 2.1, stage 2, step 1 to step 3) 
The microarray datasets were imported into GeneSpring using the software import 
wizard, then ‘back-transformed’ from log2 to linear data, and normalised as previously 
described (see methods, 2.2.9.3.3). The principle aim of microarray analysis in GeneSpring 
was to identify HCMV genes that were differentially regulated in comparisons of infected 
cell lines over a time course. One-way ANOVA tests between HFFF-2 vs RPE, and HFFF-2 
vs U373Mg (see methods, 2.2.9.4.4) were performed to identify statistically significant 
differences between individual HCMV genes for each cell type. Further quality control 
analysis was undertaken prior to the application of the combined statistical tests.  
4.2.7.1  Clustering analysis  
(Fig. 2.1, stage 2, step 3) 
Condition trees generated by hierarchical clustering show how gene expression is related 
between microarray datasets. Comparisons made between individual datasets serves as a 
useful quality control step since datasets should cluster together according to time PI. 
Clustering was performed in GeneSpring generating distances based on Spearman’s 
correlation (separation ratio 1, minimum distance 0.001), in which average linkage was 
applied in order to assemble the clusters into a hierarchical plot. Fig. 4.13 shows the 
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Figure 4.13. Condition trees for the (A) HFFF-2, (B) RPE and (C) U373Mg
microarray datasets.  
The condition trees show the relationships among the gene expression levels for
each dataset, which are clustered accordingly. The time (h PI) is shown along with
the biological replicate number (a, b, or c). The distances between the clusters are
also displayed on the trees. Note that the distance value is calculated as:  distance =
1 - correlation, hence values can range from 0 to 2, because Spearman’s correlation
reports values from –1 to +1.   
A. B.  C. 
12a   12b   12c  24a  24b   24c   48a   48b  48c   72a   72b  72c                             12c  12a  12b   24a   24b   24c  48a  48b   48c   72a  72b   72c                                  12a   12b  12c   24a   24b  24c   48a   48b  48c    72a   72b   72c 
Low gene expression 
High gene expression 
0.33 
0.43 
0.58 
0.13  0.16 
0.23 
0.92 
0.88  0.1 
0.02 
0.71 
0.27
0.49 
0.14 
0.29 
0.32
0.07  0.1
0.16 
0.1  0.09 
0.09 
0.044 
0.03 
0.043 
0.02 
0.16 
0.06 
0.017
0.022  
condition trees for HFFF-2, RPE and U373Mg cells. The branches within each condition 
tree have been assigned distance values between the array datasets. Each row on the tree 
represents the expression level of an individual gene. It should be noted that the 
GeneSpring normalisation step (per gene: normalise to the median) was removed so that 
the array datasets could be compared independently. Mock-infected datasets were 
excluded from this analysis. 
Fig. 4.13A shows the condition tree for the infected HFFF-2 cell line. There are 4 major 
clusters each representing a single time point, indicating good reproducibility between 
the triplicate biological samples. The 4 clusters are part of two branches, with the 24, 48 
and 72 h PI clusters forming one branch, and the 12 h PI cluster forming the second. At 12 
h, relatively few genes are expressed, but the number of expressing genes increases with 
time. At later time points, the triplicate dataset clusters are more conserved (confirmed by 
decreased distance values at later times PI between clusters), this could be due to either a 
greater uniformity in the regulation of gene expression with time, or reduced error given 
a larger P-flagged sample size at later time points.  
Fig. 4.13B shows the condition tree for the infected RPE cell line. The branching pattern is 
more poorly conserved than that obtained for HFFF-2 (Fig. 4.13A). The 12 h dataset, 
replicate 12(c) forms an individual branch (displayed at the extreme left of the tree). The 
number of genes expressed in dataset 12(c) is much lower than in datasets 12(a) and 12(b) 
(which exhibit a similar banding pattern, representing good reproducibility between these 
two datasets). Dataset 12(c) exhibiting little positive expression data is therefore 
considered a cluster in its own right; although the expression data is more closely related 
to that of 12(a) and 12(b), than any other cluster. The reduced dataset in 12(c) may be due 
to experimental variation at the level of virus infection, microarray hybridisation, or the 
stringent cutoff points employed for these experiments. The remaining datasets 
representing the 24, 48 and 72 h PI time points cluster as expected. In the case of RPE cells, 
the two main arms of the condition tree group the 12 and 24 h PI clusters together on one 
branch while the 48 h and 72 h PI cluster together on the other branch. 
Fig. 4.13C shows the condition tree for the infected U373Mg cell line. At the early time 
points, 12 and 24 h PI, the replicate datasets appear less conserved; one cluster is formed 
containing two 12 h and three 24 h PI datasets. As with the infected RPE cell line, 
increased error rates may be responsible for the branching pattern observed at these early 
time points. At 48 and 72 h PI, however, two discrete clusters are formed containing the 
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dataset for each time point, (note the almost perfect reproducibility for the triplicate 
datasets).  
The condition trees generally demonstrate good reproducibility between the triplicate 
array datasets for each cell type. Where discrepancies appear, they are associated with the 
early time points (12 and 24 h PI), and may be due to increased error caused by either the 
limited number of genes expressed early in the virus replication cycle, or to a more 
coordinated regulation of gene expression at later time points (48 and 72 h PI). In general, 
the condition trees demonstrate a good and consistent clustering pattern.  
4.2.7.2  Analysis based on present and absent flags  
(Fig. 2.1, stage 2, step 4) 
Following ROC analysis, present (P) or absent (A) flags were manually assigned to all 
probes in the array datasets (see methods, 2.8.5.2), with signals of 0.01 flagged as (A).  As 
there were 12 datasets per microarray (excluding mock infected cell datasets), a single 
gene could have present flags in 1 to 12 datasets. Genes that had no present flags (i.e. only 
absent flags), were described as ‘absent’. Table 4.5 lists the number of datasets containing 
present flags for all Merlin ORFs (AY446895) in each cell type.  
For infected HFFF-2 and RPE cells, datasets contain a range of present signals for the 
genes, and are generally in agreement: this is not the case for the U373Mg data. Present 
flags are generally found in 10 or more datasets for each HCMV gene in U373Mg cells 
(each time point having the potential to score present flags in 3 datasets).  This implies 
that the majority of genes are expressed at all time points, including genes that are 
reported to be expressed with late kinetics in infected HFF cells (Chambers et al., 1999). In 
HFFF-2 and RPE cells, HCMV genes that are reported to follow early expression kinetics 
(e.g. UL54, UL55, US18, US22) tend to have present flags in more datasets than those 
previously reported as late genes (UL99, UL128, UL130, UL144). This reflects the nature of 
gene expression in HCMV, which has been described as a regulated temporal cascade. It 
is not clear why the temporal expression of HCMV genes differs in U373Mg cells; it is 
possible that the temporal cascade is rapidly completed within the first 12 h of lytic 
infection, or alternatively, there may be a general breakdown in the cascaded regulation 
of HCMV gene expression U373Mg cells.  
Absent genes are those whose expression cannot be detected at any time point in one or 
more cell types. Identification of such genes provides valuable information, particularly in 
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Table 4.5. Microarray dataset information for individual Merlin genes in each cell type. 
 
Gene   HFFF-2  RPE  U373Mg 
UL51 2  2  12 
UL52 6  6  9 
UL53 8  8  12 
UL54 11  10  12 
UL55 9  9  12 
UL56 9  9  12 
UL57 5  4  12 
UL69 10  7  12 
UL70 6  4  12 
UL71 3  4  12 
UL72 6  3  12 
UL73 5  4  12 
UL74 3  1  7 
UL75 6  5  11 
UL76 2  1  10 
UL77 3  1  10 
UL78 9  8  12 
UL79 2  1  7 
UL80_UL80.5 6  7  12 
UL82 9  8  12 
UL83 8  7  12 
UL84 6  8  12 
UL85 7  6  12 
UL86 6  4  9 
UL87 2  1  9 
UL88 4  8  12 
UL89 6  6  12 
UL91 7  7  11 
UL92 4  5  12 
UL93 6  5  12 
UL94 6  8  12 
UL95 4  5  12 
UL96 7  8  12 
UL97 9  11  12 
UL98 11  11  12 
UL99 10  11  12 
UL100 6  5 12 
UL102 2  1 11 
UL103 6  5 12 
UL104 6  2 9 
UL105 2  3 12 
UL111A 0  0  6 
UL112 8  10  12 
UL114 6  6 12 
UL115 9  11  12 
UL116 9  8 12 
UL117 9  9 12 
UL119 7  7 12 
UL120 2  1 11 
UL121 2  1 7 
UL122 6  8 12 
UL123 4  4 12 
UL124 3  1 10 
UL128 3  2 11 
UL130 4  1 11 
Gene   HFFF-2  RPE  U373Mg 
RL1 4  1  12 
RL5A 6  6 11 
RL6 2  1  4 
RL10 5  6  9 
RL11 8  9  12 
RL12 8  9  12 
RL13 9  8  12 
UL1 5  3  10 
UL2 2  1  7 
UL4 12  11  12 
UL5 10  10  12 
UL6 5  2  10 
UL7 4  1  10 
UL8 4  1  11 
UL9 5  1  11 
UL10 5  3 11 
UL11 7  5 12 
UL13 6  6 12 
UL14 2  1 12 
UL15A 2  1  11 
UL16 11  4 12 
UL17 9  7 12 
UL18 2  1 11 
UL19 2  2 11 
UL20 4  4 12 
UL21A 6  7  12 
UL22A 9  8  12 
UL23 2  3 11 
UL24 4  4 11 
UL25 5  5 12 
UL26 3  9 12 
UL27 2  2 11 
UL28 2  2 12 
UL29 0  0 2 
UL30 6  5 11 
UL31 2  3 10 
UL32 6  4 8 
UL33 5  6 12 
UL34 6  8 12 
UL35 4  3 11 
UL36 10  10  12 
UL37 2  1 7 
UL38 9  10  12 
UL40 10  9 12 
UL41A 7  8  11 
UL42 8  7 12 
UL43 9  9 12 
UL44 10  11  12 
UL45 11  9 12 
UL46 9  5 12 
UL47 3  1 10 
UL48 6  6 12 
UL48A 0  0  0 
UL49 10  11  12 
UL50 9  11  12 
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Gene  HFFF-2  RPE  U373Mg 
UL131A 3  2  12 
UL132 11  11 12 
UL148 12  11 12 
UL147A 12  11  12 
UL147 10  11 12 
UL146 3  1  9 
UL145 3  2  12 
UL144 8  9  12 
UL142 4  2  6 
UL141 8  7  12 
UL140 5  4  12 
UL139 5  2  12 
UL138 11  10 12 
UL136 9  12 12 
UL135 11  12 12 
UL133 9  9  12 
UL148A 2  2  12 
UL148B 2  3  11 
UL148C 3  3  12 
UL148D 6  7  12 
UL150 2  1  12 
IRS1 12  11  12 
US1 0  0  0 
US2 2  0  7 
US3 2  1  12 
US6 2  1  12 
US7 3  1  8 
US8 7  2  12 
US9 4  5  12 
US10 8  6 12 
US11 11  10  12 
US12 12  11  12 
US13 12  11  12 
US14 12  11  12 
US15 11  9 12 
US16 9  9 12 
US17 3  2 12 
US18 12  11  12 
US19 12  11  12 
US20 12  11  12 
US21 4  3 10 
US22 10  10  12 
US23 9  6 12 
US24 4  3 12 
US26 2  1 12 
US27 8  6 12 
US28 9  8 12 
US29 6  4 11 
US30 7  5 12 
US31 6  2 12 
US32 7  4 12 
US34 3  1 12 
US34A 0  0  0 
TRS1 4  6 12 
Table 4.5. Microarray dataset information for individual Merlin genes in each cell type.  
The table shows the number of Presence (P) flags for every Merlin gene in each cell type. As there were 12
datasets (representing 4 time points) for each cell type, the maximum number of Presence (P) flags for a
gene in each cell type is 12. A gene with no presence flags is defined as absent.  
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cases where a gene could be present in one cell type, but absent in another, therefore 
providing evidence of cell-type specific differential regulation of gene expression. In the 
case of US2, present flags are found in two datasets in HFFF-2 cells, seven datasets in 
U373Mg cells, but US2 is absent in RPE cells; it should be noted that the difference in the 
expression of US2 in HFFF-2 and RPE cells is the only case where a gene is present in 
HFFF-2 cells, but absent in RPE cells. Gene US2 could be classified as a candidate for 
differential regulation. The two datasets containing present flags for US2 expression in 
HFFF-2 cells were obtained for the 72 h PI samples only, making it less likely that US2 is 
differentially expressed in RPE compared to HFFF-2 cells. It is probable that the US2 gene 
is expressed at low levels in both RPE and HFFF-2 cells. When comparing profiles from 
HFFF-2 and U373Mg infected cells, gene US2 is over-expressed in U373Mg compared to 
HFFF-2; however, this conclusion was not supported by the statistical tests (see Table 4.6). 
There are additional examples of genes which contain present flags in 1 dataset in RPE 
cells, but in 3 or 4 datasets in HFFF-2 cells (e.g. RL1, UL7, UL74). As with gene US2, 
examination of the expression profiles for RL1, UL7 and UL74 fails to provide strong 
evidence for differential regulation between HFFF-2 and RPE infected cells, but does 
appear to support differential expression between HFFF-2 and U373Mg cells; however, as 
before, these genes were not identified as differentially expressed by the statistical tests. 
There are two examples where genes UL29 and UL111A are flagged as absent in both 
HFFF-2 and RPE cells, but present in U373Mg cells. In the case of UL29, there are two 
datasets containing present flags in U373Mg cells. However, comparison of the expression 
profiles for UL29 in HFFF-2 and U373Mg cells does not provide good evidence of 
differential regulation of UL29 expression; for the same reasons previously described for 
US2. There are six datasets containing present flags for gene UL111A in U373Mg cells, 
representing expression from at least 2 time points. Indeed, the statistical tests between 
HFFF-2 and U373Mg cells confirms expression of this gene to be significantly different 
(Table 4.6). Expression of genes such as UL111A in two or more time points (representing 
≥ 4 datasets with present flags) against one or no time points provides better evidence for 
differential regulation. 
Finally, there were three genes (UL48A, US1 and US34A) where no expression was 
detected at all in any of the cell types. No present flags are assigned to any dataset in any 
cell type. Possibly these genes are simply not expressed in any of the cell types tested 
here, or are expressed at very low levels and fail the statistical tests used in this analysis. 
Alternatively, there could be a problem with the oligonucleotide probes for these genes 
(e.g. poor thermodynamic performance), resulting in failure to bind under the 
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experimental conditions used. In order to resolve which of the above explanations is 
correct would require further application of techniques such as real-time PCR and/or 
northern blotting studies.  
4.2.8  Expression profiles for representative non-differentially expressed 
immediate-early, early, and late regulated HCMV genes in HFFF-2 and RPE cells  
Before dealing with HCMV genes that are differentially regulated, it is appropriate to first 
examine expression kinetic profiles obtained for non-differentially regulated genes 
representing IE, E and L classes, as determined by the combined statistical tests (Table 
4.6). The expression profiles for TRS1 (IE), US22 (E), UL119 (E-L), UL25 (L), UL32 (L), 
UL54 (E), UL75 (E-L) and US10 (E) are shown in Fig. 4.14. No significant difference in the 
expression levels in HFFF-2 and RPE cells were found for these genes in the combined 
statistical tests, and examination of the expression profiles (Fig. 4.14) confirmed the 
statistical test p-values (Table 4.6). Biphasic expression kinetics were obtained for TRS1 
(Fig. 4.14A), US22 (Fig. 4.14B) and US10 (Fig. 4.14D). Expression kinetics of TRS1 andUS22 
increased between 12 to 24 h PI, plateaued between 24 and 48 h PI, then increased again 
from 48 to 72 h PI; however, there was an overall decrease in the expression kinetics of 
US10 between 12 to 48 h PI, followed by an increase from 48 to 72 h PI. Expression of 
HCMV gene UL119 (Fig. 4.14C) and UL53 (Fig. 4.14F) accumulated continuously from 12 
through to 72 h PI, whereas expression of HCMV genes UL25, UL32 and UL75 all 
increased from 24 to 72 h PI in both HFFF-2 and RPE cells. The microarray data are in 
accord with the protein expression data (see results I, section 3.3) that showed that the 
k i n e t i c s  o f  p r o t e i n  e x p r e s s i o n  w e r e  t h e  s a m e  i n  i n f e c t e d  H F F F - 2  a n d  R P E  c e l l s .  
Correlations between reduced transcript and protein levels in RPE cells compared with 
HFFF-2 cells are observed between these two cell types. 
4.2.9  Differential gene expression  
(Fig. 2.1, stage 2, step 5) 
In order to identify HCMV genes whose expression was differentially regulated, mean 
expression levels were compared using combined statistical tests performed 
independently between HFFF-2 vs RPE, and HFFF-2 vs U373Mg (see methods, 2.8.5.4). 
The null hypothesis (no difference in the gene expression intensities of individual HCMV 
genes in HFFF-2 and RPE or U373Mg cells) was tested, with significant differences 
identified at the 95 % significance level. The Benjamini and Hochberg false discovery rate 
(see methods, 2.2.9.4.4) was applied in order to reduce the error incurred by multiple 
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testing; note that % of genes reported as differentially expressed will have passed this 
restriction by chance. The statistical tests compared the overall level of transcript 
abundance across all time points without specific reference to the transcript expression 
kinetics. Because of this, there were genes whose overall expression was not determined 
to be significantly different when assessed by the statistical tests between HFFF-2 vs RPE, 
and HFFF-2 vs U373Mg, but exhibited expression kinetics that were different. Conversely, 
there were genes whose overall expression was determined to significantly different by 
the statistical tests, but did not exhibit differential expression kinetics (see discussion, 
section 4.3). Subsequently, differential gene expression was based on both the combined 
statistical test results and the assessment of the expression kinetics. All gene expression 
profiles were examined following the application of the combined statistical tests in order 
to compare the p-values with the associated gene expression kinetics. Note that these 
comparisons were also made for genes not determined to be differentially expressed 
according to the statistical tests. 
Table 4.6 lists the p-values for all Merlin ORFs determined by the statistical tests between 
HFFF-2 and RPE, or HFFF-2 and U373Mg. Genes that are differentially expressed in 
HFFF-2 and RPE or U373Mg are shown in Tables 4.7 and 4.8 respectively. Genes arranged 
in genome order are listed with the corresponding p-value, the temporal kinetic class of 
gene expression (Chambers et al., 1999) and the gene function where known. The 
corresponding expression profiles for each gene in Table 4.7 (HFFF-2 vs RPE) are shown 
in Fig. 4.15. Note that significant differences in the expression of HCMV genes UL4, IRS1, 
US12, US14, US18, US19 and US20 were identified in the comparison between both HFFF-
2 and RPE (Table 4.7) and the comparison between HFFF-2 and U373Mg (Table 4.8).  
Expression of UL4 was detected from 12 h PI in all three cell types. The magnitude of 
expression of UL4 in HFFF-2 cells was greater than in U373Mg (from 24 to 72 h PI), and 
significantly higher than in RPE cells (from 12 to 48 h PI); though there is a steep incline in 
the expression of UL4 between 48 and 72 h PI in RPE cells. The combined statistical tests 
showed UL4 expression to be significantly different in each of the three cell types (Table 
4.6). The UL4 expression profile for HFFF-2 and RPE was in accord with this p-value, as 
there is a clear difference in the expression profile in magnitude and the temporal kinetics 
of expression. When UL4 expression in HFFF-2 and U373Mg were compared, the overall 
level of expression was lower in U373Mg, but the expression profile appeared similar. 
Comparison of the corrected p-values for UL4 shown in Table 4.6, reported p-values of 
0.00555 (HFFF-2/RPE) and 0.0126 (HFFF-2/U373Mg), which reflects the larger difference 
in the overall expression kinetics of UL4 in HFFF-2 and RPE cells, compared to HFFF-2 
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Table 4.6. Student’s t-test p-values for HFFF-2 and RPE or U373Mg 
Gene  Kinetic 
class 
HFFF-2 vs  
RPE  
(p-value) 
HFFF-2 vs  
U373Mg  
(p-value) 
Gene  Kinetic 
class 
HFFF-2 vs  
RPE  
(p-value) 
HFFF-2 vs  
U373Mg  
(p-value) 
RL1   0.342  0.109 UL52 L  0.61  0.987 
RL5A   0.569  0.856 UL53 E  0.371  0.746 
RL6 L  1 1  UL54  E  0.0342  0.0559 
RL10  E-L  0.717  0.746 UL55 E  0.253  0.626 
RL11  L  0.347  0.907 UL56 E  0.359  0.869 
RL12  E-L  0.347  0.985 UL57 E  0.556  0.201 
RL13  E-L  0.213  0.681 UL69 E-L  0.112  0.437 
UL1 E-L  0.468  0.505 UL70 E-L  0.468  0.582 
UL2 L  0.617  0.286 UL71   0.931  0.0734 
UL4 E  0.00555  0.0126  UL72 E-L  0.4  0.626 
UL5 E  0.187  0.303 UL73 E-L  0.569  0.238 
UL6  0.45  0.296 UL74   0.47  0.626 
UL7 L  0.347  0.312 UL75 E-L  0.527  0.857 
UL8  0.4  0.136 UL76   0.639  0.0666 
UL9 L  0.253  0.312 UL77 E  0.495  0.173 
UL10   0.468  0.221 UL78 E  0.253  0.892 
UL11  E  0.341  0.745 UL79   0.57  0.461 
UL13 E  0.556  0.312  UL80_UL80.5  L  0.686  0.684 
UL14 L  0.624  0.0126 UL82  L  0.257  0.519 
UL15A   0.569  0.0126  UL83  L  0.347 0.746 
UL16 E  0.00257  0.27  UL84  E-L  0.703  0.665 
UL17  E  0.213  0.815 UL85 E-L  0.451  0.977 
UL18 L  0.61  0.0269 UL86  E-L  0.47  0.977 
UL19   0.746  0.0126 UL87   0.61  0.156 
UL20   0.818  0.0594 UL88   0.717  0.175 
UL21A   0.746  0.175 UL89 E-L  0.569  0.672 
UL22A   0.255  0.523 UL91 L  0.556  0.907 
UL23   0.974  0.0217 UL92  L  0.987  0.137 
UL24   0.737  0.248 UL93 L  0.548  0.505 
UL25 L  0.687  0.32  UL94  L  0.717  0.665 
UL26 E  0.468  0.0594 UL95  E-L  0.971  0.136 
UL27 E  0.82  0.0159 UL96  E-L  0.624  0.746 
UL28   0.81  0.0126 UL97  E-L  0.468  0.752 
UL29 L  1  0.29  UL98  E-L  0.0874  0.1 
UL30   0.564  0.815 UL99 E-L  0.193  0.201 
UL31 L  0.819  0.0126 UL100 E-L  0.556  0.643 
UL32 L  0.459  0.896  UL102 L  0.671  0.0184 
UL33 E  0.818  0.286  UL103 L  0.52  0.626 
UL34 E-L  0.718  0.505  UL104 E  0.253  0.952 
UL35 E  0.569  0.148  UL105 E  0.987  0.0126 
UL36 E  (IE)  0.253  0.907  UL111A  E-L  1  0.0326 
UL37 IE  0.569  0.505  UL112 E  0.569  0.746 
UL38 IE  0.296  0.76  UL114 E  0.569  0.643 
UL40  E-L  0.15 0.263  UL115  L 0.385  0.746 
UL41A   0.556  0.76  UL116  E-L  0.284 0.922 
UL42   0.4 0.922  UL117 L  0.257  0.935 
UL43 L  0.347  0.733  UL119 E  0.4 0.815 
UL44 E-L  0.213  0.286  UL120 L  0.687  0.0126 
UL45   0.0414  0.116  UL121 L  0.569  0.505 
UL46 E-L  0.213  0.62  UL122 IE,  L  0.671  0.684 
UL47 E-L  0.48  0.224  UL123 IE  0.150  0.443 
UL48 L  0.569  0.746  UL124 E  0.468  0.204 
UL48A   1  1  UL128  E  0.737 0.092 
UL49 E-L  0.213  0.29  UL130 E-L  0.347  0.211 
UL50   0.569  0.94  UL131A  L  0.717  0.0621 
UL51   0.987  0.0126 
 
UL132 E-L  0.103  0.227 
   147 
 
  
Gene  Kinetic 
class 
HFFF-2 vs  
RPE  
(p-value) 
HFFF-2 vs  
U373Mg  
(p-value) 
  Gene  Kinetic 
class 
HFFF-2 vs  
RPE  
(p-value) 
HFFF-2 vs  
U373Mg  
(p-value) 
UL148   0.0342  0.0615  US9  E  0.987  0.0594 
UL147A   0.0178 0.0594  US10  E  0.253  0.907 
UL147 E-L  0.341  0.461  US11  E  0.0342  0.0594 
UL146   0.434  0.746  US12  E  0.00988  0.0126 
UL145   0.61  0.0376  US13  E  0.0342  0.0666 
UL144   0.411  0.952  US14  E  0.0322  0.037 
UL142   0.468  0.952  US15  E  0.037  0.204 
UL141   0.45  0.952  US16  E  0.342  0.856 
UL140   0.556  0.397  US17  E  0.556  0.125 
UL139   0.254  0.417  US18  E  0.00555  0.0126 
UL138   0.0342  0.116  US19  E  0.00446  0.0126 
UL136   0.556  0.907  US20  E  0.00988  0.0457 
UL135   0.193  0.29  US21  E  0.527  0.296 
UL133   0.4  0.705  US22  E  0.213  0.505 
UL148A   0.569  0.0195  US23  E  0.213  0.746 
UL148B   1  0.0445  US24  E  0.61  0.175 
UL148C   0.974  0.0594  US26  E  0.569  0.0126 
UL148D   0.671  0.505  US27  E  0.342  0.94 
UL150   0.573  0.109  US28  E  0.197  0.439 
IRS1 IE  0.00555  0.0126  US29  E-L  0.433  0.746 
US1   1  1  US30  E  0.434  0.907 
US2   0.347  0.189  US31   0.213  0.443 
US3 IE  0.556  0.0126  US32  L  0.347  0.856 
US6 E-L  0.61  0.0126  US34  E  0.434  0.0594 
US7 E-L  0.501  0.355  US34A   1  1 
US8 E  0.213  0.519 
 
TRS1 IE  0.931  0.15 
 
 
 
   
Table 4.6. Student’s t-test p-values for HFFF-2 and RPE or U373Mg. 
The table shows the corrected p-values for the Student’s t-test between HFFF-2 and RPE, 
and HFFF-2 and U373Mg cells. Significant differences were considered at the 95 % 
significance level (p < 0.05). 
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Gene  HFFF-2 
vs RPE 
(p-value) 
Kinetic 
Class  
 
Function 
UL4  0.00555  E  Glycoprotein, function unkown; Upstream cis acting 
element for NF-Y and Elk1. Upstream short ORF controls 
translation of the downstream mRNA. 
UL16  0.00342  E   Evasion of immune surveillance. Expressed at early times 
and peaks at late times.  
UL45  0.0414  L  Tegument protein; reported anti-apoptotic activity and role 
in cell-to-cell spread of infection. 
UL148 0.0342     
IRS1  0.00555  IE    Important transactivator of gene expression. Efficient 
assembly of virus particles. Binds double stranded RNA and 
inhibits cellular interferon response. Internal transcription 
start site, produces a 263 aa protein that negatively regulates 
IRS1 expression. US22 family 
US11  0.0342  E  Evasion of immune surveillance. Glycoprotein that targets 
MHC Class I heavy chains for degradation. 
US12  0.00988  E  Putative transmembrane protein 
US13  0.0342  E  Putative transmembrane protein 
US14  0.0322  E  Putative transmembrane protein 
US15  0.037  E  Putative transmembrane protein 
US18  0.00555  E  Putative transmembrane protein 
US19  0.00446  E  Putative transmembrane protein 
US20  0.00988  E  Putative transmembrane protein 
 
 
 
      Table 4.7. HCMV genes that are differentially expressed in HFFF-2 and RPE cells.  
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Gene  HFFF-2 vs 
U373Mg 
(p-value) 
Kinetic Class 
(Chambers et 
al., 1999) 
Function 
UL4  0.0126  E  Glycoprotein, function unkown; Upstream cis 
acting element for NF-Y and Elk1. Upstream short 
ORF controls translation of the downstream 
mRNA 
UL14  0.0126  L  UL14 family; putative membrane glycoprotein 
UL15A  0.0126    Putative membrane protein 
UL18 0.0269  L  gpUL18,  similar  to  MHC class I; immune evasion 
UL19 0.0126     
UL23  0.0217    US22 family member 
UL27 0.0159  E   
UL28  0.0126    US22 family member 
UL31 0.0126  L   
UL51  0.0126    DNA packaging protein 
UL102 0.0184  L  Helicase-primase 
UL105 0.0126  E  Helicase-primase 
UL111A 0.0326  E-L  vIL-10 
UL120 0.0126  L  Glycoprotein 
UL145 0.0376     
UL148A 0.0195    Membrane  protein 
UL148B 0.0445    Membrane  protein 
IRS1  0.0126  IE  Important transactivator of gene expression. 
Efficient assembly of virus particles. Binds double 
stranded RNA and inhibits cellular interferon 
response. Internal transcription start site, produces 
a 263 aa protein that negatively regulates IRS1 
expression 
US3 0.0126  IE  Glycoprotein,  inhibits processing of MHC class I 
and II; immune evasion 
US6  0.0126  E-L  Glycoprotein, inhibits TAP mediated peptide 
transport; immune evasion 
US12  0.0126  E  Putative transmembrane protein 
US14  0.037  E  Putative transmembrane protein 
US18  0.0126  E  Putative transmembrane protein 
US19  0.0126  E  Putative transmembrane protein 
US20  0.0457  E  Putative transmembrane protein 
US26  0.0126  E  Putative transmembrane protein 
 
 
 
Table 4.8. HCMV genes that are differentially expressed in HFFF-2 and U373Mg. 
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and U373Mg cells. Indeed, this difference is approximately 2 fold between HFFF-2 and 
RPE, and 1.5 fold for U373Mg. It seems probable that expression of gene UL4 is up-
regulated in HFFF-2 compared to RPE and U373Mg cells, as there was very high 
expression throughout the time course, and statistical analysis indicates that the 
difference in the expression for UL4 in HFFF-2 differs significantly from that in both RPE 
and U373Mg cells. Moreover, magnitude and expression kinetics obtained for UL4 in 
U373Mg cells is very similar to all other HCMV genes expressed in this cell type (Fig. 4.15, 
4.16).  
The expression kinetics for UL16 in HFFF-2 and RPE yields a concave profile albeit the 
profile is much flatter in RPE cells; in contrast, the expression profile in U373Mg was 
convex. UL16 is expressed at all time points in each cell type, with medium levels of 
expression in HFFF-2 and U373Mg cells, but much lower expression in RPE cells. The 
statistical test results show a significant difference in mean expression between HFFF-2 
and RPE (p-value 0.00257), but no significant difference in expression between HFFF-2 
and U373Mg. In RPE cells, expression of UL16 was extremely low (3-fold lower than in 
HFFF-2), suggesting possible down-regulation of gene UL16 in this cell type. While no 
statistically significant difference could be found in UL16 expression between HFFF-2 and 
U373Mg cells, the kinetics of expression were different, although the significance of that 
finding is not clear.  
The expression kinetics of genes UL45, UL148 and IRS1 were similar in all three cell types. 
In HFFF-2, UL45 and UL148 transcripts increased steadily with time, while IRS1 transcript 
levels reached a plateau at 24 h PI. In RPE cells, UL148 and IRS1 expression was detected 
at 12 h PI with little change in transcript levels until after 48 h PI. UL45 expression was 
not detected in RPE cells until 24 h PI, thereafter transcript levels were of a similar 
magnitude and shared similar kinetics to those of IRS1. The expression profiles for UL45, 
UL148 and IRS1 in U373Mg were similar in kinetics and magnitude over the time course. 
No significant difference was found for UL45 and UL148 in the combined statistical tests 
comparing HFFF-2 and U373Mg cells.  
US11 was detected in HFFF-2 and RPE cells from 12 h PI, after which the expression 
increased in HFFF-2 cells and plateaued at 48 h PI. However, the expression of US11 
decreased in RPE cells until 48 h PI, and increased at 72 h PI. The US11 expression profile 
in U373Mg cells is characteristic of all other genes in that cell type (medium expression 
levels accumulating at a similar rate over the time course). The statistical tests 
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demonstrated a significant difference in US11 expression between HFFF-2 and RPE cells, 
but no significant difference between HFFF-2 and U373Mg cells.  
US12, US13, US14, US15, US18, US19 and US20 are all members of the US12 gene family 
and all exhibited similar expression profiles in each of the three cell types. Since US12, 
US13, US14 and US15 are contained in one 3’ co-terminal group, and genes US18, US19 
and US20 in a second 3’ co-terminal group, this may account for the shared expression 
kinetics among the family members US12 to US15, and US18 to US20. Apparent 
expression from all of these genes was detected throughout the time course. In HFFF-2, 
expression of all of these genes was fairly high and plateaued at about 24 h PI. In contrast, 
in RPE cells, the expression kinetics for these genes yielded a biphasic profile; an increase 
from 12 to 24 h PI, followed by a plateau between 24 and 48 h PI, and a sharp rise in 
expression between 48 and 72 h PI. The expression kinetics for each gene was different in 
HFFF-2 and RPE cells, and this correlated with a finding of significant difference in mean 
expression in the combined statistical tests. However, since these genes belong to 3’ co-
terminal groups, further analysis such as northern blotting is required to confirm such 
conclusions.  
In infected U373Mg cells, the profiles of HCMV genes US12, US13, US14, US15, US18, 
US19 exhibit the same magnitude and kinetics that characterise other HCMV genes. 
Expression levels plateaued after 24 h PI and generally declined at 72 h PI. Interestingly, 
the statistical tests determined that expression of genes US12, US14, US18, US19 and US20 
as significantly different in HFFF-2 and U373Mg cells. In the case of US18, US19 and 
US20, the expression profiles obtained in HFFF-2 and U373Mg were similar, albeit slightly 
higher in HFFF-2 cells. According to the t-test p-values, there was a significant difference 
in the overall mean expression for US18, US19 and US20 between HFFF-2 and U373Mg 
cells; however, examination of the expression kinetics for these genes in these two cell 
types does not appear to show strong evidence in support of differential expression. 
Further analysis would be required to clarify such findings.    
The expression curves for representative HCMV genes from Table 4.8 whose expression 
levels differed between infected HFFF-2 and U373Mg cells, but not between infected 
HFFF-2 and RPE cells are shown in Fig. 4.16. In infected HFFF-2 and RPE cells, the 
expression of HCMV genes UL18 (Fig. 4.16A), UL23 (Fig. 4.16B), US6 (Fig. 4.16C), UL102 
(Fig. 4.16D), UL27 (Fig. 4.16E), UL31 (Fig. 4.16F), UL51 (Fig. 4.16G) and UL120 (Fig. 4.16H) 
are similar as they were generally only detected between 48 and 72 h PI, and no 
significant differences were reported by the combined statistical tests (Table 4.6). 
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However, the differences in the expression kinetics of these genes in infected HFFF-2 and 
U373Mg cells confirms the result obtained by the combined statistical tests (Table 4.8).  
4.2.10  Analysis of proposed novel ORFs and previously discounted ORFs 
The microarray was designed to contain probes for 36 novel ORFs proposed by Murphy 
et al., 2003(a) and (b), in order to investigate whether the putative ORFs expressed 
detectable levels of transcripts. Tables 4.9 and 4.10 shows the microarray results obtained 
for these novel ORFs. It should be noted that only infected HFFF-2 and RPE cells were 
investigated to determine whether these ORFs were present (P) or absent (A) 
(disagreement between the cell types are indicated by an asterix). The proposed novel 
ORFs were defined as present (P) if both the HFFF-2 and RPE cells contained present flags 
in 3 or more datasets; this being the minimum present data required for expression at one 
time point. ORFs having present flags in only 1 or 2 datasets were considered unreliable.   
Table 4.9 shows the data for the putative ORFs reported by Murphy et al., (2003a). No 
transcripts were detected for the majority of ORFs. However, signals were detected in 3 or 
more datasets for ORF4 and ORF5 in both HFFF-2 and RPE cells. Both ORF4 and ORF5 lie 
between UL54 and UL57, though coded on the opposite DNA strand. It is therefore 
possible that ORF4 and ORF5 code novel HCMV genes. ORF2 is defined as present in 
HFFF-2 cells, but absent in RPE cells. ORF2 codes in the same direction as, and overlaps 
with genes UL29 and UL30. The present flags for this gene in HFFF-2 cells could be due to 
a single transcript running through the two established HCMV genes. Supporting this 
conclusion is the observation that the only poly(A) signal in this region is located 
downstream of UL30.  
Table 4.10 shows the data for the putative ORFs reported by Murphy et al., (2003b). C-
ORF1, C-ORF3 and C-ORF4 are located within the RL region of the genome. This region 
of the genome was previously highly annotated (Chee et al., 1990) but more recently, most 
ORFs in the RL region were discounted as protein coding ORFs by Dolan et al. (2002). The 
three ORFs (C-ORF1, C-ORF3 and C-ORF4) all code in the same direction as adjacent 
established genuine ORFs, and long transcripts specifying the RL11 gene family members 
in this region of the genome could account for these positive signals. The novel C-ORF10, 
C-ORF15, C-ORF25 and C-ORF29 also code in the same direction as established genes 
(overlapping in some cases). Again, it is not possible to determine whether the positive 
signals hybridising to probes for these novel ORFs provide evidence for specific 
transcription or whether they are artefacts resulting from transcription of established 
genes within these regions. In contrast, C-ORF16, C-ORF18 and C-ORF26 all code in the 
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P  
A  
A  
A
A
A
A
P
P
P*
A
ORF12
ORF11
ORF10
ORF9 
ORF8 
ORF7 
ORF6 
ORF5 
ORF4 
ORF2 
ORF1 
P/A ORF 
 
 
P*  C-ORF29
A  C-ORF28
P*  C-ORF26
P  C-ORF25
A  C-ORF24
A  C-ORF23
A  C-ORF22
A  C-ORF21
P*  C-ORF20
P  C-ORF18
A  C-ORF17
P  C-ORF16
P  C-ORF15
A  C-ORF14
A  C-ORF13
A  C-ORF11
P*  C-ORF10
A  C-ORF8
P*  C-ORF7
A  C-ORF6
A  C-ORF5
P  C-ORF4
P  C-ORF3
A  C-ORF2
P*  C-ORF1
P/A  ORF
 
 
  
(P) Present, (A) Absent, and (*) shows disagreement between the two cell types. 
Table 4.9                     Table 4.10  
  
Table 4.9. Detection of transcripts in HFFF-2 and RPE cells hybridising to probes
specific for the novel HCMV ORFs proposed by Murphy et al., 2003(a). 
 
Table 4.10. Detection of transcripts in HFFF-2 and RPE cells hybridising to probes
specific for the novel HCMV ORFs proposed by Murphy et al., 2003(b). 
  
opposite direction to established HCMV genes in the locality and it is possible that the 
present signals obtained for these recently novel ORFs are the result of transcription from 
the proposed genes. Further work is necessary to confirm the findings reported here.  
Probes for a subset of ORFs previously annotated by Chee et al. (1990) but discounted as 
protein coding genes by Dolan et al. (2002) were also included in the microarray (Table 
4.11). Many of these ORFs were originally considered to belong to the RL11 gene family, 
while others are located within regions of the genome now thought to be non-protein 
coding. The microarray data confirmed the expectations of Dolan et al. (2002) that the 
majority of these ORFs do not express transcripts. For these discounted ORFs, that are 
flagged as present (e.g. UL41), the microarray data by itself is insufficient to determine 
whether the gene is protein-coding gene. As with all the present-flagged novel ORFs, 
additional techniques such as northern blotting are required to confirm their status as 
genes.  
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Gene  P/A 
RL3 A 
RL4 P* 
RL5 A 
RL8 P 
RL9 A 
UL21 A 
UL41 P 
UL60 A 
UL61 P* 
UL101 A 
US5 A 
US25 A 
J1S A 
 
 
Table 4.11. Detection of transcripts in HFFF-2 and RPE cells hybridising to probes 
specific for the HCMV ORFs discounted by Dolan et al., 2002. 
ORFs are reported as present (P) or absent (A); disagreement between HFFF-2 and RPE 
are marked with an asterisk.  
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4.3 Discussion 
The aim of the microarray analysis was to investigate HCMV global gene expression in 
HFFF-2, RPE and U373Mg cells in order to identify genes whose expression differed from 
that in infected HFFF-2 cells, which was used as the reference cell line. In addition, 
transcription from recently proposed novel genes and from regions of the genome now 
discounted as protein coding was also assessed in HFFF-2 and RPE cells. In HFFF-2 and 
RPE cells, the microarray detected expression from approximately 96 % of the HCMV 
strain Merlin ORFs (AY446894), and this increased to approximately 98 % in U373Mg 
cells. No transcripts binding probes for the HCMV genes US1, US34A or UL48A could be 
detected at any time point in any cell type, and since the array contained both 5’- and 3’-
probes, these were subsequently defined as absent genes. For UL111A and UL29, no 
transcripts were detected in HFFF-2 or RPE cells although expression of both genes was 
detected in U373Mg cells. There were also many examples of genes expressed throughout 
the time course in U373Mg cells, but expressed only at 1 time point (generally at 72 h PI) 
in HFFF-2 and RPE cells (e.g. UL146, UL150, US3, US6, US7, US26, UL131A). For these 
genes, and others in Table 4.5, present flags could only be detected in 1 or 2 datasets in 
HFFF-2 and RPE cells, but 11 or 12 datasets in U373Mg cells.  
 
There are several possible explanations for the above findings. It is possible that genes 
defined as absent (US1, US34A and UL48A) were not expressed at the particular time 
points examined, or are expressed at levels below the detection limit, or the microarray 
probes do not bind their targets efficiently. For genes UL29 and UL111A, whose 
transcripts were not detected in HFFF-2 or RPE cells, but were detected in U373Mg cells, it 
is possible that transcript levels were low in HFFF-2 and RPE cells, falling below the 
detection limit of the microarray, but that their levels were greater in U373Mg cells; 
present flags were detected for UL29 in two datasets, and for UL111A in six datasets. 
While the statistical tests determined UL111A to be differentially expressed between 
HFFF-2 and U373Mg cells, the data for UL29 were insufficient to determine presence or 
absence by the statistical tests. In some cases, genes UL14, UL18, UL102, UL120, UL131A, 
where expression was detected in only one or two datasets in HFFF-2 and RPE cells, the 
genes belong to the late kinetic class (Chambers et al., 1999), and their expression was not 
detected until 72 h PI. The statistical tests between infected HFFF-2 and U373Mg cells 
identified these five genes as differentially expressed. The determination of differential 
gene expression is based firstly upon statistical analysis and secondly by examination of 
the kinetics of candidate differentially expressed genes identified by the combined 
statistical tests. The t-tests did not identify genes UL146, UL150, US3, US6, US7 and US26 
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as differentially expressed in infected HFFF-2 and U373Mg cells, but examination of the 
expression kinetics showed that these genes were expressed throughout the time course 
in U373Mg cells, but only at 72 h PI in HFFF-2 cells (data not shown). In contrast, genes 
UL54, UL147A and UL138 were determined to be significantly different (p < 0.05) in 
HFFF-2 and RPE cells, but examination of the expression profiles revealed that these 
genes shared the same kinetics in these two cell types (data not shown). Further studies 
are required to confirm or reject the statistical tests.  
 
Statistically significant differences were identified with the various statistical tests for a 
total number of 13 genes in HFFF-2 and RPE cells, and 26 genes in HFFF-2 and U373Mg 
cells. Microarray experiments are generally based on a null hypothesis that there is no 
difference in the expression levels of individual genes under two (or more) conditions. For 
the HCMV microarray, the null hypothesis was: no difference in HCMV gene expression 
kinetics in HFFF-2, and RPE, or HFFF-2 and U373Mg cells. While this is true for infected 
HFFF-2 and RPE cells, the situation was less clear when comparing infected HFFF-2 and 
U373Mg cells since HCMV genes belonging to the late kinetic class were expressed at 
much earlier times in U373Mg cells than in HFFF-2. Consequently, the conclusions drawn 
from the comparison of HFFF-2 and U373Mg cells are less stringent than those drawn 
from a comparison of the data from HFFF-2 and RPE cells, where the temporal kinetics of 
viral gene expression are the same. It would be expected then that many more genes 
would be classified as differentially expressed when comparing HFFF-2 and U373Mg 
cells. Because of the differences in temporal expression of some HCMV genes and because 
individual HCMV genes were expressed at a fairly consistent level irrespective of 
sampling time PI, the combined statistical test data obtained for the HFFF-2/U373Mg 
experiment are less reliable than the data obtained for the HFFF-2/RPE comparisons. The 
data for gene expression in U373Mg cells then needs confirmation by other techniques.    
 
The combined statistical tests between HFFF-2 and RPE cells provided evidence for 13 
genes as differentially expressed. The expression kinetics were the same for each of the 
remaining genes in both cell types, although transcript and proteins levels were 
consistently lower in RPE cells compared to HFFF-2 cells. For each of the 13 differentially 
expressed genes, expression was down-regulated in RPE cells compared to HFFF-2 cells 
over the first 48 h PI, but increased thereafter, so that levels of UL4, UL45, UL148, IRS1, 
US11, US12, US13, US14, US15, US18, US19 and US20 approximated levels attained in 
infected HFFF-2 cells at 72 h PI. In contrast, the 72 h PI levels of UL16 never approached 
levels seen in HFFF-2 cells. The UL4 expression profile exhibits high expression 
throughout the time course in HFFF-2 cells (Fig. 4.15A). In addition to the reduction in 
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overall transcript level, expression kinetics suggests a delay in the induction of UL4, 
UL45, UL148, IRS1, US11, US12, US13, US14, US15, US18, US19 and US20 genes in 
infected RPE cells compared to HFFF-2 cells. The delay is gene specific and not related to 
progress through the temporal transcription cascade since other genes belonging to the 
early and late kinetic classes are expressed with the appropriate temporal kinetics and 
their overall expression level was not identified as significantly different by the statistical 
tests in HFFF-2 and RPE cells (Fig. 4.13). Expression of UL16 is down-regulated to the 
greatest degree in RPE cells, giving a 3 fold reduction compared to HFFF-2 cells. 
However, undue emphasis should not be placed on fold change in general as HCMV gene 
expression of non-differentially expressed genes in RPE cells was up to 2-fold lower than 
in HFFF-2 cells. In contrast, the statistical tests provide a more sensitive determination 
since they take into account the spread of the data rather than a single averaged point.   
 
HCMV infected U373Mg gene expression kinetics were fairly consistent over the time 
course; however, examination of the profiles identified three types of expression kinetics 
within this cell type. (1) HCMV genes whose expression increased from 12 to 24 h PI, then 
plateaued or slowly declined to 72 h PI (e.g. Fig. 4.15A, B, D, E, F, G, H, J, K and L; Fig. 
4.16B, C, D, E, G and H). (2) HCMV genes whose expression increased from 12 to 48 h PI 
then plateaued from 48 to 72 h PI (e.g. Fig 4.15C; Fig. 4.16A and F). (3) Biphasic response, 
where gene expression increased from 12 to 24 h PI, plateaued from 24 to 48 h PI, and 
increased again from 48 to 72 h PI (Fig. 4.15I). The gene expression kinetics described in 
(1) and (3) correlates with genes that belong to the early kinetic class, and in (2) the late 
kinetic class.  
 
The data suggest that in infected U373Mg cells, HCMV early gene expression peaks at 24 
h PI and late gene expression at 48 h PI. In infected HFFF-2 cells, early and late gene 
expression peaks at 48 h and72 h PI, as is the case with infected RPE cells (Fig. 4.16). These 
data suggest that HCMV gene expression progresses through the transcription cascade 
more rapidly in U373Mg cells than in HFFF-2 or RPE cells, and this may account for the 
general high level of viral transcripts in this cell type. Transcript levels of early HCMV 
genes in U373Mg cells reach saturating levels before equivalent transcripts had either 
appeared or reached significant levels in HFFF-2 cells. Consequently, overall transcript 
level averages are generally higher in U373Mg cells. In the case of those HCMV genes 
whose transcript levels were lower in infected U373Mg cells compared to infected HFFF-2 
cells, these are likely specifically down-regulated in U373Mg cells and so considered 
differentially expressed. However, in the case of the majority of HCMV genes whose 
transcript level was higher in infected U373Mg cells compared to infected HFFF-2 cells, 
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the situation is less clear. Because HCMV gene expression appears to be progressing 
through the transcription cascade at a faster rate in infected U373Mg cells compared to 
infected HFFF-2 cells, the rapid transit progression through the transcription cascade in 
infected U373Mg cells would allow transcripts to reach maximal gene expression before 
they could be reached in infected HFFF-2 cells. In these cases, the statistical tests cannot 
discriminate between differential gene expression and different rates of transit through 
the gene expression cascade.  
 
The combined statistical tests identified a total of 26 HCMV genes as differentially 
expressed in HFFF-2 and U373Mg cells (Table 4.8). However, separating these genes that 
were under- or over-expressed in infected U373Mg cells compared to infected HFFF-2 
cells identifies 7 HCMV genes (UL4, IRS1, US12, US14, US18, US19 and US20) under-
expressed and so good candidates to be truly differentially expressed in these two cell 
types. The remaining genes were all over-expressed in infected U373Mg cells compared to 
infected HFFF-2 cells (Fig. 4.15), and are regarded as less good candidates for differential 
expression. The reduction of the differentially expressed gene list for HFFF-2 and U373Mg 
cells from 26 to the 7 listed above highlights the fact that UL4, IRS1, US12, US14, US18, 
US19 and US20 are also identified as differentially expressed in infected HFFF-2 and RPE 
cells (Table 4.7). As with all microarray data, RT-qPCR, northern and western blotting 
would be required to confirm their status as differentially expressed HCMV genes. 
Interestingly, translation of transcripts into protein product (Fig. 3.5, 3.6 and 3.7) occurred 
with similar kinetics in HFFF-2, RPE and U373Mg cells as assessed by western blots. 
Rapid transit through the transcription cascade did not result in high yields of infectious 
progeny virus in U373Mg cells, conversely, virus yields were the lowest attained from any 
of the cell types (Fig. 3.1, 3.2 and 3.3).  
 
With regard to putative novel ORFs in the HCMV genome, the microarray analysis did 
not find sufficient evidence of transcription from the majority of these to support their 
status as functional ORFs. It was considered that present flags in three datasets were 
sufficient to define an ORF as present, since this represented expression at a single time 
point. However, many of the ORFs that passed this filter and were flagged as present 
could still not be unambiguously defined as genuine ORFs since they were located 
between known genes whose transcripts are likely to include the region containing the 
proposed novel ORFs. This argument does not hold for C-ORF16, C-ORF18 and C-ORF26 
which all code in the opposite direction to established HCMV genes in the locality, and 
these ORFs may represent novel ORFs. The ORFs previously annotated by Chee et al., 
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(1990) but more recently discounted, provided no evidence for expression confirming the 
expectations of Dolan et al., (2002).  
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5 RESULTS  III 
5.1  Validation of the data 
While the HCMV microarray facilitated the rapid screening of the HCMV transcriptome 
for genes that are differentially expressed in different cell types, the microarray data by 
itself is not conclusive and alternative techniques such as RT-qPCR and northern blotting 
are required to confirm the microarray expression data. The data obtained from RT-qPCR 
and northern blotting techniques allows direct comparison with microarray expression 
data since these techniques also measure transcript expression and abundance, albeit with 
considerable differences in the level of the sensitivity. Gene expression profiles obtained 
by RT-qPCR and northern blotting were compared with the microarray expression data 
reported in chapter 4 with the view to comparing expression trends for individual genes 
using different detection systems. However, in contrast to the microarray, it must be 
noted that northen blot and RT-qPCR assays were capable of detecting both sense and 
anti-sense transcripts as probes for the northern blots were generated using double-
stranded DNA PCR products (see methods, 2.2.16.3), and RT-qPCR was based on the 
amplification of double-stranded DNA. This is particularly relevant as recent evidence 
suggests that anti-sense transcripts can be detected for approximately 46 % of the HCMV 
genome, and many of these anti-sense transcripts are overlapping with established 
HCMV genes (Zhang et al., 2007). This could lead to additional anti-sense transcript 
bands detected by the northern blots, while also influencing the signal detected during 
RT-qPCR. Based on the assumption that the kinetics and abundance of transcript 
expression are directly related to the kinetics and abundance of the associated protein, 
western blotting has also been employed to further test the microarray expression data. 
However, it must be noted that the availability of antibodies against HCMV proteins is 
limited, and no antibodies were available for those genes identified as differentially 
regulated in HFFF-2 and RPE cells. Primers that were used during RT-qPCR are shown in 
Table 5.1, while northern blotting probe information is shown in Table 5.2. 
5.2  HCMV 3’ co-terminal transcripts, overlapping transcripts and spliced genes 
The microarray probes will hybridise to all transcripts running through to a common 
shared poly(A) site, and so the signal detected will derive from multiple rather than a 
specific transcript. To assess which gene probes might be affected by binding multiple 
transcripts, an evaluation of poly(A) sites proximal to HCMV ORFs is shown in Table 5.3 
and Fig. 1.2 (see introduction, 1.3.1). HCMV, like other herpesviruses, has a genome that
   165 
 
  
  
    
    
   
  
   
  
   
  
   
  
   
  
 
HCMV 
Primer 
Genome 
Position 
Sequence (5’-3’) 
UL16(F) 23062  CGACATCACCACTAACATCT 
UL16(R) 23200  AGAGGCGCTCGATTATT 
UL55(F) 84316  GGTGTGGATGTAAGCGTA 
UL55(R) 84401  GGCATCATGGTGGTCTACAA 
UL83(F) 121209  TTGCCCTGGATGCGATACTG 
UL83(R) 121285  TGCGCTCTTCTTTTTCGATA 
UL99(F) 145715  GAACTCTGCAAACGAATATG 
UL99(R) 145801  GGGATGTTGTCGTAGGAG 
UL123(F) 172421  AGGCAACTTCCTCTATCTCA 
UL123(R) 172550  CCCTCTGTCCTCAGTAATTG 
US12(F) 206920  AATTTGACGGTGAGCGATA 
US12(R) 207021  GTGCAGTCCTGGGAACCATA 
 
 
 
US18(F)    212754  CCACGCTGGTAGATGAGA 
US18(R) 212867  CCGTCATCGTCTTTTACCTA   
                    Table 5.1. List of HCMV primers used for RT-qPCR 
 
  HCMV ORF  Probe Length 
(bases) 
Genome Position  
UL4  313  13936 - 14249 
UL16  282  22861 - 23143 
UL43  288  55891 - 56179 
UL55  349  82460 - 82809 
UL83  235  121565 - 121800 
UL99  289  145796 - 146085 
UL123  472  172777 - 173249 
IRS1  286  198271 - 197985 
US12  339  206906 - 207245 
US18  328  212673 - 213001 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       Table 5.2. Northern blotting probe information 
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Table 5.3. HCMV polyadenylation signal (AATAAA) genome positions and predicted 
poly(A) usage by HCMV ORFs.  
Genome 
Position 
Strand  HCMV ORFs proximal to 
downstream poly(A) sites 
Genome 
Position 
Strand  HCMV ORFs proximal to 
downstream poly(A) sites 
132 F    2510  R  RL5A 
2367 F RL1  5917  R  
3093 F   5980  R RL6   
3932 F   6782  R  
4309 F   11609  R  
4505 F   12126  R  
4517 F   12564  R  
6969 F   12856  R  
7502 F   12964  R UL2   
9842  F  RL10, RL11   14241  R   
11014 F    15387  R   
12081 F  RL12,  RL13  16848  R   
12935 F  UL1    16990  R   
13152 F    17702  R   
14100 F    21103  R   
15088 F  UL4    22575  R   
15810  F  UL5, UL6   26803  R  UL21A  
15857 F  UL6  27895  R   
15934  F    28158  R  UL23, UL24, UL26, UL27, 
UL28, UL29, UL30 
17601 F  UL7,  UL8  37629  R  UL32 
18265 F  UL9    44792  R   
21144  F  UL10, UL11, UL13   47905  R   
22529  F  UL14  48471  R  UL36, UL37, UL38 
23966  F  UL15A, UL16, UL17   51227  R  UL37, UL38 
25557 F  UL18,  UL19  51375  R  UL38   
26787  F  UL20   53522  R  UL40, UL41A, UL42, UL43, 
UL44, UL45, UL46 
28138  F  UL22A   68788  R    
28288 F    70441  R   
32458 F  UL25    70735  R   
37582  F    71441  R  UL48A, UL49, UL50 
46379  F  UL31, UL33, UL34  74580  R  UL51 
48423 F  UL35  77551  R   
54133  F    77620  R  UL54, UL55, UL56, UL57 
54533 F    92481  R   
59257 F    92651  R  UL69,  UL70 
59934 F    105865  R  UL72 
60704 F    106669  R  UL74   
70073 F  UL47  109112  R  UL75,  UL79 
70091 F    117619  R   
71372 F  UL48  118726  R  UL82,  UL83 
92436  F  UL52, UL53  122486  R  UL84, UL85, UL86 
97111 F    129353  R   
98195 F    130820  R   
99193 F    132697  R  UL89 
104558 F    134534  R   
108127 F  UL71,  UL73  135908  R   
109052 F    148606  R  UL100 
115768  F  UL76, UL77,  UL78  149261  R  UL103, UL104 
118682 F  UL80,  UL80.5  Overlapping 
genes 
154291 R   
118734 F  UL80  and  UL80.5  156136  R   
122432 F    160460  R   
129407 F    160676  R   
139210  F  UL87, UL88, UL91, UL92  161210  R  UL114 
140263 F    165011  R  UL115,  UL116,  UL117, 
UL119 
146447  F  UL93, UL94, UL95, UL96, 
UL97, UL98, UL99 
168831 R  UL120,  UL121 
156281 F  UL102,  UL105  170607  R 
161739 F  UL111A    172236  R 
UL122 (IE2)/UL123 (IE1) 
Spliced transcripts 
157595 F    173987  R  UL128   
158069 F    176183  R  UL130,  UL131A 
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Genome 
Position 
Strand  HCMV ORFs proximal to 
downstream poly(A) sites 
Genome 
Position 
Strand  HCMV ORFs proximal to 
downstream poly(A) sites 
161739 F    178174 R  UL132,  UL148,  UL147A,  UL146, 
UL147 
164240 F  UL112  181304 R   
168146 F    181499 R  UL144,  UL145,  UL142 
174574 F  UL124  184383 R  UL141,  UL140 
174628 F    187122 R  UL139,  UL138,  UL136 
174703 F    188701 R  UL135   
182127 F    189884 R  UL133,  UL148A,  UL148B, 
UL150 
182752 F    195536 R  US1   
182822 F    199305 R  US2   
184127 F    200129 R  US3   
186856 F    200133 R   
187083 F    201597 R  US6   
191339  F    202590  R  US7, US8, US9, US10 
194306 F  UL148C,  UL148D  205300 R  US11 
199253  F  IRS1   206766  R  US12, US13, US14, US15, US16, 
US17 
200114 F    212449 R  US18,  US19,US20 
200348 F    216033 R  US21,  US22,  US23 
203416 F    219795 R  US24 
205373 F    221909 R  US26   
210531 F    227466 R   
212454 F    231967 R   
213596 F    232393 R  TRS1 
216070 F         
217037 F         
226497 F  US27,  US28       
228904 F  US29,  US30       
230186 F  US31,  US32       
231505 F  US34         
235198 F  US34A         
 
 
Table 5.3. HCMV polyadenylation signal (AATAAA) genome positions 
and predicted poly(A) usage by HCMV ORFs.  
 
The table lists the positions of the most common polyadenylation signal 
(AATAAA) in the HCMV genome. The table also lists the strand on which the 
signals are located (F, forward; R, reverse), and the HCMV ORFs proximal to 
the polyadenylation signal. This table does not predict actual poly(A) usage 
by HCMV ORFs, but serves as an indication of the complexity of the elements 
of genetic control in the HCMV genome.  
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is densely packed with ORFs, but contains relatively few polyadenylation signals, 
required for transcription termination and the subsequent addition of a polyadenylate tail 
on the free 3’-end of mRNAs. Consequently, many spliced and non-spliced HCMV genes 
share polyadenylation signals, leading to the generation of 3’ co-terminal groups of genes 
within specific regions of the HCMV genome (Wing and Huang, 1995; Smuda et al., 1997; 
Guo and Huang, 1998). Some HCMV ORFs also overlap, e.g. UL146/UL147A (Lurain et 
al., 2006), while others are spliced, e.g. UL122/UL123 (Awasthi et al., 2004) and UL37 
(Adair et al., 2004). The table lists the most common polyadenylation signal (AATAAA) 
within the HCMV genome, together with location on the forward (F) or reverse strand 
(R), and also the HCMV ORFs that are 3’-proximal to the signal. While this table suggests 
poly(A) site usage by specific HCMV genes, it should be noted that HCMV poly(A) 
signals are not utilised equally or efficiently during transcription. For example, a poly(A) 
site is located downstream of UL94; however, UL93 and UL94 specific transcripts utilise a 
poly(A) site further downstream of UL99 (Wing and Huang, 1995).   
In the case of 3’ co-terminal genes using the same poly(A) site, it is possible that cDNA 
fragments from multiple transcripts will bind to the probes thus skewing the microarray 
expression data for individual members of the co-terminal gene family. For comparisons 
between microarray expression data and that obtained from northern blots, it is necessary 
to take into account whether individual genes are part of a 3’ co-terminal family and/or 
spliced etc. The data calculated from band intensities and the band intensities of all 
transcripts detected by the microarray probe are added together to compare expression 
data in the two systems. Examples presented here include 3’ co-terminal genes US12 to 
US17, US18 to US20, UL93 to UL99 and UL54 to UL57, and spliced genes UL122/UL123 
(IE2/IE1). Summary diagrams of the relevant transcription units detected during northern 
blotting are presented for non-differentially expressed genes; UL123 (Fig. 5.1.1; note that 
microarray probe positions, the northern blot probe region, and the region amplified 
during RT-qPCR are also included in this figure), UL55 (Fig. 5.2.1), UL83 (Fig. 5.3.1), and 
UL99 (Fig. 5.4.1), and differentially expressed genes; IRS1 (Fig. 5.8.1), US12 (Fig. 5.9.1) and 
US18 (Fig. 5.10.1). Note that northern blot band sizes were determined using two RNA 
ladders (Invitrogen) that were run at either side of the gel, in the first and last lanes.  
5.3  Expression and validation of representative non-differentially regulated genes  
UL123 (IE1) transcripts were detected by the microarray (Fig. 5.1A) from 12 h PI in each 
cell type. Expression of UL123 in HFFF-2 and RPE cells differs at the early time points as 
transcript levels were stable from 12 h PI to 24 h PI in HFFF-2 cells, but decreased in RPE 
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cells. However, from 24 h PI the expression kinetics were similar in these two cell types. 
The expression of UL123 in U373Mg cells increased from 12 to 24 h PI, and plateaued 
thereafter. The RT-qPCR expression data for UL123 (IE1) (Fig. 5.1B) confirms that the 
expression kinetics of UL123 in HFFF-2 and RPE cells are similar. The RT-qPCR data 
confirms that the levels of UL123 transcript in U373Mg cells (Fig. 5.1B) are significantly 
higher than in HFFF-2 and RPE cells, and that the kinetics are broadly similar to those 
obtained with the microarray (Fig. 5.1A). The apparent over-representation of UL123 in 
U373Mg cells (Fig. 5.1B) is a result of the normalisation procedure employed for RT-
qPCR, where the cellular housekeeping gene, Lactate Dehydrogenase (LDH) was selected 
as an internal control for RNA input and the efficiency of cDNA synthesis. Examination of 
the LDH profile with RT-qPCR shows constant expression levels in all cell types over the 
72 h time course. However, expression levels of LDH were consistently lower in U373Mg 
cells compared to HFFF-2 and RPE cells. Subsequently, normalising RT-qPCR gene 
expression data with LDH resulted in an artificially elevated gene expression profile for 
U373Mg cells. It should be noted that UL123 copy numbers in each cell type were of a 
similar order of magnitude prior to normalisation.   
Northern blot analysis of the UL123 transcript (Fig. 5.1E) detected a single band of 2 kb, 
with expression from 12 h PI in each cell type. The band intensities were determined 
using the Quantity One program, where the mean intensity count (CNT) for each band 
was extracted with a global background correction. The band intensity data is displayed 
as a graph (Fig. 5.1C). The expression of UL123 as determined by the northern blot (Fig. 
5.1C) follows the same kinetics as the microarray profile (Fig. 5.1A). However, the 
expression of UL123 in U373Mg cells from 24 h PI in (Fig. 5.1C) declines more quickly 
compared to the profile in (Fig. 5.1A). 
Western blot data for IE1 and IE2 spliced variants are shown in panels (Fig. 5.1F1) and 
(Fig. 5.1F2) (HFFF-2 and RPE; HFFF-2 and U373Mg cells respectively). Expression of IE1 
(72 kDa) and IE2 (86 kDa) were detected at all time points. Within each cell type the levels 
of IE1 protein were fairly constant at each time point, while levels of IE2 (86 kDa, 60 kDa 
and 40 kDa species) appeared to increase gradually over the time course. Band intensities 
for IE1 were extracted with a global background correction, and the data displayed as a 
graph in (Fig. 5.1D). IE1 expression was very similar in each cell type, with a rise in 
expression from 0 to 12 h PI, which plateaued from 24 to 48 h PI in each cell type.  
Microarray expression data for the early-late gene UL55 (gB) (Fig. 5.2A) indicated that 
transcripts accumulated to 24 h PI and plateaued to 72 h PI in U373Mg cells; however, 
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UL55 transcripts were not detected until 24 h PI in HFFF-2 and RPE cells, but 
accumulated continuously thereafter with similar kinetics. In contrast, the RT-qPCR data 
(Fig. 5.2B) detected expression of UL55 in all cell types from 12 h PI. Expression levels of 
UL55 appear to be significantly higher in U373Mg cells compared to HFFF-2 and RPE 
cells due to the artefact of normalising as discussed previously. The kinetics of UL55 
expression in HFFF-2 and RPE cells are similar in (Fig. 5.2A and B), with a steady increase 
in expression over the time course.   
The northern blot for UL55 expression (Fig. 5.2E) detected multiple transcripts of 14 kb, 10 
kb, 8 kb, 6 kb, 5 kb and 3.7 kb coded by the 3’ co-terminal genes UL54, UL55, UL56 and 
UL57. The 5 kb and 3.7 kb transcripts are reported to be monocistronic, representing UL54 
and UL55 respectively. The remaining overlapping large transcripts (14 kb, 10 kb, 8 kb 
and 6 kb) can be specifically mapped from a TATA box within this gene region, and 
extending to one or other of two polyadenylation signals located downstream of either 
UL55 or UL54 (Smuda et al., 1997). Because UL55 is the terminal gene, the UL55-specific 
probes on the microarray would detect all the transcripts expressed within this region. 
The 14 kb, 10 kb, 8 kb, and 6 kb transcripts were detected throughout the time course in 
U373Mg cells, but accumulated from 24 h PI onwards in HFFF-2 and RPE cells (Fig. 5.2E).  
In order to compare the microarray data (Fig. 5.2A) and the RT-qPCR (Fig. 5.2B) with the 
northern blot data, it is necessary to sum the individual northern band intensities for the 
14 kb, 10 kb, 8 kb, 6 kb, 5 kb, and 3.7 kb transcripts at each time point for each cell type 
(Fig. 5.2C). The data in (Fig. 5.2C) for each cell type shows a continuous increase in 
transcripts binding to the UL55 probe over the time course, although the expression 
kinetics vary compared to (Fig. 5.2A). While it is clear that the microarray, RT-qPCR and 
northern data obtained for the UL55 probes are in agreement, the actual UL55 transcript 
(3.7 kb) is only a small part of the overall signal. Figure 5.2D was based on the band 
intensities of the 3.7 kb band as this shows the UL55 specific signal. The kinetics of UL55 
expression were similar in each cell type as the curves showed a sustained increase from 
24 h PI through to 72 h PI.  
Figure 5.3A shows the microarray data for the late gene UL83 (pp65). Expression was 
detected in each cell type from 12 h PI, and increased rapidly from 24 h PI in HFFF-2 and 
RPE cells. UL83 expression levels plateaued in U373Mg cells after 24 h PI. The RT-qPCR 
profile (Fig. 5.3B) confirmed that UL83 transcript expression in HFFF-2 and RPE cells 
shared the same kinetics, although in contrast to Fig. 5.3A, the late increase in UL83 
transcript levels was not detected until 72 h PI. The expression profile for UL83 obtained 
in U373Mg cells (Fig. 5.3B) indicated a constant level of expression throughout the time 
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course and was consistent with the microarray data (Fig. 5.3A). The northern blot for 
UL83 (Fig. 5.3E) detected a single band of 3.5 kb, band intensity data is displayed in (Fig. 
5.3C). This transcript is likely to contain both the UL82 (pp71) and UL83 (pp65) ORFs, as 
these genes share a single polyadenylation signal downstream of UL82. The expression 
profile for UL83 in HFFF-2 and RPE cells (Fig. 5.3C) exhibited similar kinetics and was 
consistent with the data obtained by both RT-qPCR (Fig. 5.3B) and microarray (Fig. 5.3A), 
albeit that UL83 expression in HFFF-2 is much greater at 48 h PI in (Fig. 5.3A) than in 
(Fig5.3B) and (Fig. 5.3C). Because pp65 (UL83) protein is a component of the virus 
tegument, it was detected at 0 h PI in western blots (Fig. 5.3F1 and F2) in each cell type. 
The levels of pp65 remained steady in both HFFF-2 and RPE cells, rising slowly from 24 h 
PI. The pp65 protein appeared to be less stable in U373Mg cells since levels decreased 
over the first 24 h, but increased again between 48 h PI and 72 h PI to give final amounts 
that were similar to those achieved in HFFF-2 cells.  
The late UL99 gene codes for a tegument phosphoprotein, pp28, which is expressed with 
late kinetics (Chambers et al., 1999). The microarray data for UL99 (Fig. 5.4A) showed a 
continuous increase in expression from 12 h PI to 72 h PI in both HFFF-2 and RPE cells. In 
U373Mg cells, expression increased until 24 h PI, then plateaued thereafter. The RT-qPCR 
expression data for UL99 in HFFF-2 and RPE cells (Fig. 5.4B) shared similar kinetic trends 
with the microarray data (Fig. 5.4A). However, the incremental rise in transcript levels in 
HFFF-2 and RPE cells was slower in (Fig. 5.4B), and the plateau in UL99 levels in U373Mg 
cells seen in the microarray data (Fig. 5.4A) was not observed in the RT-qPCR data (Fig. 
5.4B). The northern blot and associated band intensity data (Fig. 5.4E and C) showed that 
multiple transcripts of 10 kb, 8 kb, 6 kb, 5 kb, 3 kb, 1.6 kb and 1.3 kb are coded by the 3’ 
co-terminal genes UL93, UL94, UL95, UL96, UL97, UL98 and UL99. The UL99 specific 
transcripts are reported to be 1.3 kb and 1.6 kb (Wing et al., 1995). In the northern blots 
(Fig. 5.4F), the 1.3 kb transcript was detected from 24 h PI in each cell type, and the 1.6 kb 
transcript detected at 48 h PI and 72 h PI in each cell type. Note that approximate sizes of 
some transcripts differ slightly from those reported by Wing et al., who used the Towne 
strain of HCMV for transcript mapping. Because the UL99-specific probes on the 
microarray could detect all transcripts expressed in this region – UL99 being the terminal 
gene of this family of 3’ co-terminal transcripts, band intensities were aggregated 
according to time (h PI) for each cell type, and displayed in (Fig. 5.4C) for comparison 
with data in graphs (Fig. 5.4A) and (Fig. 5.4B). The expression kinetics for multiple 
transcripts binding to the UL99 microarray probe are the same in HFFF-2 and RPE cells, 
and the profile obtained from the northern blots (Fig. 5.4C) was consistent with the data 
obtained from RT-qPCR (Fig. 5.4B). In U373Mg cells, there was a continuous increase over 
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the time course, consistent with the RT-qPCR data (Fig. 5.4B), but not seen in the 
microarray data (Fig. 5.4A). Differences in UL99 expression kinetics in HFFF-2, RPE and 
U373Mg cells in (Fig. 5.4C) and (Fig. 5.4B) compared to (Fig. 5.4A) could be due to non-
biological variation. Overall, the microarray data was in agreement with the data obtained 
for UL99 by RT-qPCR and northern blotting. To assess the actual UL99 expression levels 
and kinetics in each cell type, the levels of specific UL99 1.3 kb and 1.6 kb transcripts were 
summed and compared (Fig. 5.4D) with the levels of pp28 (UL99) protein detected in 
western blots (Fig. 5.4E). Western blot data for UL99 (Fig. 5.4G1 and G2) shows low levels 
of pp28 protein at 24 h PI in each cell type, which increased rapidly between 48 h PI and 
72 h PI. The band intensity data is shown in (Fig. 5.4E). No difference is observed in the 
relative abundance or kinetics of expression of pp28 in each cell type, and this finding is 
in accord with the expression kinetics for transcripts binding the UL99 probes in (Fig. 
5.4A, B, C and D).   
Figure 5.5 shows the microarray (Fig. 5.5A) and northern blot (Fig. 5.5C) data for the late 
gene UL43, and the associated northern blot band intensity graph (Fig. 5.5B). The 
microarray detected UL43 from 24 h PI in HFFF-2 and RPE cells, and from 12 h PI in 
U373Mg cells (Fig. 5.5A). UL43 levels increased continuously over the 72 h period in 
HFFF-2 and RPE cells but reached plateau levels after 24 h PI in U373Mg cells (Fig. 5.5A). 
The northern blot (Fig. 5.5C) detected a single band of 5.4 kb, which is expressed from 24 
h PI in HFFF-2 and RPE cells, but from 12 h PI in U373Mg cells. The band intensity data 
(Fig. 5.5B) confirms the increase in UL43 expression in HFFF-2 and RPE cells over the 
course of the experiment with the exception that in HFFF-2 cells levels were dramatically 
increased between 48 and 72 h PI. A steady increase in expression is observed in U373Mg 
over the time course. The microarray data (Fig. 5.5A) and the northern blot data (Fig. 5.5B) 
obtained for UL43 gene expression exhibit similar trends and are in agreement with each 
other.  
5.4  Expression and validation of differentially regulated genes 
Microarray expression data for the early gene UL4 showed that transcripts were detected 
from 12 h PI in all cell types (Fig. 5.6A). UL4 expression levels were very high throughout 
the time course in HFFF-2 cells, and combined statistical tests determined significant 
differences in expression in both comparisons of HFFF-2 and RPE, and HFFF-2 and 
U373Mg cells. Expression in RPE cells was much lower during the first 48 h PI, but by 72 
h PI, levels were similar to those in HFFF-2 cells. The UL4 expression kinetics in U373Mg 
cells was similar to those for other early genes with maximum expression at 24 h PI. 
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Northern blots (Fig. 5.6C) detected a single UL4 transcript of 1.8 kb from 12 h PI in 
U373Mg cells (Fig. 5.6C), but in HFFF-2 and RPE cells, UL4 was not detected until 24 h PI. 
Band intensity data for the northern blot (Fig. 5.6B) showed that UL4 expression in 
U373Mg and RPE cells remained fairly constant, with a gradual increase in expression 
over the time course. In contrast, UL4 expression levels in HFFF-2 and RPE cells were the 
same from 12 h PI to 24 h PI, but in HFFF-2 cells, UL4 expression increased sharply from 
24 to 72 h PI. Despite the differences in temporal kinetics of UL4 expression between the 
microarray data (Fig. 5.6A) and the northern blot data (Fig. 5.6B and C), it is clear that the 
differential expression of UL4 in infected HFFF-2 and RPE, and HFFF-2 and U373Mg cells 
was confirmed by the northern blots. 
Expression of the HCMV early gene UL16 is in RPE cells is considerably lower than in 
HFFF-2 cells, although expression kinetics were similar (Fig. 5.7A). In contrast, the 
expression profile of UL16 in U373Mg cells conforms to that of other early genes in this 
cell type with maximal expression levels at 24 h PI. The RT-qPCR expression profiles 
obtained for UL16 (Fig. 5.7B) in HFFF-2 and RPE cells were similar to those obtained with 
the microarray (Fig. 5.7A). UL16 expression in U373Mg cells assessed by microarray (Fig. 
5.7A) and RT-qPCR (Fig. 5.7B) were also similar, differing in the time of maximal 
expression, although the large error bars in (Fig. 5.7B) may mask more similar kinetics.  
The northern blot for UL16 (Fig. 5.7D) showed a single UL16 transcript of 1.3 kb that was 
present throughout the time course in both HFFF-2 and U373Mg cells, but which 
appeared to be absent from infected RPE cells. It is clear from the microarray (Fig. 5.7A) 
and RT-qPCR (Fig. 5.7B) data that UL16 expression was very low in RPE cells; too low to 
permit detection by northern blotting. Northern blot band intensity data for UL16 is 
displayed in (Fig. 5.7C). Expression of UL16 increased gradually in HFFF-2 cells and 
plateaued at 48 h PI; this result was in conflict with the kinetic data obtained from both 
the microarray (Fig. 5.7A) and RT-qPCR (Fig. 5.7B) data. A similar disparity in UL16 
expression kinetics in U373Mg cells is also apparent. Nevertheless, all three techniques 
support the conclusion that UL16 gene expression is down-regulated in RPE cells, 
compared to that in HFFF-2 and U373Mg cells.   
The microarray expression kinetics obtained for the HCMV IE gene IRS1 (Fig. 5.8A) were 
reminiscent of those obtained for the UL4 gene (Fig. 5.6A). The expression kinetics for 
IRS1 in infected HFFF-2 and U373Mg cells correspond, increasing over the period 12 to 24 
h PI, and plateauing thereafter. In contrast, the profile obtained for IRS1 expression in 
RPE cells exhibited a constant level to 24 h PI, increasing gradually thereafter to levels 
comparable to those found in the other cell types at 72 h PI. The northern blot (Fig. 5.8D) 
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identified two IRS1 specific bands of 1.7 kb and 3.5 kb. IRS1 has an internal transcription 
start site, which accounts for the small 1.7 kb transcript (Romanowski and Shenk, 1997). 
As the 3’ proximal microarray probe would be able to detect both the 1.7 kb and 3.5 kb 
transcripts, the intensities of the 1.7 kb and 3.5 kb bands were summed at each time point 
in order to compare northern data (Fig. 5.8B) with the microarray data (Fig. 5.8A). The 
northern blot and microarray data show similar trends for IRS1 expression in HFFF-2 and 
RPE cells, except that in HFFF-2 cells, the northern showed a decline in IRS1 transcripts at 
72 h PI, and in RPE cells, expression of IRS1 did not rise to levels seen in HFFF-2 cells. 
When IRS1 expression in HFFF-2 and U373Mg cells was compared, the microarray data 
(Fig. 5.8A) showed a fairly constant level of expression over the time course, but the 
northern blot data showed a sharp decline at 72 h PI (Fig. 5.8B), mirroring the kinetics 
seen in HFFF-2 cells. Examination of the IRS1 specific full length transcript (3.5 kb) in 
HFFF-2 cells shows that expression increases rapidly from 12 h PI, plateauing at 48 h PI 
(Fig. 5.8C). The magnitude and kinetics of expression of the 3.5 kb IRS1 transcript are 
different in RPE and U373Mg cells, where IRS1 is down-regulated in both cell types 
compared to HFFF-2 cells (Fig. 5.8C). Thus the data were in agreement with the results of 
the statistical tests, confirming that gene IRS1 was differentially expressed in infected 
HFFF-2 and RPE cells, and infected HFFF-2 and U373Mg cells.  
HCMV US12 gene family members can be separated into two 3’ co-terminal groups: US18, 
US19 and US20 forming one group using a polyadenylation signal downstream of US18 
(Guo and Huang, 1993), and US12, US13, US14, US15, US16 and US17, forming a second 
group that are thought to use the polyadenylation signal downstream of US12. Possibly 
because the US12 gene family members form 3’ co-terminal groups, they are over-
represented in the ‘differentially expressed’ gene lists generated by the combined 
statistical tests.  
The microarray expression profiles for transcripts binding the US12 probes (Fig. 5.9A) 
were similar for infected HFFF-2 and U373Mg cells, while expression levels in RPE cells 
were significantly lower from up to 48 h PI, and increased thereafter to levels similar to 
those in HFFF-2 cells at 72 h PI. The US12 expression data obtained by RT-qPCR (Fig. 
5.9B) for infected HFFF-2 and RPE cells showed a steady-state level of expression over the 
time course, this deviates markedly from the kinetics obtained from the microarray data 
(Fig. 5.9A), although both techniques agree that US12 expression levels are lower in RPE 
cells. The apparently higher levels of US12 expression in U373Mg cells (Fig. 5.9B) is due to 
a normalisation artefact as previously discussed. The northern blot for US12 (Fig. 5.9D) 
shows two major bands of 4 kb and 1.1 kb. Since US12 is the terminal gene within the 
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US12 gene family, the 4 kb and 1.1 kb band intensities were summed for each time point 
(h PI) plotted in the graph (Fig. 5.9C). It is clear from the northern blot (Fig. 5.9D) that the 
expression of both the 4 kb and 1.1 transcripts are much lower in RPE cells, and this is 
reflected in (Fig. 5.9C). Clearly, the microarray expression data (Fig. 5.9A) and the 
northern blot data (Fig. 5.9C) are in close agreement, confirming the down-regulation of 
transcripts binding the US12 probe in RPE cells. To further investigate which of the US12 
gene family members whose transcripts bind the US12 gene probe is down-regulated will 
require detailed mapping of the 3’ and 5’ ends of the transcripts. The 4 kb transcript is 
likely to start at US15, therefore not taking into account genes US16 and US17; however, 
from its size, it is likely that the 1.1 kb transcript is specific for the US12 gene itself.  
The microarray expression data for the second group of US12 gene family members i.e. 
those that bind the US18 probe (US18, US19 and US20) is shown in (Fig. 5.10A). All three 
cell types exhibited the same expression kinetics as those of the US12 group (US12, US13, 
US14, US15) (Fig. 5.9A). The expression kinetics for US18 obtained from the RT-qPCR 
data (Fig. 5.10B) yielded similar kinetic profiles to those obtained from the microarray for 
each cell type (Fig. 5.10A), except that in infected HFFF-2 cells, US18 expression decreased 
between 48 and 72 h PI. The northern blot (Fig. 5.10D) shows two major bands of 3.5 kb 
and 1.4 kb; the 3.5 kb band represents expression from the start of US20 through to a 
polyadenylation signal downstream of US18, and the 1.4 kb transcript represents 
expression from the start of US18 (Guo and Huang, 1993). The summed 3.5 and 1.4 kb 
band intensities at each time point are displayed in (Fig. 5.10C). The expression kinetics 
assessed by the northern blot (Fig. 5.10C) were similar to those obtained from the 
microarray (Fig. 5.10A) and RT-qPCR data (Fig. 5.10B). All three techniques agree that 
expression of US18 is lower in RPE cells then in HFFF-2 or U373Mg cells confirming the 
combined statistical tests that identified US18 as differentially expressed in RPE cells.  
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5.5 Discussion 
5.5.1  Genes differentially expressed in HFFF-2 and RPE cells 
The majority of HCMV genes were not differentially expressed in HFFF-2 and RPE cells 
as determined by the combined statistical tests, and this was confirmed for representative 
IE, E and L kinetic class genes (UL123 (IE1), UL55 (gB), UL83 (pp65), UL99 (pp28), and 
UL43) by comparing the microarray expression profile data with RT-qPCR, northern and 
western blot data. All techniques supported the conclusions that the selected HCMV 
genes were non-differentially expressed in HFFF-2 and RPE cells. 
 
Thirteen HCMV genes (UL4, UL16, UL45, IRS1, US11, US12, US13, US14, US18, US19 and 
US20) were differentially expressed in HFFF-2 and RPE cells (as assessed by the combined 
statistical tests at the 95 % significance level), and exhibited different expression levels 
and kinetics in the two cell types. Differentially expressed HCMV genes in HFFF-2 and 
RPE cells are considered specifically down-regulated in RPE cells; this was confirmed by 
RT-qPCR and/or northern blotting for UL4, UL16, IRS1, US12 and US18. Multiple 
transcripts were detected in the northern blot for HCMV genes US12 and US18 due to 3’ 
co-terminally expressed groups of the US12 family members. Assessment of US12 and 
US18 specific bands in the northern blots confirmed that these genes were down-
regulated in RPE cells. Due to an internal transcription start site in HCMV gene IRS1 
(Romanowski and Shenk, 1997), two distinct bands were obtained in northern blots. Both 
bands were significantly reduced in intensity in RPE cells confirming the microarray data 
indicating that IRS1 gene expression is down-regulated in RPE cells compared to HFFF-2 
cells. When northern blot and/or RT-qPCR data were compared to HCMV infected HFFF-
2 cells, the down-regulation of UL16 and UL4 was also confirmed in RPE cells. Thus, all 
techniques supported the conclusion that UL4, UL16, IRS1, US12 and US18 were 
differentially expressed in HFFF-2 and RPE cells.  
 
5.5.2  Gene differentially expressed in HFFF-2 and U373Mg cells 
Interpretation of the microarray gene expression data for HCMV infected U373Mg cells 
was made more difficult due to the unusual transcription profile of many HCMV genes, 
and because the dynamic range of expression over the time course is relatively small for 
most virus genes in this cell type. The microarray data for U373Mg cells found the 
majority of genes to be expressed from 12 h PI, irrespective of their kinetic class 
previously reported for infected HFF cells by Chambers et al. (1999). It is not known if the 
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rapid transit through the gene expression cascade results from a regulated acceleration in 
U373Mg cells, or whether there is a complete breakdown in the regulated cascade. It 
should be noted that according to the combined statistical tests, representative IE, E and L 
genes determined as differentially expressed in HFFF-2 and RPE cells were also found not 
to be differentially expressed in HFFF-2 and U373Mg cells. The status of UL123 (IE1), 
UL55 (gB), UL83 (pp65), UL99 (pp28) and UL43 as non-differentially expressed genes in 
HFFF-2 and U373Mg cells was confirmed by northern and western blotting; RT-qPCR 
data was inconclusive due to the elevated HCMV gene expression profiles obtained in 
U373Mg cells caused by the normalisation artefact (discussed previously). Importantly, 
expression of the late UL43 gene was detected by the microarray from 24 h PI in HFFF-2 
and RPE cells, but from 12 h PI in U373Mg cells. This finding was confirmed by northern 
blotting, where UL43 transcripts were clearly expressed earlier (12 h PI) than in HFFF-2 
and RPE cells (24 h PI). The microarray detected expression from most HCMV genes in 
U373Mg cells from 12 h PI, irrespective of the kinetic class of genes previously described 
in HFF cells by Chambers et al., 1999. This independent confirmation that the true-late 
UL43 gene is expressed as early as 12 h PI in U373Mg cells supports the conclusion that 
the HCMV transcriptome cascade is completed more rapidly in this cell line. 
 
The statistical tests identified 26 genes as differentially expressed in HFFF-2 and U373Mg 
cells; however, removing genes in this list that are over-expressed and identification of 
genes that were down-regulated in U373Mg cells compared to HFFF-2 cells results in a 
more robust list of differentially expressed HCMV genes: UL4, IRS1, US12, US14, U18, 
US19 and US20. Comparisons of the microarray expression data for UL4, IRS1, US12 and 
US18 with northern blot data confirms that these genes are down-regulated in U373Mg 
cells compared to HFFF-2 cells. Interestingly, each of the genes down-regulated in 
U373Mg cells (UL4, IRS1, US12, US14, US18, US19 and US20) was also found to be down-
regulated in RPE cells compared with HFFF-2 cells.  
5.5.3 Conclusion 
HCMV gene expression data generated by RT-qPCR and northern blotting were generally 
in accord with the expression kinetics identified by the microarray. The combined 
statistical tests, together with examination of the microarray gene expression profiles 
allows discrimination between non-differential and differentially regulated HCMV genes 
in different cell types. The HCMV (Merlin) microarray is therefore a robust tool for 
HCMV transcriptome profiling. 
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6 GENERAL  DISCUSSION 
6.1  Virus replication kinetics and the impact on gene expression 
A custom DNA microarray was designed in order to profile the transcriptome activity of 
HCMV genes with the specific aim of identifying genes that were differentially expressed. 
The microarray design was based on the most up-to-date assessment of HCMV coding 
potential using a virus strain (Merlin) as close as possible to that of wild-type virus. The 
microarray was also utilised to assess transcription from regions of the HCMV genome 
recently proposed to code putative novel ORFs (Murphy et al., 2003a and b), and also 
regions of the genome now considered to be non-protein coding (Dolan et al., 2002). This 
thesis reports the first study to assess and compare the kinetics of HCMV gene expression 
in a time course experiment in multiple cell types in order to identify HCMV cell-type 
specific gene expression kinetics.  
 
Previous HCMV microarray studies investigated the classification of HCMV genes 
according to their temporal (or kinetic class) of expression in HFF cells, using 
cycloheximide prior to and during viral infection to limit expression to the immediate-
early (IE) class of genes, and gancyclovir from the time of viral infection to inhibit viral 
DNA synthesis to limit expression to the early (E) genes, while the absence of both drugs 
allowed expression through to the late (L) genes (Chambers et al., 1999). In contrast, this 
study investigated HCMV gene expression over a time course in multiple cell types 
(HFFF-2, RPE and U373Mg) in the absence of drugs. The use of three different cell types 
to investigate HCMV gene expression presented several challenges with respect to the 
differential replication kinetics of HCMV observed in these cell types. Several factors 
probably contribute to differential replication kinetics of HCMV in different cellular 
environments; different concentrations of specific cellular transcription factors and/or 
inhibitors of transcription within different cell types, and varying selective pressures 
resulting in the differential regulation of viral tropism factors. Ultimately, the degree of 
permissiveness of different cell types to HCMV infection can affect the interpretation of 
the virus gene expression data, if the virus transcription programme progresses at 
different rates. Transcriptome profiling of VZV (strain Dumas) was compared in two 
different cell types (human melanoma cell line, MeWo cells; and human atrocytoma cell 
line, SVG cells) at a single time point (72 h PI), when maximal CPE was observed in both 
cell lines, then compared the relative expression of VZV transcripts (see introduction, 
section 1.7.7). It was found that VZV gene expression was markedly reduced in infected 
SVG cells compare to infected MeWo cells and of the top six expressed VZV genes in 
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MeWo cells, only three (ORFs 49, 57 and 58), were also significantly expressed in infected 
SVG cells. It was concluded that the cellular environment did influence the expression of 
the viral transcriptome, but it was not possible to elaborate on cell-type specific 
expression kinetics as only one time point was examined (Kennedy et al., 2005). In 
contrast, Yamagishi et al., (2003) examined AcMNPV (autographa californica multicapsid 
nucleopolyhedrovirus) gene expression at 4 time points in two insect cell lines (Sf9; S. 
frugiperda; and TnHigh-Five; T. ni) (see introduction, section 1.7.7). They were able to 
identify 6 differentially expressed viral genes, one of which (AcMNPV gene p35) has anti-
apoptotic function and is required for virus origin specific DNA replication, and a second 
(AcMNPV gene p10) is reported to be required for the release of virus from infected cells, 
the remaining genes have functions that are unknown. Data was not provided for 
AcMNPV growth kinetics in Sf9 or TnHigh-Five cells (Yamagishi et al., 2003).   
 
This study compared HCMV differential gene expression in different cell types. In order 
to characterise the replication kinetics of HCMV in HFFF-2, RPE and U373Mg cells, 
infectious virus yields were measured in each cell type over a period of 7 days. The one 
step HCMV growth curves in RPE and U373Mg cells showed that there was a delay in 
infectious virus yield from the cells, resulting from effects on maturation and release of 
virus to the extracellular medium (Fig. 3.1 to 3.3). However, assessment of the protein 
expression kinetics in a time course experiment revealed that IE, E and L proteins were 
expressed at similar times although lower amounts of protein were made in RPE cells 
compared to HFFF-2 cells. This could be accounted for by an apparent delay in the exit 
from the eclipse phase in RPE cells, but the infection rises at a similar intracellular rate in 
HFFF-2 and RPE cells (Fig. 3.2), suggesting that the release of HCMV to the extracellular 
medium is impaired in RPE cells. The situation is similar in U373Mg cells compared to 
RPE cells, where there is an equivalent delay in the exit of virus from the eclipse phase 
(Fig. 3.1 and 3.3); however, unlike replication in RPE cells, the increase in infectious virus 
is slower and shorter in duration in U373Mg cells resulting in an approximately 1000-1500 
fold lower infectious yield than in HFFF-2 cells. As is the case in RPE cells, IE, E and L 
protein expression kinetics are similar to those in HFFF-2 cells, but the release of 
infectious virus to the extracellular medium is also impaired in U373Mg cells (Fig. 3.2). In 
both RPE and U373Mg cells, the delay in the exit of the eclipse phase could be due to 
different mechanisms of HCMV entry into these two cell types and the subsequent 
delivery of nucleocapsids to the cell nucleus. It is known that HCMV enters RPE and 
HUVEC cells by endocytosis, whereas entry into fibroblasts occurs via fusion of the host 
and viral membranes (Bodaghi et al., 1999b). The entry mechanism of HCMV in U373Mg 
cells at present remains unknown. Immunofluorescence experiments showed that there 
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was no difference between the cell types in the numbers of cells infected and expressing 
UL44 (DNA polymerase processivity factor) at 48 h PI, but this does not exclude the 
possibility of delayed entry and/or delivery of nucleocapsids to the nucleus.  
 
The microarray data showed that the temporal regulation of HCMV gene expression in 
U373Mg cells was perturbed compared to that in HFFF-2 or RPE cells. Moreover, 
infectious virus yields from U373Mg cells were the lowest of the cell types tested. These 
observations may be caused by rapid transit through, or breakdown in the regulation of 
the normal HCMV transcription cascade. Perturbed gene expression might be expected to 
impact on virus production and maturation, and could account for the short duration and 
low levels of infectious progeny made in U373Mg cells. One possible explanation for 
rapid transit through the HCMV gene expression cascade may be that the requirements 
for regulated HCMV gene expression are reduced in U373Mg cells. In fibroblasts, 
progression from immediate-early to early gene expression involves a complex interaction 
between the viral IE1 (72 kDa) and IE2 (86 kDa) proteins along with other viral and 
cellular gene products that provide gene specific accessory functions. In HCMV infected 
U373Mg cells, however, it has been reported that the IE2 (86 kDa) protein is the only viral 
gene product required to efficiently transactivate early and late viral gene promoters 
(Klucher et al., 1993; Wu et al., 1998; Wu et al., 2001), and that IE2 (86 kDa) can modulate 
the binding of the cellular transcription factor Sp1 in a cell type specific manner (Wu et al., 
1998).  
 
The finding that the cellular p53 gene is mutated in the U373Mg cell line (Van Meir et al., 
1994) provides another explanation for the perturbation of the HCMV gene expression 
cascade. p53 plays a central role in several important cellular processes such as cell cycle 
regulation, DNA repair and apoptosis, and naturally occurring p53 mutations are 
associated with glioma oncogenesis (Louis et al., 1993). The effect of commonly 
encountered p53 mutations on viral gene promoter activity has been studied in transient 
transfection assays, and it was reported that the HCMV MIEP and HSV-1 UL9 promoters 
were activated by mutated p53 constructs. Viral gene activation induced by mutant p53 
was enhanced in the presence of CREB, a cellular transcription factor induced by HCMV 
infection and which binds to the HCMV MIE promoter (Deb et al., 1992). It was also 
shown that the minimal promoter sequence required for activation by mutant p53 
products was a functional TATA box (Deb et al., 1992). It may be then that, the mutant 
p53 in U373Mg cells binds all or most HCMV promoter sequences inducing early or 
deregulated expression from HCMV genes.  
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HCMV infection of fibroblasts, astrocytes and human umbilical vein endothelial cells 
results in elevated steady-state levels of (wild-type) p53 (Muganda et al., 1994; 
Lokensgard et al., 1999; Kovacs et al., 1996), but this is not associated with the activation 
of p53 responsive genes, or p53 activation of viral and cellular promoters (Subler et al., 
1992; Tsai et al., 1996; Chen et al., 2001). Recently, an investigation into the ability of 
HCMV (strain Towne) to replicate in p53 negative fibroblasts and p53 positive fibroblasts 
revealed interesting observations that accord with the growth kinetics of HCMV in 
U373Mg cells presented here. It was shown that HCMV replication in p53 negative 
fibroblasts was delayed, with decreased infectious virus production and slow 
accumulation of viral DNA. In p53 negative fibroblasts, the onset of UL44 and pp28 
protein expression was delayed compared to p53 positive fibroblasts (a phenomenon not 
observed in our U373Mg experiments). In p53 positive fibroblasts, p53 was sequestered at 
replication centres and enhanced the ability of HCMV to grow to high titres (Casavant et 
al., 2006).  
 
The microarray data for U373Mg cells showed that HCMV early transcripts peaked at 24 
h PI and late transcripts between 24 and 48 h PI, while in infected HFFF-2 and RPE cells, 
early transcripts peaked between 24 and 48 h PI and late transcripts between 48 and 72 h 
PI. In contrast, the temporal expression kinetics of viral proteins IE1 (72 kDa), and IE2 (86 
kDa), pUS22, pp65, pp28 (representative of IE, IE, early, early/late and true late kinetic 
classes respectively) did not differ in the three cell types despite differences in transcript 
kinetics in U373Mg cells. This suggests some degree of post-transcriptional control over 
translation of transcripts in U373Mg cells, possibly operating at the level of nuclear export 
of mRNA or mRNA stability, or its binding to ribosomes and translation.  
 
In summary then, it is speculated that in HCMV infected U373Mg cells, mutant p53 and 
IE2 (86 kDa) activate early promoters in the presence of specific cellular transcription 
factors e.g. CREB and Sp1, followed by late promoters that contain only TATA element. 
This leads to accelerated transition through the transcription cascade. Protein expression, 
however, is regulated, but the formation of viral replication centres is compromised by 
the absence of wild-type p53 (Casavant et al., 2006), resulting in a reduction of DNA 
replication and impairment of virus maturation and egress.  
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6.2  Viral genes specifying cell tropism factors 
The HCMV Towne-BAC construct in which the US1 to US12 region of the genome have 
been replaced by the BAC sequence was used in a study to identify HCMV genes 
involved in cell tropism (Dunn et al., 2003). Transposon insertion mutagenesis provided a 
library of HCMV mutants covering most of the virus ORFs, which were then used to 
a s s e s s  t h e  r e p l i c a t i o n  e f f i c i e n c y  o f  e a c h  m u t a n t  i n  H F F ,  R P E  o r  H M V E C .  K n o c k o u t  
mutations in genes UL10 or UL16 enhanced replication in RPE cells 100 fold, while a UL64 
knockout (now considered to be non-protein coding) and US29 knockout mutations each 
decreased virus replication by 100 fold in RPE cells. While disruption of either the US16 
and US29 ORFs enhanced replication by 100 fold in HMVEC, a UL24 knockout decreased 
replication by 100 fold (Dunn et al., 2003). In another study using the Towne-BAC, a US18 
deletion mutant exhibited a 100 fold decrease in growth in cultured human gingival tissue 
compared to HFF cells (Hai et al., 2006). The finding that many HCMV gene products 
function to suppress virus replication is interesting and indicates the sophisticated level of 
control that HCMV exerts over its own replication, presumably to avoid immune 
surveillance.    
 
The transposon mutant studies showed that the UL10, UL16, US29 ORFs, and sequences 
around the discounted UL64 ORF region may play a role in RPE cell tropism, while ORFs 
US16, US19 and UL24 may be involved in HMVEC tropism. US18, identified as 
differentially regulated gene in the microarray study, is a determinant of gingival tissue 
tropism (Hai et al., 2006). Since disruption of most of these ORFs resulted in a specific 
enhancement of virus replication in a single cell type, it might have been expected that 
during wild-type virus infection, the expression of such cell specific tropism factors 
would be down-regulated at the level of the promoter and would have been identified as 
differentially controlled genes in the microarray experiments. However, only one HCMV 
gene, UL16 identified as a determinant of RPE cell tropism, was found to be differentially 
expressed in the microarray experiments. In this case, there was a correlation between the 
findings that UL16 was down-regulated in infected RPE cells and that the knockout 
mutant exhibited a enhanced growth in RPE cells. The general lack of correlation between 
the list of HCMV genes identified as differentially expressed and the list of potential 
tropism factors is puzzling. In part, the discrepancy may be due to the use of the Towne-
BAC virus to generate the mutants, since the Towne virus is itself a multiple mutant. The 
use of a transposon as a gene disruption tool may also have contributed. Because HCMV 
has many overlapping genes, genes that share a common poly(A) site or genes that are 
spliced, it may be that the transposon insertion has effects on the expression of upstream 
   200 
 
  
or downstream genes that are real cell tropism factors. Another factor may be that the fact 
that the cell lines used in the two studies are separately sourced and derived from 
different lineages. Similar arguments regarding overlapping 3’ co-terminal and spliced 
genes apply equally to the microarray study for those genes identified as differentially 
expressed, but whose true identity has not yet been confirmed by northern blotting.  
 
A well-reported cell tropism factor that was not identified in the transposon based study 
or found to be differentially expressed in the microarray study is the function provided by 
the HCMV UL128 gene locus. This gene locus comprises three adjacently located ORFs 
UL128, UL130 and UL131A, whose products function co-operatively. Since the Towne 
strain has a premature termination mutation in gene UL130, and the Merlin strain has a 
termination mutation in UL128, the gene locus was non-functional in the viruses used in 
both studies (Akter et al., 2003; Dolan et al., 2004). While the UL128 mutation in Merlin 
would not be expected to impact on expression of the UL128 transcript per se, lack of 
function from the gene locus might eliminate the selective pressure to down-regulate 
expression from the gene locus in fibroblast cells. For reasons that are as yet unclear, 
expression of a fully functional UL128 gene locus is detrimental to growth in fibroblast 
cells and one or more of the UL128, UL130 and UL131A genes are invariably mutated in 
HCMV strains during passage in fibroblast cell cultures. In contrast, a fully functional 
UL128 gene locus is essential for propagation of HCMV in endothelial (HUVEC) cells 
(Hahn et al., 2004). How expression of the UL128 gene locus affects the replication of 
HCMV in different cell types in vivo at present remains unknown.  
 
Transcriptome profiling of HCMV global gene expression in HFFF-2 and RPE cells 
revealed 13 HCMV genes that were differentially expressed during the time course (UL4, 
UL16, UL45, UL148, IRS1, US11, US12, US13, US14, US15, US18, US19 and US20). The 
application of combined statistical tests for HFFF-2 and U373Mg cells showed that 26 
genes were expressed at significantly different levels (p < 0.05), although removing genes 
that were over-expressed in U373Mg cells compared to HFFF-2 cells reduced this list to 7 
candidates (UL4, IRS1, US12, US14, US18, US19 and US20). That UL4 expression was 
down-regulated in both RPE and U373Mg cells compared to HFFF-2 cells was confirmed 
by comparison of UL4 northern blot expression data with the associated microarray data. 
UL4 is a glycoprotein that has an unusual mechanism of control over the translation of its 
protein product. The transcript leader of UL4 contains three transcription start sites, of 
which the second (designated as uORF2) is critical for the inhibition of the downstream 
cistron (Degnin et al., 1993). The uORF2 peptide is synthesised, but then retained on the 
ribosome blocking translation termination, stalling the ribosome on the transcript leader, 
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and restricting access to the downstream UL4 cistron (Cao and Geballe, 1995). With 
regard to UL4 as a candidate for differential gene expression, it has been shown that the 
UL4 promoter contains cis-acting elements for the cellular transcription factors NF-Y (that 
binds a CCAAT box) and Elk-1 (that binds to site 2), and activate UL4 gene expression 
along with IE2 (86 kDa) (Huang et al., 1994; Huang and Stinski, 1995; Chen and Stinski, 
2000). It is known that HCMV infection of HFF cells activates ERK1/2 (MAPK) which has 
many substrates including AP-1, CREB, STAT proteins, SAP-1a and Elk-1. UL4 expression 
is influenced by cellular transcription factors (Elk-1) that are activated by the MAPK/ERK 
pathway (Chen and Stinski, 2000). As the function of UL4 is unknown, the significance of 
UL4 differential expression in these three cell types is unclear. The mechanism by which 
UL4 expression is controlled must involve the ability of Elk-1 and NF-Y to promote 
expression of this gene via upstream cis-acting regulatory elements. It is possible that 
these transcription factors are present in different concentrations in the three cell types, or 
there is a delay in their activation in RPE cells and/or U373Mg cells, that subsequently 
affects the expression from the UL4 promoter. Because UL4 appeared to be down-
regulated in both RPE and U373Mg cells, it is equally viable to suggest that UL4 
expression is up-regulated in HFFF-2 cells.  
 
UL16 and US11 were both down-regulated in RPE cells compared to HFFF-2 cells, and 
both provide immune evasion functions. The UL16 gene codes for a glycoprotein 
dispensable for growth in cell culture (Kaye et al., 1992), but which binds to and retains 
the NK cell receptor ligands ULBP1, ULBP2 and MIC-B in the ER preventing their 
expression on the cell surface, thus avoiding NK cell activation (Cosman, 2001; Welte et 
al., 2003). Compared to HFFF-2 cells, UL16 gene expression was significantly reduced in 
RPE cells throughout the time course. It has been shown that a Towne-BAC ∆UL16 
knockout mutant specifically enhanced replication in RPE cells by 100 fold compared to 
the parental HCMV Towne-BAC virus (Dunn et al., 2003). This suggests that high levels 
of UL16 expression are detrimental to growth and replication in RPE cells supporting the 
finding that UL16 is down-regulated in RPE cells. The expression of the US11 gene was 
also down-regulated in RPE cells compared to HFFF-2 cells (this observation was 
confirmed by northern blotting: data not shown). Interestingly, US2 was also a possible 
candidate for down-regulation in RPE cells compared to HFFF-2, although the data was 
not conclusive (see section 4.2.7.2). Both US2 and US11 are responsible for the targeting of 
MHC Class I heavy chains (HC) for ubiquitin-mediated proteasome degradation, thus 
preventing the activation of CD8+ CTLs (Wiertz, 1996a and b). Despite the down-
regulation of US11, UL16, and possibly US2, there are many more HCMV genes whose 
products are involved in immune evasion, e.g. HCMV UL18; homologue for HLA-I 
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(Cosman, 1997), gpUL40; up-regulation of HLA-E (Tomasec et al., 2000), UL141; down-
regulation of CD155 (Tomasec, 2005), UL142 inhibition of NK cell activation (Wills et al., 
2005), and US3, US6, US9 and US10; inhibition of MHC Class I surface expression in 
HCMV infected cells (Loureiro and Ploegh, 2006), whose expression was not affected by 
growth in different cell types. The expression of HCMV gene UL18, a homologue of the 
human leukocyte antigen (HLA class I) protects against NK lysis of HCMV infected 
fibroblasts (Cosman, 1997), while the induction of CD8+ CTLs is avoided by the down-
regulation of MHC class I molecules conferred by US2, US3, US6, US9, US10 and US11 in 
fibroblasts (Loureiro and Ploegh, 2006). However, it was reported that NK cytotoxicity of 
endothelial cells and macrophages is independent of the expression of UL18 or cellular 
HLA class I A, B and C antigens, because a ∆UL18 HCMV mutant, and a mutant lacking 
HCMV genes US1 to US9 and US11 (HCMV strain RV670) were both less susceptible to 
NK lysis in these two cell types than in fibroblasts (Odeberg et al., 2002). Based on this 
evidence, it is possible that the immune evasion functions provided by UL16 and US11 in 
HFFF-2 cells are not essential in RPE cells, and that resistance to NK and/or CD8+ CTL 
activity in RPE cells is independent of the expression of UL16 and US11.  
 
A possible explanation for the down-regulation of some HCMV genes involved in 
immune evasion might be due to the fact that RPE cells located in the eye are an immune-
privileged site in vivo, and this might alter their characteristics as antigen presenting cells 
(APCs) (Gabrielian et al., 1994). In contrast to HCMV infection in fibroblasts, infection of 
RPE cells circumvents the stimulation of NF-κB in order to avoid cell-mediated 
inflammatory mechanisms induced by this transcription factor. Clearly, the down-
regulation of US11 and UL16 (and possibly US2) in RPE cells is part of a much more 
complicated network of immune effector mechanisms, for which cross-talk between these 
pathways and the possibility of antagonistic interactions and/or hierarchy within 
immune-privileged RPE cells remains unclear. Furthermore, as UL16 function is not 
required in RPE cells, this suggests that UL16 might have another function other than 
immune evasion, especially as Towne-BAC ∆UL16 replication was dramatically enhanced 
compared to parent Towne-BAC in RPE cells (Cosman, 2001; Welte et al., 2003; Dunn et 
al., 2003). Similarly, the US11 gene might also have an additional function that is 
detrimental to growth in RPE cells. Overexpression of these genes (US11 and UL16) in 
RPE cells would be required to gain understanding of their effects on the growth of 
HCMV in this cell type.  
 
The expression of UL45 was down-regulated in RPE cells compared to HFFF-2 cells, as 
evidenced by examination of UL45 expression kinetics and the combined statistical test p-
   203 
 
  
values (p < 0.05). This gene was not found to be differentially expressed in HFFF-2 and 
U373Mg cells. UL45 is a tegument protein that is related to the cellular riboncleotide 
reductase (RNR) large subunit (R1), and is reported to be dispensable for growth in HFF 
and endothelial cells (Hahn et al., 2002). However, the MCMV homologue (M45) of 
HCMV UL45 has been reported to be a determinant of MCMV endothelial cell tropism, 
and indispensable for virus growth and pathogenesis in vivo (Brune et al., 2001; Lembo et 
al., 2000; Lembo et al., 2004). The MCMV M45 product exhibits strong anti-apoptotic 
activity (Brune et al., 2001). Assessment of the growth of a HCMV UL45-KO mutant in 
HFF cells displayed a growth defect at low m.o.i. and its ability for cell-to-cell spread was 
diminished. The UL45 gene product displayed mild anti-apoptotic activity (Patrone et al., 
2003). It is possible that HCMV UL45 plays a role in RPE cell tropism; however, in 
contrast to the studies of M45 in MCMV where it is reported to be essential for virus 
growth, UL45 was down-regulated in RPE cells. As it has been reported that UL45 is 
involved in fibroblast cell-to-cell spread at low m.o.i. (Patrone et al., 2003), it is possible 
that UL45 down-regulation in RPE cells might play in role in limiting the spread of 
HCMV within the retinal epithelium. This hypothesis is supported by the identification of 
several HCMV genes that appear to moderate the replication and/or spread of HCMV in 
a cell type specific manner (Dunn et al., 2003).  
 
The US12 gene family were over-represented in the gene lists generated by the combined 
statistical tests between HFFF-2 and RPE cells, and between HFFF-2 and U373Mg cells. As 
discussed previously, these 10 genes (US12 to US20) form two distinct 3’ co-terminal 
groups. However, expression kinetics of HCMV genes US16 and US17 were the same in 
HFFF-2 and RPE cells, and overall expression was not considered significantly different in 
combined statistical tests for HFFF-2 and RPE, or HFFF-2 and U373Mg cells. For the 
remaining genes (US12 to US15; US18 to US20), the microarray data was supported by 
RT-qPCR and northern blot data (specifically for US12 and US18). The fact that these 
genes are 3’ co-terminal explains why so many family members appear to be differentially 
expressed. The US12 family are putative multiple transmembrane proteins (Rigoutsos et 
al., 2003). The localisations of US14, US17 and US18 have been studied in HFFs with the 
following observations: 1. US14 is distributed throughout the cytoplasm, but is 
occasionally found concentrated at virus assembly compartments (AC) in the cytoplasm; 
2. US17 is expressed in a segmented manner (cleaved post-transcriptionally) with the N-
terminus localising at the periphery of AC, and the C-terminus localising in the nucleus 
and cytoplasm; 3. US18 is distributed throughout the cytoplasm but localised at ACs at 
late stages of infection (Das et al., 2006; Das and Pellett, 2007). It has therefore been 
suggested that these gene products have roles in virus maturation and egress (Das and 
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Pellett, 2007). The down-regulation of ORFs US12 to US15 and US18 to US20 in RPE cells, 
and the down-regulation of US12, US14, and US18-US20 in U373Mg cells may impact on 
virus maturation and egress because it is apparent from the cell-released virus one step 
growth curves that virus egress is strictly limited in these cell types (Fig. 3.2). The down-
regulation of these genes could be important in controlling cell-to-cell spread of infection 
in these cell types, promoting direct membrane-to-membrane route of egress rather than 
release of cell-free virus to the bloodstream or extracellular spaces. It is possible that 
different mechanisms of virus dissemination are appropriate in different organs and 
tissues.    
 
IRS1 is a tegument protein that is dispensable for growth in fibroblast cell culture, but 
which cooperates with IE1/IE2 in the transctivation of early and late viral promoters 
(Jones and Muzithras, 1992; Pari et al., 2000). IRS1 was down-regulated in RPE and 
U373Mg cells compared to HFFF-2 cells, and this was confirmed by northern blotting. 
IRS1 and TRS1 are closely related genes that work synergistically with other 
transactivators (IE1/IE2) and immediate-early gene regulators (UL36-38 and UL69) for 
activation of early and late gene expression in infected HFF cells. It has also been shown 
that IRS1 or TRS1 are independently capable of initiating ori-Lyt dependent HCMV DNA 
replication together with UL36-38 and UL112-113 genes (Iskenderian et al., 1996). Recent 
studies have shown that IRS1 and TRS1 are protein kinase R (PKR) evasion genes. TRS1 
sequesters PKR in the nucleus of infected cells, preventing interaction of PKR with 
cytoplasmic ds-RNA. This prevents the activation of PKR and the subsequent 
phosphorylation of elongation initiation factor-2-alpha (eIF2α), therefore preventing host 
protein synthesis shutoff (Hakki et al., 2005; Hakki et al., 2006). These data also suggest 
that IRS1 expression is not essential in the presence of TRS1. While TRS1 is not 
differentially expressed in HFFF-2 and RPE, or U373Mg cells, IRS1 was confirmed as 
differentially expressed in HFFF-2, RPE and U373Mg cells. Although related IRS1 and 
TRS-1 have different sequences at their 3’-ends, IRS1 gene expression is autoregulated by 
a protein that is expressed from an internal transcription start site within IRS1, and this 
protein negatively regulates the expression of the full length IRS1 transcript (Romanowski 
and Shenk, 1997). However, TRS1 does not exhibit a similar mechanism of control. The 
down-regulation of IRS1 in RPE cells and U373Mg cells suggests that IRS1 might have a 
unique function within these two cell types. Alternatively, since IRS1 was under-
expressed in both RPE and U373Mg cells, it may be that IRS1 was up-regulated in HFFF-2 
cells.  
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To summarise the above findings, HCMV genes with immune evasion or transactivation 
functions were down-regulated in RPE cells (UL16, US11, UL45 and IRS1), and U373Mg 
cells (IRS1), while HCMV genes that might have roles in virus maturation and egress 
were also down-regulated in RPE cells (US12-US15, US18-US20) and U373Mg cells (US12, 
US14 and US18-US20). The finding that the same viral genes are differentially expressed 
in both RPE and U373Mg cells compared to HFFF-2 cells is particularly relevant as both 
RPE and U373Mg cells are derived from immune privileged sites. HCMV infection of 
these two cell types may be subject to a more controlled replication strategy resulting in 
the dissemination of infection in the surrounding tissue via cell-to-cell junctions. This 
would contribute to immune evasion as it would prevent a large burst of virus to the 
extracellular space, leading to a delay the stimulation of the immune system. Moreover, 
genes that are essential for HCMV replication and envelopment are not affected in HFFF-
2, RPE or U373Mg cells e.g. IE1/IE2 (Mocarski et al., 1996), pUL44 (Leach and Mocarski, 
1989), and pUL99 (pp28) (Silva et al., 2003). In contrast, fibroblasts have a basic function in 
the formation of connective tissue within the body. HCMV replication in vivo in 
fibroblasts results in the quick release of virus into the blood stream that is disseminated 
throughout the body either as cell-free virus or by transient transfer to circulating 
neutrophils/monocytes. It is known that HCMV infection of the kidneys results in the 
release of HCMV into the urine, which ultimately contributes to the maintenance of 
HCMV within the human population. As fibroblasts are not major components of 
immune privileged organs, the virus will express all genes that function as immune 
evasins, to protect the infected cells from the host’s immune response. High yields of cell-
free infectious progeny from fibroblasts cells  during a primary HCMV infection may be 
required to ensure establishment of persistence in the host, and to promote person-to-
person spread of the virus via host secretions.   
 
In order to fully understand the roles of individual differentially expressed HCMV genes 
in cell tropism or immune evasion requires further investigation. However, as the data 
stands, it can be concluded that certain HCMV genes are differentially regulated in HFFF-
2, RPE and U373Mg cells. The mechanism by which differential expression of HCMV 
genes are affected is unclear, but may operate at the level of the promoter, 
polyadenylation and nuclear export of mRNA, or the stability of mRNAs. It is clear from 
this and other studies that the outcome of HCMV infection in a given cell type is a 
function of both the cell type and the virus itself. The HCMV microarray platform we 
have employed has provided valuable insight regarding the expression kinetics of HCMV 
genes in different cellular environments.  
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6.3  Future work on HCMV cell tropism 
This is the first investigation to examine the temporal kinetics of HCMV global gene 
expression in different human cell types: fibroblasts, epithelial cells and astrocytes. The 
main conclusions from this study were that the majority of HCMV genes were expressed 
with similar kinetics in infected HFFF-2 and RPE cells, however, 13 genes (UL4, UL45, 
UL148, IRS1, US11, US12, US13, US14, US15, US18, US19 and US20) were expressed with 
cell-type specific kinetics. In HCMV infected U373Mg cells, the viral gene expression 
cascade appeared to be accelerated compared to that observed in HFFF-2 and RPE cells, 
probably as a consequence of a mutation in p53 in U373Mg cells. However, it was 
concluded that 7 HCMV genes (UL4, IRS1, US12, US14, US18, US19 and US20) were 
differentially expressed in U373Mg cells compared to HFFF-2 cells, and that each of the 7 
genes differentially expressed in U373Mg cells were also differentially expressed in RPE 
cells.  
 
Future studies might investigate the effects of specifically up- or down-regulating the 
expression of individual differentially expressed genes in order to examine their effects on 
the replication of HCMV in each cell type. This might be accomplished using interfering 
RNA (RNAi) technology to silence the expression of specific genes in order to examine the 
effects on the growth of the virus. Similarly, cells stably expressing specific HCMV genes 
under the control of an inducible promoter could also be engineered to examine their 
effects on the growth of the appropriate null mutant virus. Furthermore, antibodies could 
be raised against gene products that have been identified as differentially expressed in 
order to examine the intracellular distribution and/or potential interactions of the 
differentially expressed gene products with other viral or cellular proteins. It would also 
be interesting to examine the rate of HCMV DNA replication, and to examine virus 
maturation and egress in HFFF-2, RPE and U373Mg cells in order to gain further insight 
into the growth kinetics of HCMV in these cell types. Quantitative PCR could be used to 
measure the accumulation of HCMV genomic DNA in each cell type, while electron 
transmission microscopy could be used to examine the intracellular accumulation of virus 
particles. These techniques could highlight different strategies or mechanisms employed 
by HCMV when replicating in different cellular environments. Together, these studies 
will allow greater understanding of the complex nature of HCMV cell tropism.  
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